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ABSTRACT 
 
The use of natural products is becoming increasingly popular worldwide. Flaxseed is a 
source of natural products that are rich with bioactives and have been reported to modulate 
inflammation, blood pressure, glucose levels and lipid profiles in both humans and animals. 
Currently, several known bioactives including fibers, lignans, alpha-linolenic acid, and 
linoorbitides (LOBs) are believed to impart those pharmacological activities. Previous studies have 
focused on the ability of flaxseed bioactives to provide their pharmacological action in the 
systemic circulation. However, our increasing understanding of their pharmacokinetics and 
chemical structures, suggests enhanced abundance of LOBs and lignans at the level of the intestinal 
epithelium due to the potential lack of permeation of LOBs, and susceptibility of lignans to 
enterohepatic circulation. Our aim in this work is to evaluate the effects of the lignan enterolactone 
(ENL) and LOBs on intestinal epithelium function and how it might influence associated 
pathologies like inflammatory bowel disease (IBD) and hypercholesterolemia.  
We first assessed LOBs and ENL effects on barrier integrity (a pathological hallmark of 
IBD) in vitro using a monoculture transwell system, and the potential mechanisms involved in 
maintenance of the barrier. Next, we examined their effect in a coculture system that more closely 
simulates the intact intestinal mucosa. These studies triggered the evaluation of pyruvate kinase 
M-2 (PKM2) as a possible biomarker of IBD. Lastly, we evaluated the effect of lignans on 
cholesterol metabolism in a human intestinal epithelial cell line (Caco-2). Our barrier integrity 
assessments of LOBs and ENL in the monoculture system identified differential effects of LOBs 
and ENL, and both showed increased protein levels of anti-inflammatory peroxisome proliferator-
activated receptor gamma (PPAR-γ) and tight junction protein zonula, occludin (ZO-1). Further, 
in newly diagnosed IBD patients, PKM2 was indicative of disease presence with less variation 
than other biomarkers like fecal calprotectin and fecal lactoferrin. Lastly, altered cholesterol 
trafficking was observed in Caco-2 cells, an effect best attributed to the glucuronic acid conjugated 
form of enterolactone.  
These studies confirmed the importance of the flaxseed bioactives, ENL and LOBs in 
maintaining barrier integrity and modulation of cholesterol metabolism. More importantly, and 
due to their increased abundance at the level of the intestinal epithelium, those effects are crucially 
important in IBD and hypercholesterolemia. However, these effects remain to be evaluated in an 
animal models of colitis and dyslipidemia. 
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2 
 
1.1 INTRODUCTION 
 
Flaxseed is one of the highly abundant agricultural products in Canada, especially in 
Saskatchewan1. Consumption of flaxseed is associated with an array of health benefits such as 
amelioration of disease markers in pathologies like cardiovascular-related disorders, diabetes, and 
cancer2-7. These health benefits have been attributed to an assortment of favorable reported 
biological effects including anti-inflammatory8, antioxidant9 and immunosuppressive activity10, 
but the exact mechanisms of these activities are largely unknown. In dyslipidemia and diabetes, 
those activities were broadly studied for flax by the virtue of using standardized flax products as a 
nutritional intervention in human and animal models2, 11, 12. Conversely, immunosuppression in 
inflammatory diseases did not gain much attention in previous studies.  
The health benefits of flaxseed consumption relate variably to a number of known bioactives 
including lignans, alpha-linolenic acid, and linoorbitides (LOBs)13-16. The limited known 
pharmacokinetic information regarding the flaxseed bioactives, lignans and cyclic peptides 
(LOBs), indicate a very limited oral bioavailability of these bioactives following oral consumption. 
The lack of extensive systemic absorption of the lignans and the large molecular weight of the 
LOBs (~1000 g/mol) suggest high concentrations and local effects on the gastrointestinal tract is 
possible. Very few studies have examined the role of lignans and LOBs on gastrointestinal function 
and how local effects might contribute to some of the health benefits associated with flax 
consumption17, 18. The overall objective of this research is to have compelling preclinical data to 
support the significance of flaxseed consumption to aid in pathologies like IBD and 
hypercholesterolemia. This will be carried by the study of local effects of flaxseed bioactives on 
intestinal function and to what extent this can be used to ameliorate chronic diseases like IBD and 
hypercholesterolemia. In addition, my research involves establishing the initial basis for their 
usage in a human clinical trial as an add-on supplement or nutritional intervention.  
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1.2 LITERATURE REVIEW 
1.2.1 Flaxseed  
Flax (Linum usitatissimum) is a name originating from a combination of a Celtic (lin; thread) 
and Greek word (usitatissimum; the most useful). Flaxseed has been used historically for several 
purposes like industrial oil, food, and as a source of fiber production19. In Canada, flaxseed is a 
major economic crop, especially in Saskatchewan, with an average production of 584 thousand 
tons yearly as the country`s leading province of flax production20, 21.  
Flaxseed has been widely studied for health benefits like improving lipid profiles, diabetic 
conditions, and in distinct types of cancer22-24. Flaxseed is composed of 28% dietary fiber, 41% 
oils, 21% proteins, lignans, and minerals along with some vitamins, carbohydrates, and negligible 
amounts of cyanogenic glycosides and other compounds25. Several components have been 
proposed to elicit the biological activities attributed to flaxseed, explicitly attributed to its three 
major components, omega-and alpha-linolenic acid (ALA), soluble and insoluble dietary fibers, 
and lignans. A fourth significant component of flaxseed, the cyclic peptides LOBs, have gained 
recent interest as potential bioactive compounds that add an important contribution to the health 
benefits of flax10, 26. These bioactive components exhibit a wide variety in chemical structure and 
their reported pharmacological activities encourage a more detailed and thorough scientific 
investigation of individual components for their significance in individual disease states. 
1.2.1.1 Flaxseed historical applications 
Flax is believed to be native to the areas eastern to Mediterranean basin and thought to be first 
domesticated in the Fertile Crescent27. Flax, which is also known as linseed when used in feed and 
clothing industry28, has been widely used for several purposes including clothing (linens), dyes, 
paper and burial chambers dating back to about 3000 B.C.13, 27. Previously, flaxseed was 
recognized as a good source of industrial oil and fiber but has been replaced in the United States 
by cotton after the 1940’s27. However, in the past two decades flaxseed gained major interest as a 
nutritional supplement or functional food due to the discovery of several pharmacologically active 
ingredients. 
1.2.1.2 Flaxseed and health promoting components 
Current knowledge of flaxseed extracts shows that the oil and seed coat have major 
components involved in health benefits29. Distribution of several flaxseed components is 
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summarized in table 1.1, where the main constituents are moisture, fiber, nitrogen containing 
compounds, and oil. Specific elements that are known to elicit health benefits like ALA is present 
in flaxseed oil products at significant levels, while the plant lignan, secoisolariciresinol diglucoside 
(SDG), which exists as a complex and produce mammalian lignans, enterodiol (ED) and 
enterolactone (ENL), through colonic fermentation, is present in the seed hull22. Flax contains 
considerable levels of soluble and insoluble fiber, which are considered beneficial for the bowel 
and for the maintenance of healthy intestinal microbiota30, 31. Finally, the previously discovered 
cyclic peptides14, 15, 32, have undergone more significant investigation recently warranting a 
renaming of these peptides to LOBs33. Furthermore, LOBs extracted from flaxseed are presented 
in large variations; Burnett et al. quantified up to 25 different LOBs extracted from flaxseed34. 
These compounds are found mainly with the nitrogenous components in the cotyledons and 
embryo of the seed, and can be extracted with the lipophilic part of flaxseed29.  
Table 1.1 Different components of flaxseed and their distribution within the whole seed. Table 
adapted from Shim et al. (2014)29. 
 
Inherently to natural products that are available in the market, there is a lack of standardization 
of constituents, and flaxseed is not an exception. In clinical and in vitro studies, we observe these 
variations as well. For example, Pan et al  reports in a cross over trial using 360 mg/day lignan 
without identifying of the type of lignans included, neither their ratios in the final product, creating 
a difficulty to reproduce their results in other labs2. This comes in addition to the natural variations 
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in different cultivar in different areas at different times of cultivation35.  With this variation in the 
bioactive components of flaxseed, it is a pivotal process to refine flax products and standardize 
natural products in order to attain maximum benefit and proper correlation between observed 
effects and content utilized. Typical drug regimens are composed of one molecule. Conversely, 
natural products are more frequently produced as a mixture. Mixtures in natural products are 
believed to elicit multiple pharmacological activities and target several targets, providing superior, 
safe health promoting activities. The term used for multiple targeting, in this case, is “multi-
targeted phytotherapeutics”36. Owing to the complexity of diseases like cancer, diabetes, 
hypertension and autoimmune disease, it is believed that targeting several pathways is a better 
substitute to the ‘one drug-one target’ classic approach37. At the core of phytomedicine is the 
understanding that multicomponent therapy imparts strong synergistic or additive effects, where 
historically, extraction processes of the natural medicine enrich multiple components rather than a 
single component38.  
1.2.2 Pharmacological mechanisms of flaxseed derivatives 
Current knowledge of flaxseed extracts reveals a strong association in several chronic 
diseases. These activities can be attributed to significant anti-inflammatory activity, 
immunosuppressing potential, antioxidant activity and a debatable sex hormone modulating 
effects.  
1.2.2.1 Anti-inflammatory potential 
The anti-inflammatory effect of flaxseed is reported in the context of post-menopausal 
women, lipid profile abnormalities, and cardiovascular diseases8, 39-41. The exact mechanism is yet 
to be evaluated for each component of flaxseed, but reports on cyclooxygenase-2 (COX-2) 
inhibition and its inflammatory cascade is abundant in literature. Flaxseed ALA is specifically 
associated with COX-2 inhibition42, in addition to inhibition of nitric oxide production and via 
Nuclear Factor Kappa-B (NF-κB) and Mitogen-Activated Protein Kinase (MAPK) Pathways43. 
With respect to lignans, the mammalian lignan metabolite, ENL, is similarly associated with NF-
κB modulation and subsequent inhibition of inflammatory cytokines44. 
1.2.2.2 Immunosuppression  
Flaxseed cyclic peptides (LOBs) are a major contributor to the immunosuppressive activity of 
flax45, 46. LOBs are not as well studied as compared with other flaxseed constituents. One LOB, 
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LOB-A was synthesized and evaluated among other LOBs for immunosuppressant activity in 
mouse splenocytes and suppressed its proliferation46. This superior activity for LOB-A was 
attributed to the amino acid phenylalanine (Phe) at position number 4 in the cylic-peptide46. In 
addition, LOB-A has undergone limited investigation in vitro and in an animal model of humoral 
immunity to assess its immunosuppressive effects. In this model, LOB-A combined with 
methotrexate (MTX), a well-known immunosuppressant used in post xenograft transplant 
surgeries, improved graft rejection outcomes47.  This immunosuppressive activity was compared 
to cyclosporine A (CsA) capacity to inactivate T-lymphocytes, which are major players in graft 
rejection, suggesting that co-administration of LOB-A and CsA will reduce the dosing 
requirements of CsA10 and thus protect from potential side effects. The exact mechanism of action 
for LOB-A is not entirely understood. It is postulated to bind to cyclophilin A, a protein that is 
believed to inhibit calcineurin production that, in turn, prevents graft rejection10. Siemion et al 
studied LOB-A and compared it against several other structural analogues like antamanide, 
cycloamanides, hymenistatin, hymenamides and Cyclosporin, to understand what segment of the 
peptide results in the immunosuppressive activity48. Results from this study confirmed the 
importance of Phe, but also emphasized the need for a Proline-Hydrophobic amino acid-Phe 
sequence as an important player in this activity48. Finally, as an application for the use of LOB-A 
as immunosuppressant it has been investigated for its antimalarial activity and found to have 
advantageous activity49.  
1.2.2.3 Anti-oxidant activity 
The flaxseed lignans demonstrate anti-oxidant activity which is attributed to their diphenolic 
nature50. The antioxidant activity of lignans is due to their capacity to scavenge free radicals 
through donation of a hydrogen (primary antioxidant function)51 or by modulation of superoxide 
decomposition and enzyme regulation (secondary antioxidant mechanism)52. For lignans, anti-
oxidant activity is reported to be highest with the mammalian lignans, ENL and END, and lower 
with SDG53. The lignans of flaxseed have demonstrated antioxidant activity in in vitro models 
such as the 2,2`-azobis (2-amidinopropane) dihydrochloride (AAPH) peroxyl radical-induced 
DNA damage model52 and polymorphonuclear leukocytes (PMNLs)54. 
The primary antioxidant activities of the plant lignan, SDG, and the mammalian lignans, END 
and ENL, were evaluated in both lipid and aqueous in vitro systems. The three lignans significantly 
(p-value  ≤ 0.05) inhibited linoleic acid peroxidation at both 10 and 100 μM over a 24-48 h of 
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incubation period53. This antioxidant behavior is likely chemically attributed to benzylic hydrogen 
abstraction and potential resonance stabilization of phenoxyl radicals in an aqueous environment 
and occurs at concentrations that are considered to be achievable in vivo52. Whether it is benzylic 
hydrogen abstraction or resonance stabilization, most studies showed the need for micromolar 
concentrations of lignans to elicit an antioxidant effect52-55. 
1.2.2.4 Sex hormone modulation 
Lignan effects on sex hormones stems from its structural similarity to estrogen56. Further 
analysis on lignan binding to sex steroid binding protein ranked the lignans with highest to lowest 
inhibitory effect as follows: ENL followed by Nordihydrogaiaretic acid, Equol and Genistein56. 
This effect granted the nomenclature of phytoestrogen to lignans. 
Sex hormone activity modulation is unique to the lignan component of flaxseed. In a 
randomized cross-over study performed in post-menopausal women, flaxseed fortified diet 
reduced the concentrations of circulating 17-β estradiol, estrone and increased prolactin57. Also, 
significant positive correlation (participant on conventional diet) between ENL excreted in urine 
and Sex Hormone Binding Globulin (SHBG) in blood was observed58. Binding of lignans to SHBG 
is believed to disrupt its interaction with dihydrotestosterone, which is thought to reduce 
proliferation in prostate cancer cells59, 60. In addition, inhibition of aromatase (an enzyme that 
converts testosterone to 17-β estradiol) was seen in human preadipocytes cells, suggesting a 
significant role in both estrogen and testosterone plasma concentrations61. Sex hormone 
modulation is associated with several cancers including breast and prostate cancers. Furthermore, 
they are involved in cholesterol metabolism and distribution in different body tissues.  
1.2.3 Flaxseed in chronic diseases 
Flaxseed intake has been linked to several benefits in chronic disease amelioration such as 
cancer, cardiovascular disease, and inflammatory conditions. 
1.2.3.1 Colorectal, breast and prostate cancers 
Phytoestrogen containing natural products and standardized supplements such as flavonoids 
and lignans have shown significant improvement in cancer such as colon, breast and prostate62, 63.  
Colorectal cancer is considered the second most common type of cancer in men and third in 
women, and ranked as the third cause of cancer-related deaths worldwide64. Several modifiable 
risk factors can be controlled to reduce colorectal cancer risk, and among those factors are obesity, 
8 
 
physical activity and consumption of red and processed meat65, 66. As a cancer related to the 
gastrointestinal system, it is pivotal to evaluate and understand the influence of dietary intake on 
such a neoplastic disorder. In colon cancer, unlike ω-6 PUFA, ω-3 fatty acids like ALA and the 
other mammalian lignans ENL and enterodiol (END) can reduce the size of the tumor in 
azoxymethane-induced colon cancer animal model67. ENL induced apoptosis and decreased cell 
proliferation in Colo-201 human colon cancer cells both in vitro and in vivo68, 69 when administered 
in doses of 10 mg/kg three times weekly in athymic mice, assuring a considerable safety profile in 
such range. In contrast, clinical trials in humans did not support the correlation between END (no 
lignans were intentionally administered, just circulating dietary products) plasma concentration 
and risk reduction in colorectal cancer. Moreover, an increased risk was noted in the smoking 
population70. This discrepancy between clinical and bench results urges further investigation to 
understand the effect of flaxseed lignans against colorectal cancer.  
In breast cancer, nutritional intervention with lignan-containing derivatives has been 
demonstrated clinically to reduce circulating tumor markers, size and metastasis, especially in 
postmenopausal populations in contrast to premenopausal5. Generally, clinical trials assess 
circulating levels of the mammalian lignan ENL as a metabolite for the parent lignan, SDG71, 72. 
One of those prospective clinical studies (evaluating lignans from conventioanl diet) pursued a 
follow-up of ENL concentrations for a median of 6.1 years to find that postmenopausal women 
with ENL concentrations equal to or exceeding 21.4 nmol/L lived longer than those who had 
circulating ENL concentrations less than 17 nmol/L. In general, the clinical literature identifies a 
possible important role of dietary intervention in chronic diseases.  
The prostate is a gland related to the endocrine system and due to its involvement in sex 
hormone production and secretion, the prostate is affected by estrogen receptor modulation. As 
weak phytoestrogens, lignan consumption might modulate hormone receptor function in prostate 
cancer73, but thus far clear, conclusive data does not exist. Prostate cancer and flaxseed studies 
have not been consistent globally. Clinical trials in the United States positively correlate ENL 
(from diet) levels with reduced prostate cancer risk74. In Nordic countries, though, this correlation 
was insignificant, but with several drawbacks on study design that included the lack of dietary 
monitoring and follow up75. Plasma insulin-like growth factor-I (IGF-I) has been associated with 
increased risk of prostate cancer76. In a rat model of breast cancer, flaxseed extract showed unique 
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ability to reduce IGF-I suggesting that modulation of IGF-I might be another possible mechanism 
in addition to estrogen receptor modulation to reduce the risk of prostate cancer76.  
Several mechanisms of action were proposed to explain the activity of flaxseed extract in 
cancer, including inhibition of growth factors, alteration of angiogenesis, and increased apoptosis 
through modulation of estrogen metabolism and estrogen receptor-related growth pathways77. 
Flaxseed oil that is rich in ALA is thought to provide its effect through activation of transcriptional 
factors like NF-κB and peroxisomal proliferator-activated receptors (PPARs) that would, in turn, 
influence cellular proliferation, angiogenesis, and differentiation. Moreover, increased 
peroxidation of ALA and other related ω-3 Poly Unsaturated Fatty Acids (PUFA), 
Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA), is assumed to be responsible 
for reduced tumor size and growth77. This same study also revealed a vital outcome, where co-
administration of either flaxseed or its oil and anti-cancerous agents will not negate the activity of 
drugs like Tamoxifen and Trastuzumab, but rather enhance their effectiveness during the course 
of treatment.  
Despite that mechanistic variations of biological activities in flaxseed, different bioactives of 
flax have been reported to have distinct effects in different tumor environments. For example, 
ALA is more efficient in MCF-7 breast cancer when estrogen levels are high, while SDG is more 
potent when estrogen levels are low78. These pronounced variations in mechanisms and tumor 
susceptibilities suggest the possible capacity of flaxseed bioactives to be involved in multiple 
pathways of protection against cancer, in particular, and possibly other chronic diseases.  
In addition to studies involving breast, prostate, and colorectal cancer in animal models and 
human clinical studies, flaxseed lignan consumption is positively correlated with reductions in 
other tumor models.  For example, in a dimethylbenzanthracene tumor induction animal model, 
administration of the flaxseed lignan, SDG, resulted in a 37% reduction in the number of tumors 
per tumor-bearing rats4. Collectively, these consistent reports in animal tumor models favor the 
translational potential of flaxseed utilization in the animal model as a means to extrapolate its 
benefits to humans. 
1.2.3.2 Flaxseed and cardiovascular health 
1.2.3.2.1 Flaxseed and risk factors of cardiovascular disease 
 Cardiovascular disease (CVD) is a leading cause of mortalities worldwide. It has two major 
classes, Coronary Heart Disease (CHD) and Coronary Artery Disease (CAD), both associated with 
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several chronic diseases like diabetes, atherosclerosis, hypertension and dyslipidemia with its 
variations79. Risk factors responsible for CVD include smoking, diet, gender, blood pressure, and 
chronic inflammation80. The use of flaxseed products to modulate risk factors of cardiovascular 
disease has undergone extensive study in vivo and in vitro. Among those risk factors are blood 
pressure, glucose levels and cholesterol11, 12, 30, 81-85. 
1.2.3.2.2 Cardiovascular health and hypercholesterolemia 
Hypercholesterolemia has been widely studied from a nutritional aspect as a significant 
cardiovascular disease risk factor, and the long-term correlation between nutrition, obesity and 
CVDs is well established86. Nutritional intervention with low-carbohydrate diet improved 
atherogenic dyslipidemia even when weight loss is absent87. Similarly, National Cholesterol 
Education Program in Canada approved lifestyle change that embodies exercise and decreased 
intake of saturated fatty acid in addition to supplements like fish oil, oat bran and plant sitosterols 
as these interventions are considered to be efficacious in reducing cholesterol levels in those 
diagnosed with dyslipidemia88.  
Several therapeutic classes are in the market to help reduce circulating harmful cholesterols 
and lipids including statins, fibrates, bile acid binding resins and cholesterol absorption inhibitors. 
Statins are first-line agents in the treatment of dyslipidemias. Statins act by inhibiting HMG-CoA 
reductase, the enzyme that controls the production of cholesterol89. Only 50% of patients attain 
their target cholesterol levels upon the administration of statins, with differential responses among 
different statins90. This drawback combined with the side effects associated with statins like 
rhabdomyolysis, myositis, neuropathies and liver function alteration compel further investigation 
into safer and more effective medications in an attempt to reduce mortalities and morbidities 
associated with dyslipidemia89.  
Fibrates are peroxisomal proliferator-activated receptor alpha (PPAR-α) agonists. PPARs are 
nuclear transcription factors that induce the expression of several proteins and genes that are 
important in lipid homeostasis91. Fibrates are used to treat hypertriglyceridemia and mixed 
hyperlipidemia as they can reduce TGs and increase HDL-C92. Fibrates provided the maximum 
benefit when they are added to statins in order to improve HDL-C93. 
Bile acid sequestrants act by binding to bile acid in the gut resulting in a reduction of low-
density lipoprotein-cholesterol (LDL-C) by increasing the production of LDL-C receptors in the 
liver. Receptor upregulation increases liver capacity to clear cholesterol metabolites. However, the 
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bile acid-binding resins interact with the absorption of lipid soluble vitamins and other critical 
nutritional elements like iron, folic acid, and magnesium. This interaction may require more 
attention in patients suffering from imbalances in those vitamins and minerals92.  
Ezetimibe is a cholesterol absorption inhibitor that acts by binding to Niemman-Pick C-1 like 
1 (NPC1L1) protein. It is used as an add-on medication to statins in order to improve LDL-C 
levels94. Ezetimibe is very well tolerated and is not associated with side effects that would affect 
its adherence or long term functionality, but yet not thoroughly studied 92.   
Lipid lowering agents have been available on the market for a while now, as they confer 
favorable effects to reduce the incidence of atherosclerosis and consequently CVD events in half 
of the population suffering from impaired lipid profiles (case specific to statins)95. The urge to 
bring more lipid-lowering agents is justified by the need to provide more effective drugs with 
reduced potential of adverse events92.  
1.2.3.2.3 Interventional cholesterol reduction studies 
A- Animal studies 
 Different types of studies have been performed in animals, where either flaxseed extract 
complex or a purified lignan component was administered. Prasad et al. reported that chronic 
administration (4 months) of flaxseed complex to rabbits resulted in reduced serum lipids and 
aortic atherosclerotic events84. Similarly, Syrian Hamsters treated for 120 days with flaxseed 
extract (contains fiber, ALA, and lignans)  showed reduction of plasma cholesterol but surprisingly 
increased triglyceride (TG) levels83. Previously published research in our laboratory investigated 
the effect of the lignans, SDG and secoisolariciresinol (SECO), in hyperlipidemic rats, after 
induction of nutritional hypertriglyceridemia by 10% fructose and hypercholesterolemia by 1% 
cholesterol. This study concluded that flaxseed lignans could reduce LDL-C and total cholesterol 
in serum, but had no effect on TG levels, which is consistent with sesamin (a sesame seed lignan) 
results in an LDL-receptor knock out animal model12. The exact mechanism of action is not 
understood, but hepatic regulation of lipid homeostasis through well-known possible targets were 
excluded12. 
 Enterolactone was investigated in metabolic syndrome. Urinary excretion of lignans, and 
specifically ENL, was positively correlated with increases in HDL-C and reduction in LDL-C but 
had no influence on other parameters like waist circumference or blood pressure96. Previous 
studies have directly correlated the concentration of enterolignans (ENL and END) excreted in 
12 
 
urine to increased HDL-C levels and reductions in TG, while LDL-C levels were not substantially 
affected in 1492 U.S adult hypercholesterolemic patients97. Furthermore, a dose-response 
correlation was observed between SDG extract consumption and blood levels of SECO, ENL, and 
END and cholesterol lowering capacity11. SDG might protect liver function as oral SDG 
administration is correlated with decreased Gamma Glutamyl Transpeptidase (GGT) levels (an 
enzyme that is activated in liver injury)82. Furthermore, in clinical trials of moderately 
hypercholesterolemic patients (see table 1.2), dosing with SDG improved lipid profiles through 
significant reductions in LDL/HDL ratios, suggesting that it has multiple effects on cholesterol 
transport in the systemic circulation.  
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B- Human interventions 
 
Table 1.2 Summary of clinical experiments that used flaxseed lignan enriched products to observe changes in lipid profile. 
 
Reference  Dose 
 
Study 
population 
Duration 
in weeks 
N HDL-C 
change 
LDL-C 
change 
Tri-glycerides Total 
cholesterol 
Pan et al. 
(2007)2 
SECO 124 mg 
(360 mg SDG) 
/ capsules 
Diagnosed 
with type 2 
Diabetes and 
>2.9 mmol 
LDL-C 
12 73 -0.77 
mg/dL 
-4.25 
mg/dL 
-17.70 mg/dL -6.56 mg/dL 
Hallund et 
al. 
(2006)98 
SECO 172 mg 
(500 mg SDG) 
/ muffins 
Healthy post-
menopausal 
women 
6 22 -1.54 
mg/dL 
-7.72 
mg/dL 
3.5 mg/dL -8.88 mg/dL 
Zhang et 
al. 
(2008)11 
SECO 103 mg 
(300 mg SDG) 
/ tablets 
Hypercholester
olemic Patients 
8 18 -3.86 
mg/dL 
-28.6 
mg/dL 
-46.0 mg/dL -39.8 mg/dL 
Cornish et 
al. 
(2009)99 
SECO 187 mg 
(543 mg SDG) 
/ tablets 
Men over 50 
and post-
menopausal 
women 
26 
26 
92 
49 
N/A N/A N/A 
Increased 
No effect 
1
3
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1.2.3.3 Inflammatory diseases (Inflammatory Bowel Disease (IBD) 
1.2.3.3.1 Nutritional Intervention in IBD 
Among the numerous biological effects of flaxseed bioactives, these compounds have been 
reported to exert anti-inflammatory effects. This activity is considered important in diseases that 
have inflammation as a critical player in their pathologies like cancer, cardiovascular disease, and 
inflammatory bowel disease52.  
IBD is viewed by both clinicians and patients to be influenced directly by the type of dietary 
regimen patients are adhering to. Yet, there are no comprehensive recommendations on what type 
of diet might reduce antigen exposures or alter gut microbiota to improve intestinal barrier 
integrity100. Different types of food have resulted in a variable effect on intestinal inflammation. 
Refined sugar and high fat/high protein diets are associated with exacerbated intestinal 
inflammation101. Dietary linoleic acid, which is one of the main components found in flaxseed, has 
been related to the improvement of ulcerative colitis in human clinical trials102. On the other hand, 
dietary intake has an indirect effect on intestinal microbiota, which in turn significantly influences 
barrier integrity and immunity31, 103. To this date, there are no clear nutritional intervention 
guidelines that help mitigate signs and symptoms of IBD.   
1.2.3.3.2 Inflammatory Bowel Disease (IBD). 
 Inflammatory bowel disease (IBD) is characterized by idiopathic chronic inflammation 
along the intestine with varying locations and clinical presentations and is subdivided to Ulcerative 
Colitis (UC) and Crohn`s Disease (CD). IBD’s unclear multifactorial etiology could be correlated 
to variable environmental, genetic, cellular, and immunological factors104. While UC 
manifestation is limited to the intestinal mucosa, CD inflammation extends transmurally. CD also 
shows histological granulomas and intestinal thickening localized to the proximity of the colon, 
unlike UC that has a more continuous presentation overall in the intestine105. 
 Internationally, IBD has a prevalence rate of 369/100,000106. In Canada, 9,200 cases of IBD 
are diagnosed every year and 55% of cases are CD. In 2008, 201,000 patients (0.5% of population) 
suffered from IBD, 112,000 with CD and 88,500 with UC107. Canada ranks among the highest 
prevalence rates worldwide of IBD108 and just after New Zealand with an incidence rate of 
13.4/100,000 for CD104. Canada spends more than $1.8 billion yearly to cover costs associated 
with the health management of IBD patients. This cost is segmented to direct costs, which include 
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hospitalization, treatment, and clinic visits, and indirect costs that comprise more than one billion 
dollars to compensate lower labor participation, patient pocket money, and short-term work 
absence107, 108. 
Like other autoimmune diseases and chronic inflammatory disorders, IBD is characterized by 
complex interactions between anatomic, genetic factors, environmental conditions, and the 
immune system109, 110. Therefore, a multitude of defense mechanisms have evolved to protect the 
intestinal epithelium. Those mechanisms orchestrate to maintain a healthy intestinal epithelium 
with high integrity, and reduced inflammatory status is generally categorized under; 1- Innate and 
2- Adaptive immune response111. Functional participation of innate immunity, adaptive immunity, 
and intestinal microbiota in the intestinal epithelium is critical for our understanding of both the 
pathogenesis and possible targets for bioactives that might alter the intestinal epithelial functions.  
• Innate Immune response 
 The gastrointestinal capacity to secrete acidic juices, mucus, non-specific antibodies and 
digestive enzymes helps to kill non-host substances. In addition, peristaltic contractions reduce 
intestinal epithelial exposure time to noxious substances in the intestinal lumen112. Together these 
comprise the innate immune defense. Furthermore, production of chemokines and recruitment of 
white blood cells, followed by the release of cytokines and reactive oxygen species (ROS) will 
counteract the invading organism or particle, but such interactions may result in long-term 
activation of tissue damage and repair cycles, which will eventually trigger the adaptive immune 
response. To summarize, innate immunity in the intestine is primarily granted by intestinal 
mucosal layer, the intestinal epithelium barrier itself, oxidative stress, and immune cells like 
macrophages and dendritic cells113 
A. Mucosal layer  
 Mucus is mainly composed of three principal components; mucin, a glycoprotein that is 
encoded by MUC2 gene and produced by goblet cells; trefoil factors (TFF), a group of 
polypeptides that are protease resistant; and secretory IgA (sIgA). Disruption of those three factors 
is considered as a fingerprint for development of IBD114. 
 The intestinal mucosa is considered the first line innate immunity checkpoint against invading 
microorganisms and noxious particles. Secretory antibodies (sIgA) and the viscosity of mucin 
lining the mucosa (due to mucin itself) that concomitantly assist in trapping microbes and exposing 
them to antimicrobial agents produced by the intestinal epithelial cells add to the first line defense 
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of the mucosa114, 115. This function is boosted by pattern recognition receptors (PRR), such as toll- 
like receptors (TLR), retinoic inducible gene I like receptor (RLR), and nucleotide oligomerization 
domain-like receptors (NLR), that will modulate the production of mucus and simultaneously 
trigger the adaptive immune response115, 116. Each of those receptors will initiate different defense 
mechanisms. For example, the activation of NLR and TLR will induce NF-κB, which turns on the 
nuclear production of cytokines and pro-inflammatory responses, a function that will elicit an 
adaptive immune response116. As well, pattern recognition receptors functionally initiate intestinal 
epithelial secretion of antimicrobial agents like defensin, calprotectin, cathelicidins, and 
antimicrobial polypeptides, an important component of the innate immune system110, 117. The 
mucus layer’s inherent functionality is complemented with intestinal peristaltic contractions. 
Those contractions will help reduce the exposure time to noxious materials and, hence, 
mechanically reduce possible inflammatory triggers111, 118. 
B- Intestinal Barrier 
 The intestinal epithelium functions to protect the internal milieu of the body from luminal 
noxious materials like nutrients, microbes, and drugs. This protection is maintained through 
several mechanisms. Anatomically the intestinal epithelium is a polarized epithelium composed of 
a single layer of cells achieving a barrier between the external environment and the body and 
transport across this barrier is mediated through different mechanisms that allow selective 
movement of molecules based on their physicochemical characteristics119. The intestinal barrier 
maintenance is granted by tight junctions that prohibit paracellular flux of intestinally localized 
components and vice versa120. Tight junctions consist of clustered proteins including zonulin (ZO)-
1, -2 and -3, cingulin and 7H6, and the transmembrane proteins occludin and claudin121. 
Furthermore, protection is maintained  by the presence of a microenvironment in close vicinity to 
the epithelial cells composed of an unstirred layer of water, glycocalyx, and mucus layer containing 
secreted antimicrobial agents and immunoglobulins, which act as the first line of defense that is 
boosted by the innate immune response of the intestine122. 
C- Dendritic cells and Macrophages 
 Mononuclear phagocytes are divided into macrophages and dendritic cells. These cells 
physiologically emerge from the monocyte that comes from myeloid lineages. Macrophages are 
more prominent on both sides of the intestinal epithelium (basal and apical) and are maintained 
through the maturation of monocytes that are introduced to the intestine via the lymphatic 
system123. Dendritic cells (DCs) are surveillance cells able to recognize harmful and harmless 
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constituents in the gastrointestinal luminal space by sampling the exterior environment. Depending 
upon the stimulus, DCs either stimulate adaptive immune response or repress possible 
inflammatory status based on the antigen sampled109, 124. This possible activation of adaptive 
immunity is governed by interaction with tissues and cells like Pyere`s Patches (PP), Mesenteric 
Lymph Nodes (MLN), and Isolated Lymphoid Follicles (ILF)111, 125. Upon activation, 
differentiation of T-cells to Foxp3 + T-regulatory cells occur as a result of TGF-β and retinoic 
acid. This, in turn, leads to the production of IgA, which is a critical part of the innate immune 
response126-128. 
 DCs vary significantly depending upon the type of integrin attached to the DC. CD103+ DC 
are thought to be the cells responsible for sampling antigens, and subsequent up-regulation of 
inflammatory markers and maturation of lymphoid structures rich with T-lymphocytes and B-
lymphocytes125, 129, 130. Intestinal CD103+ DC are mostly involved in an immune suppressive 
activity in the intestine, as they can stimulate the production of thymic stromal lymphopoietin, 
which inhibits Th17 and allows the differentiation of Treg cells109, 131. Treg shares the 
responsibility of homeostasis; CD4+CD25+ Treg cells maintain homeostasis through screening of 
self and non-self-antigens, which was found to activate the anti-inflammatory cytokines IL-10 and 
TGF-β (see figure 1.1). Moreover, Treg cells regulate the expression of Foxp3+  transcription 
factor that influences the production of IL-10 that would aid in suppressing the immune respone128, 
132, 133. 
 Integrins are also expressed on macrophages and variants include CD11c, 11b, and CX3CR1 
macrophages134, 135. The subtype (CX3R1) is characterized by a relatively short half-life, which is 
estimated to be three weeks136. This subtype is responsible for sampling from the intestinal lumen 
while they reside in lamina propria. This process is called trans-epithelial sampling, where 
dendritic extensions from mature macrophages paracellulary pass toward the lumen and sense non-
host substances and samples them, a function that is critical in maintaining the balance between 
intestinal microbiota and host defense124. Depending on the antigen source whether it is bacterial, 
parasitic or others, different cellular lineages will be activated accordingly. The following figure 
summarizes the interaction between APCs, cells activated and cytokines produced and their 
corresponding effector cells that will be activated (Figure 1.1). 
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Figure 1.1 Depiction of different cells that are involved in maintaining immunological 
homeostasis in the intestine. Several noxious materials will initiate different immunological 
responses. Intestinal Epithelial Cells (IEC) join with Antigen Presenting Cells (APCs) to 
stimulate both innate and adaptive immune responses and result in the production of cytokines 
and inflammatory mediators. The predominant effect of mucosal recovery is highly attributed 
to the activity of Treg cells and their corresponding cytokines, IL-10 and TGF-β, in addition to 
Foxp3+ transcriptional pathway. 
 
D- Oxidative stress and IBD 
 Prolonged production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) 
signaling might magnify the oxidative process and, thus, reduce barrier integrity and eventually 
lead to the pathogenesis of IBD137. Oxidative and nitrative damage to cells occurs through DNA 
breakage, damage, and mutation emergence. DNA damage will progress toward carcinogenesis in 
animals and humans; this damage is caused by continuous chronic exposure to radicals where 
natural cellular repair mechanisms start to malfunction138. Several enzymes and endogenous 
molecules with redox activity (e.g. superoxide dismutase-1 (SOD-1), catalase, glutathione 
peroxidase-1 and 2, reduced glutathione, ascorbic acid, carotenoids) are clinically correlated to 
IBD as biomarkers for disease severity55, 139-142. Also, thioredoxin and aquaporin have reportedly 
increased activity in response to inflammation and are suggested to be a protective mechanism 
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against persistent inflammatory status in IBD142, 143. Intestinal epithelial cells, macrophages, and 
lymphocytes are all involved in the generation of ROS and RNS as a part of their natural defense 
mechanism137.  
 Intestinal epithelial cells are equipped with Toll-like receptors (TLRs) that are capable of 
identifying pathogenic organisms, and signaling activation of cytokines and chemokines through 
the activation of NF-κB144, 145. In clinical scenarios of ischemia and reperfusion, a state of oxidative 
stress is developed and results in tissue damage146. Interestingly, the TLR-4 agonist, Lipo-
polysaccharide (LPS), will provide protection in intestinal ischemia by reducing intestinal 
permeability, lipid peroxidation, and glutathione depletion147. The dual role of LPS and TLRs 
suggests a homeostatic role of TLRs to maintain oxidative stress pathways. 
 Macrophages produce high amounts of peroxynitrite (ONOO-) and H2O2 in response to an 
inflammatory stimulus137, in addition to other cytokines like TNF-α and IL-1β148, 149. This 
excitatory state is mainly inhibited by IL-10, which results in reduced heme oxygenase and TNF-
α expression through p38 MAPK pathway150. This generation of different oxidation generators by 
macrophages is attributed to the pathogenesis of IBD151, 152. Therefore, macrophages are crucial in 
initiating oxidative stress, inflammation, and later in recruiting other inflammatory mediators.  
 Lymphocytes that are resident in the lamina propria (the layer between intestinal epithelium 
cells and muscularis mucosa) are recognized to play a role in thioredoxin expression153. 
Thioredoxins are the major cellular protein disulfide reductases. They serve as electron donors for 
enzymes such as ribonucleotide reductases, thioredoxin peroxidases (peroxiredoxins), and 
methionine sulfoxide reductases, and, therefore, thioredoxins have multiple biological functions 
like protection against oxidative stress, control of growth, and activation of cytokine production154. 
Upon stimulation of the lamina propria, T-cell activation of the enzymatic activity of thioredoxin 
is elevated, which modulates oxidative stress in the intestine153. Increased expression of 
thioredoxin results in increased resistance to the immunosuppressive activity of CsA, and, 
therefore, again confirming the sensitivity of the intestinal microenvironment153. 
 Although basal levels of nitric oxide (NO) are necessary for the maintenance of intestinal 
homeostasis, enhanced NO production is also correlated with IBD progression. Two enzymes are 
involved in the production of NO, inducible nitric oxide synthase (iNOS) and eNOS, which is 
produced constitutively in many cell lineages137, 155, 156. When challenged by dextran sodium 
sulfate (DSS: colitits model), mice that are deficient in both iNOS and eNOS showed a progression 
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of the disease and higher disease activity scores155, 157. In humans, iNOS deficiency is also 
considered a marker for chronic progression of disease activity, increasing leukocyte adhesion and 
disruption of barrier integrity158.  
• Adaptive Immune response 
 Both innate and adaptive immune responses often function at the same time and behave 
simultaneously to achieve homeostasis in the intestine and prevent the emergence of unnecessary 
excessive inflammation. A significant crosstalk between different cell types including epithelial, 
endothelial, and leukocytes is necessary to assure immunological homeostasis in the 
gastrointestinal tract. 
 Historically, T-cells were identified to be a major player in autoimmune diseases, and Th1 
and Th2 were explicitly described to be involved in CD and UC, respectively118. Initially, IBD was 
thought to be solely driven by Th1 activation. This cell type induces the production of IL-12p40, 
a cytokine that has been associated with chronic inflammatory diseases in general118, 159. Recently, 
the activation of a different type of differentiated T helper cells, the Th17, is believed to be also 
critical in autoimmune diseases160, 161. Th17 activation in addition to Th1 activation leads to the 
production of the structurally similar cytokines, IL-23 and IL-12 (IL-23 is a heterodimeric cytokine 
that belongs to IL-12 family that is composed of Il-23p19 combined IL-12p40 subunits)118. This 
activation is mediated by IL-6 and TGF-β, which upon activation induce the expression of retinoic 
acid-related orphan receptor γt (RORγt), which, in turn, increases the expression of IL-23159.  
 Interleukin-23 (IL-23) and its producer cells, Th17, were correlated to several types of 
autoimmune diseases including arthritis, brain, and intestinal colitis160, 162-164. Currently, the 
activation of Th17 is considered a major player in adaptive pathogenesis of IBD. Therefore, several 
therapeutics are currently in clinical trials to target IL-23164, 165. 
 Another important player in both adaptive and innate immunity is Breg cells, especially those 
marked with the integrin CD1d. These cells are abundant in the gastrointestinal tract and lymphoid 
tissue and suppress the immune response through secretion of the anti-inflammatory cytokine IL-
10166. IL-10 achieves its anti-inflammatory protective effect by upregulating the STAT3 pathway 
and IL-1 expression150. 
• Microbiota and intestinal immunology 
 A growing trend of experiments and hypotheses exist suggesting that intestinal commensal 
microorganisms play a role in initiating, maintaining, and determining the phenotype of IBD167.  
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The precise function of the microbiota in the etiology of the disease is largely unknown; however, 
four mechanisms have been postulated to explain the complex relationship between commensal 
microorganisms and IBD: 1- Dysbiosis (microbial imbalance) of conventional microbiota, 2- 
Induction of intestinal inflammation by pathogens and altered microbiota, 3- Host genetic defects 
of maintaining homeostasis, and 4- Malfunctioning host immunregulation167. All these 
mechanisms will result in a persistent antigenic activation for T-lymphocytes and macrophages168.  
Pathologically, IBD is more predominant in the colon and distal ileum, which are both highly 
populated with commensal microbiota169. Dysbiosis in IBD favors an 8-fold increase in the 
mucosal-associated bacteria (aerobic and anaerobic) in patients with IBD in comparison to 
asymptomatic patients170. In addition, the diversity of microbiota in active IBD patients is 
considerably reduced; this presents as a contraction of Firmicutes and Bacteroidetes and an 
expansion of Proteobacteria169.  
Induction of inflammation is considered as a consequence of dysbiosis, but more profoundly 
it is attributed to pathogens171. Intestinal inflammation is induced by species like Clostridium 
Difficile and it's associated toxin-A that is capable of reactivating IBD through inducing apoptosis 
in intestinal epithelial cells172. C. difficile infection, in particular, is clinically typical upon usage 
of broad-spectrum antibiotics, which results in reduced microbiota populations and hence 
considered to be a potential trigger for excessive inflammation. 
 Host genetic polymorphism and mutation are able to influence microbiota populations thus 
causing dysbiosis. The most frequently reported genetic polymorphism associated with IBD is 
related to the intracellular pattern recognition receptor, NOD-2 (nucleotide oligomerization 
domain-2)173. Once mutated, a reduced intestinal capacity to produce cytokines is observed and 
thus an increased population of commensal bacteria, and subsequent dybiosis171. In addition to 
NOD-2, other disease-related genes like ATG16L1, NCF-2 and IRGM would be anticipated to 
reduce luminal and intracellular bacterial killing, and therefore result in dysbiosis that is critical in 
IBD174, 175. 
 Intestinal microbiota also has a beneficial effect on intestinal epithelium integrity. Clusters IV 
and XIVa of clostridium bacteria induce the activation of Foxp3+ Treg cells in the colon, which 
helps the production of IL-10 and TGF-β; both are previously discussed as anti-inflammatory 
cytokines176. Bacteroides fragilis is involved in symbiosis and expressing IL-10 and TGF-β 
through the interaction between LPS of Bacteroides and the (Pathogen recognition receptors) 
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PRRs the TLR-2177. Interestingly, Bifidobacterium longum is capable of secreting acetate as a 
nutrient for intestinal epithelial cells, a protector against E-coli infections and an enhancer of 
barrier integrity178, 179.   
1.2.3.3.3 Current IBD treatments and their limitation 
IBD is attributed to notably increased levels of pro-inflammatory immune modulators like 
TNF-α and INF-γ and specific interleukins. These molecules became targets for different 
pharmacologically active candidates to treat IBD. Currently, IBD intervention involves the use of 
salicylate derivatives, oral corticosteroids, immunosuppressive agents, anti-TNF-α biologics, 
antibiotic therapy, and surgery in refractory cases180.  
A multicenter study to investigate IBD disease outcomes in patients across Europe showed 
that usage of conventional therapies (mentioned above) will result in complete relief of complaints 
reported in 48% of UC patients, and only in 35% of patients with CD181. In adherence predictor 
studies, it was found that patients suffering from IBD and on immunosuppressant medications are 
more likely not to adhere to their medications182. In addition, self-reported non-adherence for all 
IBD medication reaches up to 21% in certain populations183, which generally ranges between 30-
45%184. Patients’ belief and fear of side effect were reportedly listed to be one of the leading causes 
of non-adherence183-185.  
In regards to cost, Canada spends more than $1.8 billion yearly to cover costs associated with 
the direct and indirect health management of IBD107. In the United Kingdom, individual patient 
costs ranged from £73 to £33 254 per six months treatment period, with a mean of £1256 for colitis 
and £1652 for Crohn’s disease186. The addition of Infliximab biologic to patients` management in 
the United States costs a commercial insurer an average of $2,800 for a single dose (every 4-6 
weeks)187. Both public and private sectors suffer from the current high cost of IBD management 
in general and biologics specifically. 
In addition to therapeutic challenges, there is a considerably important challenge in staging 
and diagnosis of disease course. Currently, several biomarkers and their combinations are 
considered to aid diagnosis of IBD including C-reactive protein (CRP), erythrocyte sedimentation 
rate (ESR), fecal lactoferrin, fecal calprotectin and calgranulin C188. In addition, biomarkers to 
distinguish between IBD phenotypes have also been utilized in clinical practice to help assess the 
severity of disease including anti-Saccharomyces cerevisiae antibody, anti-glycoprotein-2, anti-
granulocyte macrophage colony-stimulating factor, anti-neutrophil cytoplasmic antibody, anti-
23 
 
mannobioside carbohydrate IgG antibody, and anti-CBir1189. However, these biomarkers lack 
sufficient sensitivity, and specificity190-192,193, 194 and endoscopy remains the gold standard to 
diagnose and to stage disease severity in IBD patients 189, 195.  
1.2.3.3.4 Use of Flaxseed to mitigate intestinal inflammation 
Several lignans such as Manassantin A and B and saucerneol D and E reduced TNF-α 
expression in LPS induced inflammation (In BV-2 microglial cells) in a dose-dependent manner196. 
Following LPS stimulation of human peripheral blood lymphocytes, ENL and END demonstrated 
a concentration dependent inhibitory effect on Nf-κB with ENL showing greater potency than 
END and thus reducing the potentiation of inflammation44. Furthermore, flaxseed derived products 
that contained ALA were tested against two different expiremental models of colitis to show 
positive outcomes on disease activity indices197. Although several studies have shown the possible 
IBD amelioration potential by lignans, the literature is not as rich when it comes to flaxseed lignans 
or LOBs. Studies that used flaxseed extract showed conflicting results, which could be attributed 
to the extract type used in those studies. For example, in an acetic acid model of colitis flaxseed 
oil was not equivalent to fish oil in regards to amelioration of mucosal inflammation17. Similarly, 
Zarepoor et al. reported exacerbation of acute mucosal injury after three weeks of different flax 
extracts (10% flaxseed, 6% kernel and 4% hull). However, this conclusion was drawn for 10% 
flaxseed but not the other extracts that are considered richer sources of lignans, where 
improvement in disease activity scores was actually observed with the 4% hull extract source. 
These results encourage further investigation on multiple components of flaxseed in IBD to 
identify a flaxseed natural product with a primary effect of amelioration of IBD18.  
1.2.4 Flaxseed natural products (Chemoprevention Vs Chemotherapeutics) 
With its reported pharmacological activities and role in chronic disease, flaxseed has gained 
public attention for its potential use as a sole therapeutic, adjuvant therapy, or chemopreventive 
agent. There is a public shift toward natural products as a safe source of medication due to ease of 
access and higher potential to target several pathways of activity with multicomponent plant 
extracts currently available on the market198.  
The use of health related product falls into two categories; chemopreventive and 
chemotherapeutic, where the latter typically represents the conventional process of drug discovery 
that has rigorous drug regulatory agency oversight on their utilization to help treat diagnosed 
disease. On the other hand, chemoprevention in cancer is defined as “the involvement of chronic 
24 
 
administration of a synthetic, natural or biological agent to reduce or delay the occurrence of 
malignancy199”, a concept that can be extrapolated to other chronic pathologies. Regardless of its 
role as a chemopreventive or chemotherapeutic, a natural product that will be introduced to the 
market has to go through effectiveness and safety evaluations. These requirements compel more 
focused investigations with natural products to promote a better understanding of their biological 
activities, mechanisms, multicomponent effects, and safety in order to substantiate their health 
benefits with more robust scientific support. 
1.2.5 Natural products regulations 
Regulations for NHPs differ from one country to another. In Canada, the Food and Drugs Act 
9 (FDA), governs the marketing of a NHP, which requires approval by the Food Directorate (FD), 
Therapeutic Products Directorate (TPD), or Natural and Non-Prescription Health Products 
Directorate (NNHPD), depending on what class of product is submitted for approval. Health 
Canada defines a NHP as a substance set out in Schedule I or combination of substances in which 
all their medicinal ingredients are listed in Schedule I under the umbrella of homeopathic medicine 
or traditional medicine that is manufactured, sold or presented in the use of: 1)  restoring or 
correcting organic function in humans, 2) modifying organic function by either promoting or 
maintaining health, or 3) diagnosis, treatment or mitigation of disease, disorder or abnormal 
physical function in humans200. 
In order for a NHP to be licensed in Canada, it has to undergo rigorous refinements that are 
regulated in the Natural Health Product Regulation under FDA, which is divided to six parts; first 
part regulates the product license application, second part regulates the site licensing, third part 
regulates Good Manufacturing Practices (GMPs), fourth part involves regulations for clinical trials 
in human, fifth part includes general regulations and finally the sixth part which includes 
amendments and transitional provisions and coming into force regulations201. Once licensed for 
sale in Canada a NHP will be assigned either a DIN-HM (Drug information Number-Homeopathic 
Medicine) or eight digits Natural Product Number (NPN)202. In light of these regulations, and in 
order to supplement flaxseed extracts as chemopreventive products to help ameliorate chronic 
diseases it has to fulfill effectiveness, quality and safety parameters to gain such a status.   
1.2.5.1 Flaxseed product quality 
Standardized natural products extracts are defined by Kunle et al as a “high-quality extracts 
containing consistent levels of specified compounds, and they are subjected to rigorous quality 
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controls during all phases of the growing, harvesting, and manufacturing processes”203. Regulatory 
affairs bodies have not defined standardized natural products, therefore, a plethora of products in 
the market claims standardization without solid evidence. 
For flax there are products that are standardized when it comes to content such as BeneFlax®. 
BeneFlax® is a previously marketed standardized flax product (~ 38% enriched with lignans) 
which went through the requisite quality and GMP processes. This product has gained Health 
Canada and US FDA approval as a standardized flaxseed source. Therefore, it is a potential 
candidate to be used chemopreventive entity that is able to provide symptom relief to moderate 
disease status or for the reduction in the risk for potential pathology. 
1.2.5.2 Flaxseed effectiveness 
The literature is replete with human and animal trial data that supports the possible 
effectiveness of flaxseed extracts. However, the positive effects for many of studies were not 
attributed to standardized products. To satisfy regulatory requirements, additional human and 
animal clinical trials involving standardized flaxseed products are necessary to support efficacy in 
various chronic disease conditions. Although alpha-linolenic acid has been the focus of many 
interventions involving flax, the mammalian lignans and LOBs are gaining more attention for 
further assessment due to more recent discoveries of their potential to mitigate inflammatory 
disease and modulate cholesterol homeostasis10, 204. 
1.2.5.3 Flaxseed safety 
Generally, flaxseed intervention trials in humans did not report any adverse reactions or side 
effects205, 206. In addition, the flaxseed mammalian lignans (ENL and END) or their precursors 
(SECO) have not shown any genotoxic effects in the range of 20-100 µM concentration207. 
 In a major safety randomized double-blind clinical trial where participants aged 49–87 years 
received flaxseed lignan (543 mg/day in BeneFlax®) equivalent to 200 mg of SDG, showed no 
signs of unintended side effects including hypoglycemia and hypotension during the six month 
period of the trial206. Similarly, when tested in benign prostate hyperplasic patients at two dosage 
regimens containing 100 mg and 200 mg SDG for eight weeks showed no adverse events at any 
point of the trial205. In addition to reported clinical trials, Health Canada approves that a minimum 
mass of 13 g of whole ground flaxseed is necessary to claim a cholesterol reduction capacity when 
ingested as food, which also fortifies the safety of the seed and its consumption at relatively high 
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levels208. Further understanding of flaxseed safety and efficacy requires a detailed understanding 
of the pharmacokinetic behavior of the bioactive components of flaxseed. However, despite these 
pronounced safety reports in human clinical trials, an animal study where flaxseed fed to pregnant 
rats resulted in the delivery of low birth weight pups with growth related developmental issues209. 
Such assessments in animals may provide modest evidence to restrict the use of flaxseed lignans 
in pregnant and breast feeding populations209, 210. 
1.2.6 Lignan and Linoorbitide pharmacokinetics 
1.2.6.1 Lignan Pharmacokinetics  
Our understanding of pharmacokinetic behavior is crucial in drug discovery; the more we 
know about drug pharmacokinetic behavior, the more reliable is our pharmacological utilization. 
Flaxseed lignans are not an exception, and their pharmacokinetic behavior is quite intriguing. 
1.2.6.1.1 Absorption 
In the plant, the lignan SDG exists as an oligomer with an average molecular weight of 4000 
Da211. The oligomer units are reported to be linked directly to the glucosyl moiety of SDG by an 
ester linkage212-214. Once in the gastrointestinal tract, the ester linkages are putatively hydrolyzed 
to liberate SDG, with subsequent hydrolysis of the glycosidic bonds for the release of SECO. In 
vitro incubation of SDG with fecal material found different forms of aglycones, suggesting that 
the intestinal microflora can convert SDG into other aglycone forms215. Unabsorbed SECO 
continues to the colon where colonic microflora convert SECO to the mammalian lignans (ENL 
and END). SECO, ENL, and END become available for absorption, which is supported by their 
presence in the systemic circulation216, 217. The structural differences between mammalian lignans 
and plant lignans are mainly the methyl groups on phenolic rings (Figure 1.2). 
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Figure 1.2 The transformation of SDG to SECO (plant lignans) are produced after the ingestion 
of the parent compound SDG initially from the oligomer that is further hydrolyzed to SECO. 
SECO in its turn is converted to the mammalian lignan END by the aid of intestinal microflora. 
END undergoes O-demethylation and dehydroxylation to form ENL. 
 
In vitro studies performed in a Caco-2 cell monolayer demonstrated that END and ENL can 
be transported across the epithelial membrane via passive diffusion and extensively conjugated to 
glucuronide and sulfate (END>90% and ENL>99%) metabolites within 48 h218, 219. Finally, END 
and ENL show a very low bioavailability due to an extensive first-pass effect during absorption 
from the gastrointestinal tract217. 
In the systemic circulation, there is a lack of glycosidic conjugated molecules. This 
observation is not exclusive to SDG, it also extends to isoflavone lignans that are in their glycosidic 
forms, and their bioavailability is largely dependent on β-galactosidase intestinal content220. 
Therefore, it is strongly supported that SDG is converted into aglycone forms of lignans in the 
intestine before being absorbed. This is supported by recent findings where SDG is reported to be 
incapable of passively diffusing across the polarized intestinal epithelium of Caco-2 cell lines, 
unlike the lignans SECO, ENL, and END221. 
Microbial biotransformation of flaxseed bioactives is a prominent process in lignan 
absorption, where several types of microflora are involved in the production of those bioactives222. 
28 
 
Bacteroides and Clostridium O-deglycosylate SDG to form SECO. In turn, SECO undergoes O-
demethylation and dehydroxylation catalyzed by Ruminococcus products and Eggerthella lenta, 
respectively, to form END223. END, then, is dehydrogenated by Lactonifactor longoviformis to 
produce ENL224. Therefore, the processing of orally consumed flaxseed is susceptible to 
considerable inter-individual variation, not only because of different populations of intestinal 
microflora but also to the multiple steps of biotransformation involved. 
A pharmacokinetic study in twelve healthy volunteers, where 1.31 μmol/kg dose of SDG was 
administered, showed that enterolignans (ENL and END) appeared in the plasma at around 8-10 
hours. This study showed long residence time of ENL in comparison to END reaching up to 36 
hours post purified SDG consumption225. Another pharmacokinetic study that was performed in 
male Wistar rats showed longer half-lives for SECO and END. This rat study failed to assess ENL 
due to mortalities at doses of 1 mg/kg IV and 10 mg/kg oral217. In addition, the previous study 
showed zero bioavailability for SDG and 25% bioavailability for SECO and less than 1% to END. 
This low bioavailability could be attributed to the extensive first-pass effect during absorption 
from the gastrointestinal tract217. 
1.2.6.1.2 Disposition (Distribution, Metabolism, and Excretion) 
Flaxseed lignans are widely distributed to the whole body. ENL, in particular, can be detected 
in liver, lung, kidney, heart and brain in rats with higher distribution to the kidney, liver, and 
testes226. This extensive distribution might be attributed to their lipophilicity and inherent ability 
to bind to sex hormone binding globulin (SHBG)227. Typically, the distribution is high for both 
ENL and END, but when the dose is escalated a reduced conversion of END to ENL (saturation 
of oxidation) and an increased distribution for END is observed228.  
In vivo studies show that SECO is extensively metabolized into END and ENL with only a 
small portion of SECO detected in plasma or urine. In humans, this biotransformation process is 
found to take part mainly in the colon229. During the absorption phase SECO, END, and EL 
undergo significant conjugation with glucuronic acid and sulfate as phase II metabolic processes. 
Phase I metabolic reactions represent a minor metabolic process involving SECO and the 
mammalian lignans and these are characterized by oxidation and hydroxylation products of the 
lignans, detected using human, pig, rat and rhesus monkey microsomes230, 231.  
When compared through the intrinsic clearance parameter, the extent of hepatic microsomal 
glucuronidation was greater than that of intestinal activity232. Intestinally unconjugated ENL will 
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be delivered to the liver where it gets glucuronidated, then transported to the bile233. On the other 
hand, conjugated ENL is effluxed into the portal ciruclation through the MRP3 basolateral efflux 
transporter234. This activity will result in a prolonged repetitive introduction of ENL in the intestine 
through enteohepatic recycling. Enterohepatic recycling is reported for enterolignans in human, 
rats and pigs216, 235. In a human pharmacokinetic study, the appearance of a second peak after oral 
administration of purified SDG confirms that both ENL and END are susceptible to enterohepatic 
recirculation235. The involvement of the liver and intestine in glucuronidation in addition to 
enterohepatic recycling results in the availability of enterolignans in the intestine for a considerably 
favorable period of time and thus increasing exposure of the intestinal epithelium to the lignans. 
Fecal excretion is the primary route of excretion of lignan metabolites, as 48% of an 
administered lignan dose is excreted fecally in pigs236. The fecal excretions of END, ENL and 
matairesinol conjugates in pre-menopausal women on normal diets were 80, 640 and 7.33 
nmol/day, which is increased with flaxseed consumption up to 2560, 10300 and 11.9 nmol/day, 
respectively237. Lignan glucuronides are excreted in bile and subsequently undergo 
deglucuronidation by bacterial β-glucuronidase activity. The high fecal excretion of enterolignans 
may be due to incomplete absorption and enterohepatic circulation. This assumption is confirmed 
for another structurally related lignan (genestein), which was labeled with 14C in intestinal location 
to confirm the involvement of enterohepatic circulation in the process of fecal excretion of 
glucuronidated lignans238.  
Urinary excretion is an important route for lignan metabolite excretion. Most of the ENL is 
excreted as ENL-glucuronide in urine while a minor amount is excreted as sulfates239, 240. END 
was more extensively excreted in urine when compared to ENL and SECO upon the administration 
of a standardized flaxseed supplement in women; this increase might be attributed to enhanced 
hydrophilicity of END, or potentially the higher plasma concentrations of END as a metabolite of 
flax lignan consumption241.  
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Figure 1.3 General PK scheme of lignans explains the potential hypothesis of initial 
biotransformation of SDG initially to END and finally to ENL by the aid of normal flora in the 
intestine, followed by absorption and further distribution and metabolism. Lignan susceptibility 
to enterohepatic circulation is fortified by the enzymatic activity in the intestine and the available 
microflora. 
1.2.6.2 Linoorbitide (LOB) Pharmacokinetics 
1.2.6.2.1 Chemistry of LOBs 
Generally, cyclic peptides in plants are frequently abundant, and there are 455 cyclic peptides 
in Caryophyllaceae and Rhamnaceae plant families242. Chemical structure significantly influences 
the pharmacokinetics of any molecule; flax cyclic peptides are large in size with variable sequences 
of amino acids. Although flaxseed LOBs were discovered in 1959, LOBs were not extensively 
studied due to their structural complexity and stability issues that rendered extraction, isolation, 
and purification difficult and costly32. LOBs are a group of cyclic, hydrophobic peptides composed 
of eight or nine amino acid residues with molecular weights of approximately one thousand 
Daltons. The dominant amino acids in LOBs are (Phe), Leucine (Leu), Isoleucine (Ile), Methionine 
(Met) and Proline (Pro) amino acid residues as seen in table 1.3. 
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Table 1.3. Linoorbitides (LOBs) of flaxseed, amino acid sequences, and molecular weights 229-
231. 
Name Amino acid sequence Chemical formula and MWt (Da) 
LOB-A Ile-Leu-Val-Pro-Pro-Phe-Phe-Leu-Ile C57H85N9O9 (1040) 
LOB-B Met-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile C56H83N9O9S (1058) 
LOB-C Mso-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile C56H83N9O10S (1074) 
LOB-D Mso-Leu-Leu-Pro-Phe-Phe-Trp-Ile C57H77N9O9S (1064) 
LOB-E Mso-Leu-Val-Phe-Pro-Leu-Phe-Ile C51H77N8O9S (977) 
LOB-F Mso-Leu-Mso-Pro-Phe-Phe-Trp-Val C55H73N9O10S2 (1084) 
LOB-G Mso-Leu-Mso-Pro-Phe-Phe-Trp-Ile C56H75N9O10S2 (1098) 
LOB-H Mso-Leu-Met-Pro-Phe-Phe-Trp-Ile C56H75N9O9S2 (1082) 
LOB-I Met-Leu-Mso-Pro-Phe-Phe-Trp-Val C55H73N9O9S2 (1068) 
LOB-J Msn-Leu-Val-Phe-Pro-Leu-Phe-Ile C51H77N8O10S (993) 
LOB-K Msn-Leu-Ile-Pro-Pro-Phe-Phe-Val-Ile C56H83N9O11S (1090) 
 
Linoorbitide-A (LOB-A) was the first cyclic peptide to have its structure fully resolved in 
1971 and fully identified by two-dimensional NMR analysis in 1995 (see figure 1.4)14, 15, 243. 
Conformational NMR studies concluded that LOB-A has no intramolecular hydrogen bonding. 
The analysis examined seven possible locations, five of which are exterior and two are located 
interior of the ring, and none was found to have hydrogen bonding14. 
 
Figure 1. 4 LOB-A is the first cyclic peptide identified, composed of nine amino acids (Pro-Pro-
Phe-Phe-Leu-Ile-Ile-Leu-Val) and has a molecular weight of 1040.3397 g/mol. 
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1.2.6.2.2 Pharmacokinetics of LOBs 
Due to their recent discovery and the lack of extensive in vivo experimentation, LOBs have 
never been under the scope of pharmacokinetics analysis. To further understand the potential 
pharmacokinetic behavior of LOBs, information from other currently available cyclic peptides and 
their pharmacokinetic profiles as well as pharmaceutical principles can shed some light on possible 
LOB characteristics. In order to evaluate the potential of any chemical structure to behave as a 
drug-like molecule for oral administration, four rules were elaborated, commonly named 
Lipinski`s rule of five, to make a priori assessments of a molecule’s drug likeness244. Lipinski's 
rules state that: a compound is more  likely to be an orally available drug if it does not violate more 
than one of the following rules: 1) No more than five hydrogen bond donors. 2) No more than ten 
hydrogen bond acceptors. 3) An octanol: water partition coefficient (Log P) of less than 5, and 4) 
Molecular weight lower than 500 daltons 244. According to these rules, LOBs are unlikely to exert 
any systemic pharmacological effects. The high molecular weight (~1000 daltons) and a high 
number of hydrogen bond donors and acceptors are unfavourable for oral absorption and, 
consequently, a failure to reach the systemic circulation is presumed. 
In contrast to what is hypothesized by Lipinski`s rule of five, Cyclosporin-A (CsA) is a 
structurally relevant hydrophobic cyclic peptide that is capable of permeating from the 
gastrointestinal tract lumen to the systemic circulation. Studies in an in vitro transwell system of 
polarized of Caco-2 cells showed that CsA is capable of passively moving from apical to basal 
compartments, which indicates ability of CsA to permeate across the gastrointestinal mucosa. In 
addition, CsA permeation was also influenced by the addition of efflux transporter inhibitors (P-
glycoprotein)245. Moreover, the bioavailability of CsA upon oral administration in humans reach 
as high as 29%246, 247.  
Taken together, both lignans and LOBs likely have low oral bioavailabilities. In addition to 
the significant enterohepatic recirculation of ENL and ED, lignans and LOBs will likely have high 
concentrations in the gastrointestinal lumen. Therefore, a significant need to assess their local 
effects on the intestinal epithelium is prudent to discover innovative utilization of their favorable 
pharmacological activity.  
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1.3 Rationale 
 
Currently, three out of four Canadians frequently use natural health products, and one-third of 
them use natural products on a daily basis248. This inclination toward natural products has been the 
driving force for many governmental and industrial sectors to invest further in the regulation, 
production, and improved accessibility and customer confidence in natural products. 
The reports on the effectiveness of flaxseed bioactives as anti-inflammatory agents and 
modulators of cholesterol levels, combined with the reported safety profile encourages further 
investigations with the flaxseed bioactives in several therapeutic areas. In addition, our 
pharmacokinetic knowledge about flaxseed bioactives suggests reduced systemic availability and 
high abundance at the level of the intestine. This assumption leads to their potential use as 
modulating biological activity at the level of the intestinal epithelium. Two specific pathologies, 
IBD and hypercholesterolemia, can benefit significantly from possible intestinal epithelial local 
effects. Both pathologies have need for improved treatment options as these conditions continue 
to frustrate both clinicians and scientists in their attempts to effectively mitigate disease pathology 
and significantly improve patient outcomes.  
Based upon such considerations, flaxseed as a chemopreventative or chemotherapeutic agent 
might improve therapeutic outcomes in IBD and hypercholesterolemia patients. However, 
experimental support for the lignans and LOBs and their mechanisms of action is first required to 
support the use of flaxseed in these therapeutic areas. 
1.4 Hypotheses  
 
1- Enterolactone and Linoorbitides (LOBs) maintain intestinal epithelial barrier integrity 
through anti-inflammatory and anti-oxidative effects.  
2- Inflammation increases pyruvate kinase M2 (PKM2) expression in intestinal epithelial 
cells and PKM2 is elevated in serum of newly diagnosed inflammatory bowel disease 
patients. 
3- Enterolactone and enterolactone glucuronide modulate cholesterol metabolism in intestinal 
epithelial cells.   
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1.5 Objectives  
 
1- To evaluate the efficiency of enterolactone (ENL) and linoorbitides (LOBs) to protect 
intestinal epithelial barrier integrity against an inflammatory stimulus, INF-γ and TNF-α, 
in cell lines simulating the intestinal epithelium.  
2- Assessing the role of ENL and LOBs to modulate oxidative stress in vitro using an 
intestinal epithelial cell line and a co-culture model and the possible mechanisms that might 
be involved.  
3- To determine whether newly diagnosed inflammatory bowel disease patients demonstrate 
elevated levels of circulating PKM2 and explore whether intestinal epithelial cells increase 
PKM2 expression following an inflammatory stimulus.  
4- Investigate the capacity of ENL and ENL-glucuronide to modulate cholesterol metabolism 
in intestinal epithelial cells and the mechanism of action involved.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
CHAPTER 2 
 
Linoorbitides and enterolactone differentially 
ameliorate in vitro inflammation in HCT-8 intestinal 
epithelium 
Ahmed A. Almousa, Sharyle Fowler, Jennifer Jones, François Meurens, Ed S. Krol, Jane Alcorn 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
Linoorbitides and enterolactone differentially ameliorate in vitro intestinal inflammation in 
HCT-8 intestinal epithelium. 
 
Ahmed A. Almousa1, Sharyle Fowler2, Jennifer Jones3, François Meurens4,5 
 Ed S. Krol1, Jane Alcorn1* 
Transitioning rationale: 
 The literature review provided a premise for the potential utilization of LOBs and ENL on 
the level of the intestinal epithelium.  This utilization is favored in disease states that are 
significantly related to main functions of the intestinal epithelium, namely as a barrier and first 
line immune defense and as a significant player in cholesterol metabolism. This chapter aims to 
provide a proof of concept of the potential anti-inflammatory effects of ENL and LOBs to maintain 
intestinal epithelial barrier function. An in vitro transwell system to simulate intestinal epithelium 
served as an initial simple model to explore the maintenance of barrier integrity through 
assessments of trans-epithelial electrical resistance, Lucifer yellow rejection and the expression of 
ZO-1 tight junction proteins. Finally, this chapter explores initial screening of cytokines, 
chemokines and other inflammatory mediators involved to understand the mechanism involved in 
the anti-inflammatory effects of ENL and LOBs.  
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Abstract 
Barrier integrity dysfunction is considered a hallmark of inflammatory bowel disease (IBD) 
pathogenesis, and its maintenance continues to be a target for drug discovery to ameliorate IBD. 
The current shift toward natural products to aid as adjuvant treatments in chronic diseases like IBD 
is driving the research for a better understanding of whether individual bioactives may positively 
modulate disease pathogenesis. This study investigated whether the flaxseed bioactives, 
Linoorbitides (LOBs) and Enterolactone (ENL), could maintain epithelial barrier integrity in an in 
vitro intestinal inflammation model. An inflammatory response was induced in HCT-8 polarized 
intestinal epithelia with the aid of TNF-α and INF-ɣ. The ability of LOBs and ENL to maintain 
barrier integrity was assessed through measurement of Trans-Epithelial Electrical Resistance 
(TEER), Lucifer Yellow rejection for barrier permeability, and assessment of zonula occludins 1 
by immunohistochemistry. Results showed 200 nM of LOB-J, LOB-A, and ENL prevented 
inflammation-induced reduction in TEER with relative TEER values of 108.59%, 63.19% and 
64.24%, respectively, at 24 hours. LOB-A and ENL caused a ~2- and 3.4-fold increase in PPAR-
ɣ mRNA expression relative to untreated control, while LOB-A and LOB-J, but not ENL, 
significantly downregulated TNF-α expression. Western blot analysis confirmed gene expression 
results. Immunohistochemical analysis showed ENL, but not LOB-A and LOB-J, maintained ZO-
1 expression relative to untreated, unstimulated control. The difference in magnitude, chronology, 
and nature of effect between these three flaxseed bioactives suggest their epithelial barrier 
protection is imparted through different mechanisms. Further investigations are warranted 
including evaluation in animal models of IBD.  
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2.1 Introduction 
Inflammatory bowel disease (IBD) constitutes Ulcerative colitis (UC) and Crohn`s disease 
(CD) and is characterized by idiopathic chronic inflammation along the intestine with varying 
locations and clinical presentations168. IBD has unclear multifactorial etiology correlated to 
variable environmental, genetic, cellular, and immunological factors104. Intestinal epithelial barrier 
integrity is hypothesized to be distressed during the course of the disease and is considered a 
characteristic feature of IBD249. The presence of this barrier is partly granted by a set of integral 
cellular proteins, tight junction complexes and cell cytoskeleton microtubules and filaments, which 
maintain robust intercellular connections between the epithelial cells119. After impairment of 
intestinal barrier integrity, noxious molecules and pathogens leak to the lymphatic system to 
initiate a cascade of inflammatory reactions. Such inflammation is what leads to shedding of the 
mucosal epithelial layer as in UC or transmural inflammation of the intestinal mucosa as in CD250, 
the hallmarks of IBD.  
The mainstay of IBD treatment is corticosteroids. Chronic administration is associated with 
several side effects including weight gain, gastric irritation, and potential loss of bone density and 
increased risk of fracture251, 252. In addition to corticosteroids, immunosuppressants and biologicals 
leave patients more susceptible to viral and bacterial infections253. In conjunction with 
pharmacological agents, many patients lean toward using natural products to aid the healing and 
remission of active IBD flares. Studies evaluating the use of natural products by IBD patients 
report benefit from their use254. Among those natural products used is flaxseed, which is reported 
to ameliorate inflammation in general, in addition to its potential role in hypercholesterolemia and 
cancer4, 5, 12. 
Flaxseed contains high levels of the bioactive compounds, lignans and linoorbitides 
(LOBs)29, 255. Following an oral administration of flaxseed extracts, the plant lignan, 
secoisolariciresinol diglucoside, undergoes conversion to its aglycone, secoisolariciresinol, with 
subsequent biotransformation to the mammalian lignan, enterodiol, and then to enterolactone 
(ENL) by the metabolic activity of intestinal microbiota256. The mammalian lignans have low oral 
bioavailability and are susceptibile to enterohepatic circulation233. This aforementioned factor 
favors the potential for enhanced localized pharmacological activity in the intestine238, 257. 
Although the biological activity ascribed to the different lignan metabolites is incompletely known, 
the literature identifies ENL as one of the biologically active metabolites44, 96, 257. The linoorbitides, 
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LOB-A and LOB-J, are cyclic peptides composed of nine and eight amino acids and have 
molecular weights of 1040 Da and 993 Da, respectively 15, 258. Their large molecular weight and 
hydrophilic nature hinders their permeation through the intestinal epithelium. Lack of absorption 
due to these reasons, in addition to reported immunosuppressant activity, suggest the potential 
utilization of linoorbitides to ameliorate intestinal inflammation locally. Collectively, this research 
aims to assess the potential effect of the flaxseed bioactives, linoorbitides and enterolactone, on 
intestinal epithelium integrity in an in vitro intestinal inflammation model, confirm their protective 
effects, and reveal potential mechanisms of action. 
2.2 Materials and Methods 
2.2.1 Cell culture 
The HCT-8 cell line was purchased from American Type Culture Collection (ATCC) 
(Manassas, VA, USA) and maintained in RPMI media (ATCC) supplemented with 10% horse 
serum and 1% penicillin/streptomycin (10,000 U, 10 m/mL) from Sigma-Aldrich (St. Louis, MA, 
USA). All other materials were bought from Sigma-Aldrich unless otherwise mentioned. Initially, 
cells were passaged twice after removal from liquid nitrogen vapour with media changes every 
two days. Cells grown in Corning™ T-75 flasks (Pittsburgh, PA, USA) were passaged at 70-80% 
confluency using 0.25% Trypsin-EDTA. Cells were constantly maintained at 37°C and 5% CO2. 
All experiments were conducted with cells at passage number 4-15. 
2.2.2 Cytotoxicity assays 
Cytotoxicity assays of LOBs and ENL utilized the Calcein-AM kit from Biotium (Houston, 
TX, USA). Cells were seeded in 96-well plates at a density of 10,000 cells/well within the 
calibration range of the provided kit. Cells were allowed to attach for 24 hours, the media aspirated, 
and new media containing LOB-A, LOB-J and ENL in the range of 25 nM- 200 µM or positive 
control of 4 mM 5-FU was added to the cells. Cells were exposed for 72 hours to the compounds 
and subsequently washed with Calcein washing buffer, followed by addition of Calcein working 
solution and incubated for 30 minutes at 37°C and 5% CO2. Cell viability was determined using a 
fluorescence plate reader taken at excitation and emission wavelengths of 495 and 515 nm, 
respectively, using a Biotek Synergy HT microplate reader (Fisher Scientific, Canada). 
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2.2.3 Induction of inflammation in HCT-8 monolayer 
HCT-8 cells in RPMI supplemented media were plated on Corning™ Transwell (0.4 μM, 
24-well plates; Fischer Scientific, Pittsburgh, PA, USA) at an average seeding density of 5×104 
cells per insert. The cells were allowed to polarize for 8 days to a minimum Trans-Epithelial 
Electrical Resistance (TEER) of 2000 ohms/cm2, and media was replaced every other day (200 μL 
on the apical side and 600 μL on the basal side) following vacuum suction of the old media. TEER 
values were measured using Millicell ERS™ voltohmeter by EMD Millipore® (Billerica, MA, 
USA) after 30 minutes of acclimatisation in a biosafety cabinet. At the time of inflammation 
induction, supplemented media was removed and substituted with Hank’s balanced salt solution 
(HBSS) (no calcium) combined with TNF-α (10 ng/mL) and INF-γ (50 ng/mL) added to the basal 
compartment of transwells and media in the apical compartment. The final concentration of 
cytokines used to elicit an inflammatory response was determined by optimization experiments 
with measurement of TEER changes. The flaxseed bioactives (LOB-A, LOB-J, and ENL) were 
added simultaneously with the cytokines in four replicates and at four different concentrations on 
three different experimental days to both compartments. The bioactives were initially dissolved in 
100% dimethylsulfoxide (DMSO) from ATCC, and then serially diluted to 1% DMSO with horse 
serum free RPMI media and used as a final working solution. TEER measurement was done at the 
beginning of treatment, and at 24 and 48 hours after exposure. LOB-A and LOB–J were kindly 
gifted from Prairie Tide Chemicals Inc. (Saskatoon, Canada). 
2.2.4 Lucifer yellow rejection 
After treating transwells as explained above for 48 hours, lucifer yellow (LY) was 
introduced to the apical (200 μL) compartment at a 100 µg/mL concentration and incubated for 
two hours at 37°C and 5% CO2. On the same plate the no-insert wells were either supplied with 
800 μL of HBSS at 100% epithelial integrity or 600 μL HBSS + 200 μL LY to represent 100% 
leakage of epithelium. Rejection rates were obtained by reading fluorescence at 485/535 nm in the 
basal compartment using a Biotek Synergy HT microplate reader. Rejection percentages were 
calculated to correspond to epithelial integrity. Rejection rates were calculated by subtracting 
100% Integral wells (HBSS) values from treated wells and 100% leakage wells, then dividing 
treated over 100% leakage, with subtraction of the result from 100%. Optimization experiments 
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which were guided by TEER results identified the appropriate concentrations used for these 
experiments.  
2.2.5 Zonula Occludins 1 (ZO-1) immunohistochemistry 
HCT-8 cells were grown on six well plates with glass cover slips and allowed to grow to 
90% confluency to better simulate a monolayer epithelium. Cells were then treated with TNF-α 
(10 ng/mL) and INF-γ (50 ng/mL) alone or with flaxseed (LOB-A, LOB-J, and ENL) or 1% DMSO 
alone. After 24 hours of treatment cells were fixed with 4% paraformaldehyde for 10 minutes at 
room temperature. The cells were subsequently blocked in 5% bovine serum albumin (BSA) and 
0.5% Triton-X 100 for 3 hours at room temperature before incubation with primary antibody ZO-
1 (ab59720) from Abcam (Toronto, ON, Canada) at (1:100) in blocking solution for 4 hours at 
37°C and 5% CO2. Goat anti-rabbit IgG (H+L) secondary antibody (Alexa Fluor® 488 conjugate) 
was used as the secondary antibody purchased from Thermo-Fisher Scientific (Waltham, MA 
USA). Visualization took place under a ZOE fluorescence microscope (Bio-Rad, Hercules, CA, 
USA). Optical density measurement for ZO-1 fluorescence used ImageJ software by National 
Institute of Health259. 
2.2.6 Extraction of total RNA and quantitative RT-PCR (qPCR) 
After induction of inflammation for 24 hours, total RNA was extracted from cells cultured 
on transwells by using Qiagen RNeasy mini kit and Trizol (Toronto, ON, Canada) by following 
the manufacturer protocols. A Nanoview UV spectrophotomer (GE Healthcare Life Sciences, 
Quebec, Canada) was used to assess the concentration and purity of total RNA by measuring 
absorbance at 260 nm and the absorbance ratio (A260 / A280) of a diluted sample of RNA, 
respectively. Al1 samples used for qPCR were of high purity and total RNA was stored at -80°C 
until further processing.  
Total RNA was reverse transcribed Multiscribe reverse transcriptase to cDNA, and then 
gene expression quantified using Power Sybr® Greeen PCR Mastermix, all purchased from by 
Life Technologies (Burlington, ON, Canada). The polymerase chain reaction was carried out using 
a one-step method. Initial incubation with reverse transcriptase took place at 42ºC for 30 minutes, 
followed by denaturation at 95ºC for 3 minutes, 40 cycles of annealing and extension performed 
for 15 seconds and 30 seconds, respectively, and eventually a dissociation curve as per 
manufacturer’s setting. This experiment was executed in an Applied Biosystems® 7300 system 
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(Foster City, CA, USA). Primer sequences using Integrated DNA Technologies (IDT) Primer-
Quest tool (https://www.idtdna.com/Primerquest/Home/Index) for target genes were: 5`-
CTCAAACGAGAGTCAGCCTTTA-3` (forward) and 5`-GTGGGAGTGGTCTTCCATTAC-3` 
(reverse) for PPAR-γ, 5`-GCCTGTAGCCCATGTTGTAG-3` (forward) and 5`-
AGGACCTGGGAGTAGATGAG-3` (reverse) for TNF-α, 5`-TGGGAACAAGAGGGCATCG-
3` (forward) and 5`-CCACCACTGCATCAAATTCATG-3` (reverse) for succinate 
dehydrogenase complex subunit A (SDHA). All primers were purchased through IDT (Iowa, 
USA). SDHA served as a housekeeping gene to normalize Ct values and relative quantitation was 
done using the delta-delta Ct method (2-ΔΔCT). 
2.2.7 Western blots of TNF-α and PPAR-γ 
HCT-8 cells were seeded in T-25 flasks at a density of 1×106 cells/mL, and left to attach 
for 24 hours. Treatment with various concentrations of LOB-A, LOB-J, and ENL was carried out 
in addition to an inflammatory stimulus of TNF-α and INF-γ (10 and 50 ng/mL, respectively) for 
another 24 hours. Cells were lysed for protein extraction using radioimmunoprecipitation assay 
buffer (RIPA) from Millipore (Billerica, MA, USA) in ice-cold conditions. Protein concentrations 
were determined using the Pierce™ BCA Protein Assay Kit (Rockford, IL, USA), where linearity 
of protein concentrations was verified. Twenty micrograms of total protein were transferred for 
gel electrophoresis (Bio-Rad Laboratories). Membrane blocking was carried out using 5% BSA in 
1X phosphate buffered saline Tween-20 (PBST) for one hour. All primary antibodies (1:500) were 
incubated overnight at 4°C in PBST and then incubated with the secondary antibody (1:2000) for 
2 hours at room temperature. The blots were visualized using enhanced chemiluminescence 
detection system (Novex® ECL) from Life Technologies (Burlington, ON, Canada). PPAR-γ 
antibody (sc-7273) and β-actin antibody (sc-47778) were purchased from Santa Cruz 
Biotechnology (Dallas, TX, US). TNF-α antibody (ab1793) was purchased from Abcam (Toronto, 
ON, Canada). Fab2-Goat anti-Mouse IgG (H+L) Secondary Antibody-HRP conjugate (A24512) 
was purchased from Thermo-Fisher Scientific. 
2.2.8 Statistical Analysis 
Effects of treatments relative to controls were evaluated by use of one-way ANOVA 
followed by Dunnett’s test to compare with controls. Differences were considered significant at p-
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value < 0.05. All data analysis was performed by using GraphPad Prism 5 software (San Diego, 
CA, USA). 
2.3 Results 
2.3.1 Epithelial barrier protection by linoorbitides, enterolactone, and their combination 
Cytotoxicity assay results showed that LOB-A is the most cytotoxic, followed by LOB-J 
and ENL was the least cytotoxic. These evaluations guided the concentrations used in all 
subsequent experiments. HCT-8 cells were used to simulate the intestinal epithelium monolayer 
to allow assessment of the ability of the flaxseed bioactives to maintain epithelial barrier integrity 
during an inflammatory stimulus. Relative to untreated control transwells, LOB-A, LOB-J, ENL, 
and their combinations generally maintained higher TEER values compared to time zero as seen 
in Figure 2.1 and 2.2. The usage of TNF-α and INF-γ to induce inflammation resulted in a fairly 
consistent reduction in TEER values (TEER ~30%) in untreated controls. At 24 hours, LOB-J 
reduced the degree of TEER reduction following an inflammatory stimulus in a concentration-
dependent fashion such that at the highest concentration no reduction in TEER in HCT-8 polarized 
epithelium was observed. At 48 h, only the highest concentration of LOB-J resulted in statistically 
higher TEER values relative to untreated controls. In general, LOB-A at all concentrations 
maintained TEER values between 63.2 – 76.5% at 24 h, which was higher than untreated controls 
(27.5%), and between 37.1 – 48.2% 48 h, which was greater than untreated controls (23.1%). The 
highest concentration of ENL resulted in significantly higher TEER values, 64.2% and 56.04%, 
relative to untreated controls at 24 and 48 hours (31.3% and 25.5%), respectively. With the 
combination of LOBs and ENL, the relative TEER values compared to untreated controls were 
significantly higher at 24 h with a similar pattern, but with lower TEER values, emerging at 48 h. 
The highest relative TEER values were observed with the combination of ENL with LOB-J, while 
the lowest TEER values were observed with the combination of LOB-J and LOB-A.  
2.3.2 Lucifer yellow rejection 
To provide further confirmation of the maintenance of barrier integrity, we assessed 
Lucifer yellow rejection rate as a marker of paracellular transfer across the HCT-8 epithelium. 
Only the most effective concentrations of LOB-A, LOB-J, and ENL in the TEER experiments 
were assessed with the lucifer yellow rejection assay. Results at 48 hours in the transwell system 
showed that lucifer yellow rejection values were significantly higher with ENL (99.6%) and LOB-
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J (98.8%), while LOB-A (96.9%) had similar rejection rates to untreated control (97.3%) (Figure 
2.3). 
2.3.3 Immunohistochemistry of Zonula Occludens-1 (ZO-1) 
Tight junctions represented by ZO-1 is considered a cornerstone of barrier integrity and 
barrier function. To investigate the effect of LOB-A, LOB-J, and ENL on epithelial membrane 
integrity after an inflammatory insult, we examined ZO-1 protein expression in HCT-8 cell lines 
during the inflammatory insult for 48 hours with and without the flaxseed bioactives. 
Immunohistochemistry results showed that the inflammatory stimulus reduced ZO-1 expression 
in HCT-8 approximately 2-fold relative to untreated, unstimulated control (Figure 2.4). Treatment 
with 200 nM ENL maintained ZO-1 expression relative to untreated, unstimulated control, but 
with exposure to LOB-A and LOB-J ZO-1 expression was significantly decreased to levels 
consistent with untreated HCT-8 cells exposed to an inflammatory stimulus.  
2.3.4 Up-regulation of PPAR-γ and down-regulation of TNF-α 
To evaluate other potential mechanisms involved in the protective effect of flaxseed 
bioactives, expression of several innate immune response genes was evaluated. No significant 
changes in IL-1β, IL-6, IL-8, CCL-20 and MUC-2 gene expression was noted (data not shown). 
For TNF-α and PPAR-γ results from qPCR analysis showed that the acute phase reactant protein 
TNF-α was downregulated by both 0.2 nM LOB-A and 2 nM LOB-J at 2.23 fold reduction, while 
ENL at 200 nM caused a nonsignificant reduction in TNF-α mRNA expression (Figure 2.5). High 
concentrations (200 nM) of both ENL and LOB-A caused a 2-fold and 3.5-fold increase in PPAR-
γ mRNA expression, respectively. Western blots confirmed the changes in mRNA expression for 
the respective treatments (Figure 2.5).  
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Figure 2.1 Effect of LOB-J, LOB-A and ENL on HCT-8 epithelial monolayer transepithelial 
electrical resistance (TEER) upon inflammatory insult with 10 ng/mL TNF-α and 50 ng/mL 
INF-γ for 24 hours (A) and 48 hours (B). Results represent TEER values at 24 or 48 hours 
relative to TEER at time zero. Data are presented as means ± S.D of 4 replicates determined on 
4 different occasions.  * p-value < 0.05, ** p-value < 0.01, *** p- value < 0.001. 
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Figure 2.2 Effect of combining LOB-A, LOB-J and ENL on transepithelial electrical resistance 
(TEER) in the HCT-8 epithelial monolayer upon inflammatory insult with 10 ng/mL TNF-α 
and 50 ng/mL INF-γ) for 24 hours (A) and 48 hours (B). ENL in combination with LOB-J had 
the highest TEER values at both 24 and 48 hours. Results represent TEER values at 24 and 48 
h relative to TEER at time zero. Data are presented as means ± S.D of three replicates on three 
separate occasions. * p-value < 0.05, ** p-value < 0.01, *** p- value < 0.001. 
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Figure 2.3 Lucifer yellow (LY) rejection after 48 hours incubation with LOB-A, LOB-J, and 
ENL. Data are presented as means ± S.D of three replicates on three separate occasions. * p-
value < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
Vehicle 
control  
(1 % DMSO) 
0.2 nM LOB-A 
+ 
TNF-α + INF-γ 
200 nM LOB-J  
+ 
TNF-α + 
 INF-γ 
200 nM ENL  
+ 
TNF-α  
+INF-γ 
TNF-α  
+ 
INF-γ 
D
A
P
I 
Z
O
-1
 
M
er
g
e 
50 
 
0.0
0.5
1.0
1.5
2.0
2.5
0.2 nM LOB-A + TNF- + INF-
200 nM LOB-J + TNF- + INF-
200 nM ENL + TNF- + INF-
TNF- + INF-
1 % DMSO
*
O
p
ti
c
a
l 
d
e
n
si
ty
 (
O
.D
) 
o
f 
Z
O
-1
B 
Figure 2.4 Immunohistochemistry of zonula occludens 1 (ZO-1) in HCT-8 epithelial monolayer 
(48 hours treatment). A: Immunofluorescence images showing loss of ZO-1 intensity upon 
induction of inflammation with 10 ng/mL TNF-α and 50 ng/mL INF-γ relative to control (1% 
DMSO). B: Optical density measurement for ZO-1 fluorescence using ImageJ software. Data 
are presented as means ± S.D of three replicates on three separate occasions. * p-value < 0.05. 
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Figure 2.5 Relative mRNA expression and western blots for TNF-α (solid black bars) and 
PPAR-γ (light gray bars). Data are presented as means ± S.D of three replicates on three 
different occasions. * p-value < 0.05. 
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2.4 Discussion 
Effective management of IBD remains a significant challenge to both the health system 
and to patient quality of life186, 187, 253. Although the biologics have improved treatment efficacy, 
their use has shifted health care expenditures to the actual cost of the medication260. A solution to 
these escalating costs may be the development of cost-effective adjuvant therapies that help 
improve efficacy of less expensive existing treatments. Natural products with anti-inflammatory 
and immunomodulatory activities are purported alternatives to IBD treatment and management254. 
As natural products, flaxseed bioactives, cyclic peptide Linoorbitides (LOBs) and lignans, have 
evidence of ability to mitigate inflammation and oxidative stress or elicit immune modulating 
effects8, 96. Such properties have led researchers to evaluate these flaxseed bioactive compounds 
in other chronic disease states3, 82, 85, but very few studies report on their effects in IBD17,9. In the 
present study we selected flaxseed LOB-A, LOB-J, and the mammalian lignan, ENL, based on 
their known physicochemical and pharmacokinetic properties to assess their potential use to 
protect against intestinal epithelial barrier dysfunction9, 51, 261, 46. These flaxseed bioactives 
imparted protective effects on intestinal epithelial barrier function in vitro variably involving anti-
inflammatory, antioxidant, and/or immunosuppressive effects.  
Chronic inflammation and defective intestinal epithelial barrier integrity are hallmarks of 
IBD119. The pro-inflammatory cytokines, TNF-α and INF-γ, have been shown to disrupt barrier 
integrity in both ex vivo and in vitro studies of the intestinal epithelium262, 263. Our study involving 
the HCT-8 polarized epithelium is consistent with these studies, where we observed a time-
dependent and significant reduction in TEER and LY rejection rates with exposure to TNF-α and 
INF-γ. Although the HCT-8 cell line is not frequently used to simulate the intestinal epithelium 
monolayer, its ability to form a strong barrier with a high transepithelial resistance in a short time 
(8 days) favoured its usage over the Caco-2 cell line. The reduction in TEER and LY rejection 
rates with TNF-α and INF-γ stimulation supported its use to assess the protective effect of the 
flaxseed bioactives. Both cytokines were necessary as TNF-α or lipopolysaccharide alone was not 
sufficient to cause significant reductions in TEER consistent with other studies employing the 
Caco-2 cell line263. In the HCT-8 polarized epithelium LOB-A, LOB-J, ENL, and their 
combinations generally maintained higher TEER values suggesting a protective effect of the LOBs 
and ENL against inflammation-induced loss of barrier integrity. Although Zarepoor et al.18 
reported that dietary flaxseed intensified the colonic mucosal damage in a mouse model of IBD, 
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the lignan enriched hull fraction of flaxseed did not exacerbate colitis, possibly lending support 
for use of lignans and LOBs in the absence of the oil fraction of flaxseed to mediate protective 
effects on the colonic mucosal barrier in vivo. These observations are aligned with literature reports 
on the effects of LOBs and ENL with regards to their anti-inflammatory and immunosuppressant 
effects8, 10.  
Interestingly, the protective effect of the LOBs and ENL exhibited differences in both 
magnitude and chronology suggesting the involvement of different mechanisms of action. The 
tight junction complex plays an integral role in maintenance of barrier function and zonula 
occludin 1 (ZO-1) is principally responsible for tight junction complex assembly264. Therefore, our 
assessment focused on ZO-1 protein and its subsequent morphological effect on maintaining 
barrier integrity, high trans-epithelial electrical resistance (TEER), and enhanced lucifer yellow 
(LY) rejection. Our results showed that an insult to HCT-8 with TNF-α and INF-γ reduced the 
overall expression of ZO-1, reduced TEER, and promoted leakage of LY. The mammalian lignan, 
ENL, mitigated downregulation of ZO-1 expression at 48 h, while ability of low concentration 
LOB-A to maintain ZO-1 expression was lost. With ENL, the favourable and enhanced 
concentration-response effect on TEER and LY rejection values at 48 hours, though, suggests a 
possible role for an ENL metabolite in protection of epithelial integrity since previous studies 
indicate complete glucuronidation and sulfation of ENL within 24 hours of incubation in intestinal 
epithelial cells219, 221. Alternatively, ENL is known to influence several transcription factors 
including NF-қB and, thus, its favourable effects can be delayed44. For the LOBs the loss in ability 
to maintain barrier integrity by 48 hours was associated with low expression of ZO-1. The LOBs 
antioxidant activity might be lost over time due to depletion of scavenging capacity. The potential 
for degradation is also a plausible explanation; however, when LOB-J was exposed to harsh 
thermal and oxidative stability testing it was resistant to chemical degradation and highly stable 
among other LOBs258. Interestingly, LOB-A showed a reverse concentration-response at 48 hours 
and minimal protection for the highest concentration at 24 hours. This suggests the involvement 
of significant cytotoxic effects of LOB-A at higher concentrations where barrier integrity is altered 
and apoptosis is potentially induced33.  
The difference in chronological effects between ENL and LOBs might also reflect 
differences in their ability to regulate PPAR-γ and the key inflammatory cytokine, TNF-α. ENL, 
and to a lesser extent high concentrations of LOB-A, caused sustained increases in PPAR-γ 
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expression, which seemed to relate to preservation of tight junction protein ZO-1 expression. On 
the other hand, LOB-J had short lived protection that seemed to be triggered by a greater reduction 
in the acute inflammatory mediator, TNF-α, consistent with its anti-inflammatory and anti-oxidant 
activity. 
Significant downregulation of PPAR-γ is associated with IBD in murine models 265 and 
humans with UC266. This is mainly attributed to the role of PPAR-γ in trans-repressing signal 
dependent NF-κB activity267, and further suppression of cytokines and chemokines involved in 
aggravating inflammation on the intestinal epithelium. Targeting PPAR-γ to ameliorate IBD has 
been attempted through PPAR-γ gene delivery 268 and use of the PPAR-γ agonists, such as 
rosiglitazone 269, which has been clinically shown to effectively treat mild to moderate UC in 
humans270. Similarly, we anticipate that the increased expression of PPAR-γ associated with ENL 
and LOB-A may positively reduce inflammation in IBD in general and likely with greater benefit 
in UC patients. This can be further applied to investigate the optimal composition of these 
components to reduce intestinal inflammation.  
In summary, ENL, LOB-A and LOB-J alone or in combination mitigated the loss of in 
vitro barrier integrity with an inflammatory stimulus encompassed by effects on TEER values, LY 
and ZO-1. Screening for genes involved in this protection showed that reduction of TNF-α 
expression by LOBs and ENL and increased PPAR-γ expression by LOB-A and ENL. This 
systematic evaluation of flaxseed ENL and LOBs is suggestive of different mechanisms of action 
for each individual bioactive, suggesting that their combination in appropriate ratios may result in 
improved protection of epithelial barrier. Further investigation in animal models of IBD should be 
performed to assess their therapeutic use and as adjunct treatment with conventional therapeutics 
in IBD. 
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Transitioning rationale: 
 The previous chapter provided a proof of concept of the anti-inflammatory effects of 
enterolactone and linoorbitides on intestinal epithelial cells and an ability to maintain the intestinal 
epithelial barrier. However, to better simulate the pathophysiological conditions in vivo, in this 
chapter we incorporated a co-culture model that utilized the human Caco-2 (intestinal epithelium 
cell line) and mouse RAW 264.7 (macrophage cell line). RAW 264.7 cell lines can produce 
persistent inflammation upon induction with LPS, and thus, preserve features of IBD. This 
manuscript provides further evidence of LOBs and ENL positive effects on barrier integrity in the 
presence of stimulated macrophages (RAW 264.7). Moreover, the integration of the RAW 264.7 
cell line provided a plausible element for the assessment of oxidative stress in this system. In 
addition, this manuscript continued the discovery process of potential inflammatory mediators 
involved in the observed effects of LOBs and ENL. Consequently, in this chapter the co-culture 
system enhances the relevance of the protective effects of LOBs and ENL on intestinal epithelial 
integrity and the possible inflammatory mediators.  
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Abstract 
Flaxseed extract is rich with several bioactive components believed to possess beneficial 
effects in patients with inflammation related chronic disorders. However, no clear characterization 
exists of the role individual bioactives play in reducing inflammation and disease progression. 
Inflammatory bowel disease (IBD) is an important condition where the IBD population receives 
variable value from current treatments. New or adjuvant therapies are necessary to improve 
treatment outcomes and quality of life. Few studies have specifically evaluated the role of flaxseed 
bioactives in IBD. Hence, we assessed two major classes of flaxseed bioactives, linooribitides 
(LOBs) and the mammalian lignan, enterolactone (ENL), for their effect on the hallmarks of IBD 
pathogenesis, intestinal barrier integrity and oxidative stress. To this end, a co-culture of intestinal 
epithelial cells, Caco-2, and a macrophage cell line, RAW 264.7, were plated in a transwell system 
and lipopolysaccharide (LPS) was added to the basal compartment for 48 hours to stimulate an 
inflammatory response. Additionally, RAW 264.7 cells were used to assess protective effects upon 
exposure to reactive oxygen species. Results showed that ENL (2 μM) and LOB-ACEJ (20 nM) 
resulted in 1 and 1.5-fold increases in intestinal barrier resistance, respectively, when compared to 
LPS alone. Furthermore, ENL and LOBs were capable of reducing oxidative stress. Finally, 
upregulation of IL-5 was a signature for ENL in innate and adaptive immune response microarrays. 
Our results demonstrate that after an inflammatory insult ENL and the tested LOBs protect 
intestinal barrier integrity, reduce oxidative damage, and stimulate the immune system. 
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3.1 Introduction 
Flaxseed is composed of three major components; omega-3 and alpha-linolenic acid 
(ALA), soluble and insoluble dietary fibers, and lignans. A fourth significant component of 
flaxseed, the cyclic peptides or linoorbitides (LOBs), have gained recent interest as potential 
bioactive compounds that add a significant contribution to the health benefits of flax 10, 26. 
Although many human clinical trial interventions involving flax principally focused on the benefits 
of fibre and alpha-linolenic acid, the mammalian lignans and LOBs have gained more recent 
attention due to their potential to mitigate inflammatory conditions.  
Inflammatory bowel disease (IBD) is an important condition where the IBD population 
receives variable value from current treatments. New or adjuvant therapies will be necessary to 
improve treatment outcomes and quality of life. The current shift in public attention to natural 
products as a safe source of medication with ease of access is being complemented by the current 
research which identifies the potential of these multicomponent plant extracts to target several 
pathways of pathological activity271 . IBD has a complex pathogenesis and several in vitro and in 
vivo trials have utilized natural products with multi-target activity to ameliorate inflammation and 
help induce remission272. Few studies, though, have specifically evaluated the role of flaxseed 
bioactives in IBD. 
The flaxseed lignan enterolactone (ENL), is a mammalian lignan that is detected in the 
systemic circulation upon ingestion of flaxseed standardized extracts217 and is associated with 
reduced inflammatory markers like CRP in postmenopausal women and amelioration of 
inflammation after lung injury in mouse models 8, 9. In addition, ENL has well studied antioxidant 
activity52, 261. ENL undergoes enterohepatic recirculation, which suggests increased concentration 
at the level of the gastrointestinal tract epithelium. This increased concentration is critical to elicit 
pharmacological activity in pathologies that are confined to the gastrointestinal tract like IBD. 
Conversely, LOBs have not been associated with an anti-inflammatory effect, but were more 
significantly attributed to immunosuppressive activity that is closely related to cyclosporin-A26, 46, 
47. Due to their inherent large molecular weight (~1000 g/mol), LOBs are potentially incapable of 
crossing the intestinal epithelium244 and, hence, likely to exert local effects on the epithelium.  
Few studies have evaluated a role for the flaxseed bioactives, LOBs and lignans, in IBD, 
particularly studies which examine the activity of individual bioactives in IBD pathogenesis. 
Preliminary investigations typically employ in vitro model systems to assess the ability of plant 
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bioactive compounds in modulating the key components influencing the pathogenesis of IBD, 
namely the mucosal immune system, mucosal epithelial barrier function, and mucosal 
inflammation and oxidative stress119, 120, 137, 273-275. In the present study, we investigated the effect 
of flaxseed lignans and LOBs on intestinal epithelial barrier integrity, oxidative stress, and immune 
system by employing a co-culture of intestinal epithelial cells, Caco-2, and a macrophage cell line, 
RAW 254.7, in a transwell system276. This system results in a polarized epithelium with high 
integrity277, that allows for relevant cell-cell communication between the two cell types278, and 
inflammatory and oxidative stress responses that simulate conditions in the intestine 279,125, 274. 
3.2 Materials and Methods 
3.2.1 Reagents 
 Superoxide dismutase (SOD) and catalase (CAT) assay kits were purchased from Cayman 
Chemical (Ann Arbor, MI, USA). The SOD kit measures total SOD activity (Mn-SOD and Cu/Zn-
SOD) and total of both cytoplasmic and mitochondrial SOD. The lipid peroxidation (MDA) assay 
kit was purchased from Abcam (Toronto, ON, Canada). RNA extraction was performed using 
Trizol and a Qiagen RNeasy mini kit (Toronto, ON, Canada). Innate & Adaptive Immune 
Responses PCR Array was purchased from QIAGEN (Toronto, ON, Canada). 2′,7′-
Dichlorofluorescin diacetate (DCFH-DA), lipopolysaccharide (LPS) from Escherichia coli 
0111:B4, enterolactone (ENL), fetal bovine serum (FBS) and 0.025% trypsin–EDTA were 
purchased from Sigma-Aldrich (Saint Louis, MO, USA). Colorectal adenocarcinoma-C2BBe1 
(Caco-2-BBe) and mouse macrophage (RAW 264.7) cell lines were acquired from American Type 
Culture Collection (ATCC) (Manassas, VA, USA). Corning™ Transwell (0.4 μM, 24-well plates; 
Fischer Scientific, Pittsburgh, PA, USA) was purchased from Fisher Scientific (Pittsburgh, PA, 
USA). Dulbecco’s modified Eagle medium (DMEM)-high glucose and penicillin-streptomycin 
(10,000 U/mL) were purchased from Thermo-Scientific (Waltham, MA, USA). Protein 
concentrations were determined using the Pierce™ BCA Protein Assay Kit (Rockford, IL, USA). 
All other reagents were cell culture grade. 
3.2.2 Caco-2-BB2 and RAW 264.7 Culture Conditions 
 Caco-2-BB2 and RAW 264.7 cell lines were cultured in DMEM-high glucose (0.3 g/L 
glutamine and sodium pyruvate) supplemented with 10% FBS and 1% penicillin/streptomycin, 
and maintained at 37°C with 5% CO2 in a humidified atmosphere. Cells were kept in the 
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logarithmic growth phase by routine passage every 2 – 3 days using 0.025% trypsin–EDTA 
treatment for Caco-2 and physical scraping for RAW 264.7. All experiments were carried out using 
passage numbers for 11-19 for RAW 264.7 and 52-63 for Caco-2.  
3.2.3 Co-culture of Caco-2-BB2 and RAW 264.7  
Caco-2 and RAW 264.7 cells in DMEM supplemented media (10% FBS) were plated on 
Corning Transwells. Caco-2 was plated on the apical side at an average density of 5×104 cells per 
insert and allowed to polarize for 16 days. RAW 264.7 cells were plated on the basal side of the 
transwell at an average density of 1×104 cells per transwell on day 12 of Caco-2 polarization 
interval with adaptation of the reported method by Tanoue et al276. Media was replaced every other 
day (200 μL on the apical side and 600 μL on the basal end) using vacuum suction. Transepithelial 
electrical resistance (TEER) values were measured using Millicell ERS™ voltohmeter by EMD 
Millipore®, after 30 minutes of acclimatisation in a biosafety cabinet. To optimise the 
concentrations of LPS used, we assessed TEER values by comparing several LPS concentrations 
against vehicle control of 1%DMSO at 24 and 48 hours. On the experiment day, FBS 
supplemented media was removed and substituted with Hank’s Balanced Salt Solution (HBSS) 
(no Calcium) combined with LPS (10 μg/mL) addition to the basal compartment of transwells, 
while the apical compartment received HBSS only. Four different treatments of LOB-A, LOB-J, 
LOB-ACEJ, and ENL were added simultaneously with LPS in three replicates at three different 
concentrations on three different experimental days. The concentration used did not induce any 
cytotoxic effect as per our previous assessment (data not shown). Each flaxseed bioactive was 
initially dissolved in 100% DMSO, and then serially diluted to 1% DMSO with FBS free media 
and used as a final working solution. TEER measurement was done at the beginning of treatment 
and after 4, 8, 12, 24 and 48 hours. Relative TEER values were calculated by dividing TEER values 
for each treatment at each experimental time point by TEER values of its corresponding LPS only 
well at the same time point.  
3.2.4 Reactive Oxygen Species (ROS) Activity with DCFH-DA in RAW 264.7 
RAW 264.7 cells were seeded onto a 96-well plate (10,000 cells/well), left to attach for 24 
hours, and then treated with LOB-A, LOB-ACEJ, and ENL for another 24 hours. At the end of the 
24 hour treatment, media was changed and replaced with media that contained 100 µM hydrogen 
peroxide (H2O2) and fresh flaxseed bioactives for another one hour. Finally, 25 µM DCFH-DA 
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was used for ROS detection. Readings were taken at 485 nM excitation and 525 nM emission 
wavelengths using a Biotek Synergy HT microplate reader (Fisher Scientific, Canada). For 
imaging purposes, a similar procedure was performed, but the concentration of H2O2 was reduced 
to 50 µM. For visualization, we used a ZOE fluorescence microscope (Bio-rad, Hercules, CA, 
USA) 
3.2.5 Measurement of Superoxide Dismutase (SOD) Activity, Catalase (CAT) Activity and 
Malondialdehyde (MDA) Concentration 
 Upon optimization, 200 ng/mL LPS for 24 hours resulted in a sustained quantifiable 
increased enzymatic activity of SOD and CAT. SOD and CAT activity assays in the RAW 264.7 
cell line were carried out by incubating cells with 200 ng/mL LPS and flaxseed bioactives, LPS 
alone, and 1% DMSO (vehicle control). After 24 hours of co-incubation, protein concentration 
was quantified using Pierce™ BCA protein assay kit and normalized and activity was assessed per 
the manufacturer protocol. For MDA production (end-product of lipid peroxidation), cells were 
co-incubated with 400 ng/mL LPS for 6 hours and quantified for protein concentration, then MDA 
quantity was evaluated per the manufacturer`s instruction. The high concentration of LPS (400 
ng/mL) and short duration was capable of capturing lipid peroxidation, unlike the use of 200 ng/mL 
which did not. 
3.2.6 Innate and Adaptive Immune Response Array  
RAW 264.7 cells were seeded in 6-well tissue culture plates and treated with LPS 10 μg/mL 
and flaxseed bioactives pooled at (200 nM) for 24 hours, and then total RNA was extracted from 
cells cultured on transwells by using Trizol and a Qiagen RNeasy mini kit. RNA purity and 
quantity was determined spectrophotometrically (Nanoview spectrophotometer; GE Healthcare, 
Baie d’Urfe, Quebec, Canada) by measurement at 260 nm and the OD260/OD280 ratio, respectively. 
Total RNA was then reverse transcribed using a Life Technologies-SuperScript® VILO™ cDNA 
Synthesis Kit and used for array analysis in the RT2 Profiler PCR array for mouse innate and 
adaptive immune responses per the manufacturer’s instructions. The array analysis was performed 
using Applied Biosystems® 7300 system (Foster City, CA, USA). Data analysis was performed 
on GeneGlobe Data Analysis Center website as per manufacturer recommendations. Microarray 
results were verified using quantitative RT-PCR (qPCR). Briefly, RNA from transwells as 
indicated above was quantified using Power Sybr® mastermix. The polymerase chain reaction was 
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carried out using a one-step method where an initial incubation with reverse transcriptase took 
place at 42ºC for 30 minutes, followed by denaturation at 95ºC for 3 minutes, 40 cycles of 
annealing and extension for 15 seconds and 30 seconds, respectively, and eventually a dissociation 
curve per manufacturer settings. Specific primers for target genes were designed using Integrated 
DNA Technologies (https://www.idtdna.com/Primerquest/Home/Index). Primers sequences for 
target genes were: 5`- GCTTCCTGTCCCTACTCATAAA-3` (forward) and 5`- 
CCCACGGACAGTTTGATTCT-3` (reverse) for Il-5, 5`- GGAGAAACCTGCCAAGTATGA-3` 
(forward) and 5`-TCCTCAGTGTAGCCCAAGA-3` (reverse) for GADPH, which served as a 
housekeeping gene to normalize CT values. The ΔΔCT method was used to determine the fold 
change in mRNA expression levels. 
3.2.7 Statistical Analysis 
All data represent means ± SD. Effects of treatments relative to controls were evaluated by 
using one-way ANOVA followed by Dunnett’s post-hoc test. Differences were considered 
significant at p-value < 0.05. All data analysis was performed using GraphPad Prism 5 software 
(San Diego, CA, USA). 
3.3 Results 
3.3.1 Flaxseed bioactives mitigate reductions in transepithelial electrical resistance (TEER) 
following a lipopolysaccharide (LPS)-induced inflammatory response 
We conducted several optimization steps to first elicit an appropriate inflammatory 
response to allow assessment of the ability of the flaxseed bioactives to protect epithelial barrier 
integrity. The co-culture system was optimized for cell density and LPS concentration that could 
reduce TEER values and induce an inflammation that is moderate and potentially reversible. 
Figure 3.1 shows three different concentrations of LPS (10, 25 and 75 µg/mL) and their relative 
TEER values compared to 1% DMSO (control) at two time points (24 and 48 hours). Reduction 
in TEER values behaved in a concentration dependent fashion. A concentration of 10 µg/mL was 
used to carry out the rest of the experiments in transwells as it showed a mild reduction in relative 
TEER to 92.25 % at 24 h and a persistent reduction at 48 hours (relative TEER = 55.57%).  
LOB-A relative TEER values showed a steady increase at only one concentration (2 µM), 
which plateaued between 8-24 hours and declined thereafter (Figure 3.2). In contrast, LOB-J at a 
concentration of 20 nM maintained a high relative TEER (~200% of LPS only wells) for a period 
of 48 hours. LOB-ACEJ, in a similar pattern to LOB-A, showed maintenance of high TEER for 
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24 h but TEER values declined with longer exposure periods. Increasing concentrations of ENL 
resulted in maintenance of higher relative TEER (Figure 3.2).    
3.3.2 Flaxseed bioactives reduce oxidative stress response in RAW 264.7 macrophage cell 
line 
To determine the ability of the flaxseed bioactives to mitigate oxidative stress, H2O2 was 
used to induce an oxidative stress in the murine macrophage cell line, RAW 264.7, and markers 
of oxidative stress, ROS levels, lipid peroxidation, SOD activity, and CAT activity were assessed. 
In the absence of flaxseed bioactives, H2O2 increased ROS levels 46 % in comparison to 1% 
DMSO control (Figure 3.3). 100 µM of H2O2 was used after optimizing several variables like RAW 
264.7 cell count, sensitivity to H2O2 and the quantifiably of fluorescence. The amount of ROS 
produced by H2O2 treated cells, as observed using the DCFH-DA probe, was decreased when 
treated with LOB-A, -ACEJ and ENL.  The highest percentage of reduction was observed at 2 µM 
and was 33%, 32.7%, 26.6% and 18.2% for LOB-ACEJ, ENL, LOB-A and LOB-J, respectively. 
In contrast, the amount of ROS produced by the LOB-J and LOB-A treated cells was not 
significantly reduced at the lowest concentration of 20 nM (Figure 3.3). When challenged with 
lower concentrations of H2O2, and examined under the microscope, all flaxseed bioactives at 200 
nM showed reduced fluorescence intensity when compared to H2O2 alone as seen in Figure 3.4. 
 Following LPS stimulation, assessment of SOD enzymatic activity in RAW 264.7 cells 
showed that ENL (0.2 μM and 20 μM) significantly increased SOD activity by 35% and 62% 
relative to LPS only treatment (Figure 3.5). Among the cyclic peptides, only LOB-A at a high 
concentration (2 μM) was capable of increasing (79.5%) SOD activity following LPS induced 
ROS production (Figure 3.5). Catalase activity was increased with ENL and LOB-J (20 μM) by 
44.3% and 42.6% respectively (Figure 3.6), relative to LPS only treatment. To assess lipid 
peroxidation 400 ng/mL of LPS was co-incubated with the flaxseed bioactives for 6 hours, and 
each bioactive caused a concentration-dependent reduction in lipid peroxidation with high 
concentrations of LOBs reducing MDA production (Figure 3.7) by 43.5%, 40.8% and 32.5% for 
LOB-J, LOB-A and LOB-ACEJ (all at 2 µM), respectively. ENL at 20 µM significantly reduced 
MDA production by 36.9% in comparison to LPS only treatment. 
3.3.3 Upregulation of IL-5 as a signature of flaxseed bioactives  
 Innate and adaptive immune response gene expression revealed six genes that were 
significantly altered (Figure 3.8). Those upregulated genes were signal transducer and activator of 
64 
 
transcription 4 (Stat4) and interleukin-5 (IL-5). Down-regulated genes were chemokine receptor 6 
(Ccr6), CD40 ligand (Cd40Ig), Fas ligand (Fasl) and interleukin-13 (IL-13).  
To confirm the results obtained from the microarray, we performed independent qPCR 
with a different primer design tool. When independently verified, only IL-5 provided reproducible 
results that could be replicated in a different experiment with homemade primers. When broken 
down to single bio-actives treatment, ENL was mainly responsible for the upregulation of IL-5 in 
dose response trend as in figure 3.9. Verification of microarray results using qPCR showed a 
significant 2.85 and 5.3-fold increase in IL-5 expression relative to 10 µg/mL LPS control at 2 and 
20 µM respectively. On the other hand, LOBs did not change the expression of IL-5 at the same 
concentration as ENL. 
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Figure 3.1 Effect of different lipopolysaccharide (LPS from E-coli 0111:B4) concentrations 
(open bar, 10 µg/mL; grey bar, 25 µg/mL; black bar, 50 µg/mL) on transepithelial electrical 
resistance (TEER) values relative to vehicle control (1% DMSO) in a co-culture system of RAW 
264.7 and Caco-2 cells at 24 and 48 hours. * p-value < 0.01and **p-value < 0.001.  
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Figure 3.2 Relative TEER values of flaxseed bioactives to LPS (from E-coli 0111:B4) only 
treated wells at each corresponding time point. A, B, C and D represents the simultaneous 
treatment of LOB-A, LOB-J, LOB-ACEJ and ENL with LPS exposure, respectively. Open 
circles (○) represent 2 µM, open triangles (△) represent 200 nM, open squares (□) represent 20 
nM, and closed circles (●) represent LPS 10 µg/mL. Data are represented by means ± SD with 
four replicates at each occasion in three different experimental days. 
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Figure 3.3 Effect of different bioactives on DCFH-DA oxidation in RAW 264.7 cells upon 
induction with 100 µM H2O2 for 24 hours. (open bar, 1% DMSO; black bar, 100 µM H2O2; dark 
gray bars from left to right, ENL, LOB-A, LOB-J and LOB-ACEJ). Three different 
concentrations of bioactives were used (20, 200 and 2000 nM). Data are presented as means ± 
S.D, n=3.  * p-value < 0.05, #p-value < 0.01 and **p-value < 0.001.  
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** p-value < 0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1% DMSO LOB-A (200 nM) ENL (200 nM) 
LOB-ACEJ (200 nM) 
nM) 
LOB-J (200 nM)  H2O2 (50 μM)  
Figure 3.4 Effect of 200 nM of linoorbitoids (LOBs) and enterolactone (ENL) on the 
intracellular oxidation of the reactive oxygen species (ROS) probe DCFH-DA. Images 
were taken with a ZOE fluorescence microscope. 
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Figure 3.5  Effect of LOB-A, -J, -ACEJ and ENL on SOD activity in  RAW 264.7 cells upon co-
treatment of flax bio-actives with LPS (200 ng/mL from E-coli 0111:B4) for 24 hours. Data are 
presented as means ± S.D, n=3. One way ANOVA was performed and data were compared to 
LPS alone, * p-value < 0.05, ** p-value < 0.01. 
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Figure 3.6 Effect of LOB-A, -J, -ACEJ and ENL on CAT activity in RAW 264.7cells upon co-
treatment of flax bio-actives and LPS (200 ng/mL from E-coli 0111:B4) for 24 hours. Data are 
presented as means ± S.D, n=3. One way ANOVA was performed and data was compared to 
LPS alone, * p-value < 0.05. 
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Figure 3.7 Effect of LOB-A, -J, -ACEJ and ENL on MDA concentrations in RAW 264.7cells 
upon co-treatment of flax bio-actives and LPS (400 ng/mL from E-coli 0111:B4) for 6 hours. 
Data are presented as means ± S.D, n=3. One way ANOVA was performed and data were 
compared to LPS alone, * p-value < 0.05, ** p-value < 0.01. 
 
71 
 
 
 
 
 
Figure 3.8 Innate and adaptive immune response microarray in RAW 264.7 cells after co-
treatment of pooled flaxseed bioactives (equimolar ratios of ENL, LOB-A, LOB-J and LOB-
ACEJ at 200 nM each) and 10 µg/mL LPS from E-coli 0111:B4. Solid black line (___) represent 
zero-fold change in expression between pooled treatment and LPS alone. Dashed line (----) 
represents the two folds’ regulation that used as a cut-off for significant difference between 
control and treatments groups. Upregulated genes (Yellow circles (●)) were Stat4 and IL-5, 
down-regulated genes (Dark blue circles (●)) are Ccr6, Cd40Ig, Fasl and Il-13 at p-values of < 
0.05. 
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Figure 3.9 Microarray verification with independent assay confirmed the upregulation of IL-5 
by ENL. Verification was carried out for LOB-A, -J, -ACEJ and ENL on IL-5 in  RAW 
264.7cells upon co-treatment of flax bio-actives and LPS. Data are presented as means ± S.D, 
n=3. One-way ANOVA was performed and data were compared to LPS alone,  ** p-value < 
0.001.  
 
3.4 Discussion 
 Flaxseed lignans and the cyclic peptides LOBs are purported to have anti-inflammatory, 
antioxidant and immune modulatory effect26, 44, 261. Lignans and LOBs have gained attention in 
other chronic diseases but have limited investigation in IBD. Therefore, this study investigated the 
lignan, ENL, and several LOBs (LOB-A, -J and -ACEJ) for their ability to maintain barrier 
integrity, reduce oxidative stress, and as potential immune modulators, as key hallmarks of IBD 
pathogenesis. This study used an in vitro co-culture model of Caco-2 (intestinal epithelium) and 
RAW 264.7 (macrophages) cell lines, to acknowledge the importance of intestinal epithelial cell 
and macrophage interactions in the pathogenesis of IBD276, 280, 281. Further, lipopolysaccharide 
stimulation of toll-like receptor-4 of macrophages triggers an inflammatory cascade in the co-
culture with induction of oxidative stress that simulates events in the inflamed epithelium of IBD 
patients146. This behaviour was necessary to allow evaluation of the anti-inflammatory effects of 
ENL and LOBs and their effects on oxidative stress.  
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Currently it is believed that losing integrity of intestinal epithelial barrier function is a 
critical part of IBD pathophysiology119, 120, 137, 275. In this study, barrier integrity protection in the 
co-culture model was generally maintained with ENL and the LOBs, although a reverse 
concentration-response relationship was noted with LOB-A. These results are consistent with 
effects noted in a monoculture of HCT-8 polarized epithelium (Chapter 2) although concentrations 
up to 2 µM were necessary in this study to ensure that the intended effects were observed given 
enhanced inflammatory status mediated by LPS stimulation of macrophages. With regard to the 
LOBs, the suppression of the immune response initiated from macrophages (RAW 264.7) is 
supported by the reported immunosuppressive effects of LOBs in general47, 48. The concentration-
dependent differences noted with the LOBs is likely due to the potency of immunosuppressive 
activity of certain LOBs. Immunosuppressants such as methotrexate are known to modulate 
inflammation in pathologies like rheumatoid arthritis282, while at higher concentrations and 
increased dosing frequencies it is utilized as an anticancer agent through its ability to induce cancer 
cell apoptosis283.  In this study, LOB-A had the greatest potency with respect to 
immunosuppressive activity, and at higher concentrations may induce cell apoptosis. Therefore, 
LOB-A at higher concentrations might cause an apoptotic effect on RAW 264.7 cells (the source 
of inflammatory mediators) and reduce the intensity of the inflammatory insult or epithelial cell 
apoptosis and reduction in barrier integrity.  
The ability of ENL to decrease oxidative stress in the macrophage cell line is consistent 
with the reported anti-oxidant activity of flaxseed lignans in general, an activity that is attributed 
to their diphenolic chemistry and capacity to scavenge free radicals through donation of an 
electron, more specifically from the 4-hydroxy substituents of SDG and SECO, and the meta 
mono-phenol structures of END and ENL52. The ability of ENL to increase expression of the 
antioxidant enzymes, CAT and SOD, contributes to the reduction in oxidative stress, which is also 
consistent with reported ability of the lignans to upregulate hepatic CAT and SOD activity and 
expression, and glutathione peroxidase expression in vivo under different pathological contexts 
(diabetes, cardiac damage, and liver fibrosis)284, 285. Interestingly, the LOBs generally had a more 
pronounced reduction in lipid peroxidation without consistent upregulation of CAT and SOD 
activity. The high molecular weight of LOBs and their potential lack of cellular uptake likely 
confines their effect to reductions in extracellular reactive oxygen species (ROS), which would 
explain the reduction in MDA peroxidation without changes in intracellular antioxidant enzyme 
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expression. The increased SOD and CAT activity at high concentrations of LOBs could be a result 
of cellular homeostasis in response to extracellular ROS status rather than directly influencing the 
activity of such enzymes. Furthermore, the beneficial effect of LOBs on lipid peroxidation might 
be due to the short duration of the inflammatory insult (6 hours vs 24 hours for the SOD and CAT 
experiment), which could have captured the high burst of ROS generation during the initial stages 
of LPS stimulation. However, these experiments were limited by the lack of understanding of LOB 
permeability, which is necessary to understand whether they exert intracellular or extracellular 
activity.  
Although cytokine and chemokine-mediated recruitment is essential for maintenance of 
barrier integrity149, enhanced expression of IL-5 in LPS stimulated macrophages with ENL 
treatment was unexpected. Elevation of inflammatory biomarkers such as IL-6, TNF-α and CRP, 
in IBD is typically reported in the literature286, 287, but IL-5 is an eosinophil activating cytokine288 
believed principally to be responsible for clearing parasitic, viral and bacterial infection in the 
gastrointestinal tract289-291. This effect might suggest a potential role of ENL in prophylaxis of 
intestinal inflammation rather than treatment of active disease where activation of eosinophils 
might be more deleterious288. Interestingly, in a DSS colitis mouse model activation of the 
eosinophilic pathway was associated with attenuation of inflammation292, and further this is 
indirectly supported by the incidence of eosinophilic activation as a result of 5-ASA treatment, a 
mainstay treatment in IBD 293, 294.  
In conclusion, flaxseed LOBs and ENL provide significant protection of epithelial barrier 
integrity in a co-culture model of macrophage and intestinal epithelial cells. Protection of barrier 
integrity was supported by LOB and ENL mediated reduction in oxidative stress, an effect likely 
the result of different mechanisms of action between the LOBs and ENL. In addition, ENL and 
LOBs reduced ROS generated lipid peroxidation in macrophages and upregulated IL-5 to 
modulate the immune response. Further assessment of ENL and LOBs in a colitis animal model is 
warranted to confirm their in vivo effect on barrier integrity, oxidative damage, and immune system 
modulation to mitigate these hallmarks of IBD pathogenesis. 
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Serum Pyruvate Kinase M2 (PKM2) is Elevated in Inflammatory Bowel 
Disease  
 
Ahmed A. Almousa1, Marc Morris1, Sharyle Fowler2, Jennifer Jones3, Jane Alcorn1* 
 
Transitioning rationale: 
 The previous chapter explored the effects of flaxseed bioactives on an in vitro coculture 
model of intestinal inflammation. Through the previous chapter, we assessed the effect of pooled 
flaxseed bioactives on innate and adaptive immune response gene microarray. To further 
understand the mechanism involved we applied the microarray results into gene set enrichment 
software. Results from this screen identified L-phenylalanine as a potential metabolite strongly 
associated with this screen enrichment. L-phenylalanine is a potent allosteric inhibitor of pyruvate 
kinase M2 (PKM2), an enzyme considered to exist at the interphase between inflammation and 
cellular metabolism. To enhance the translational aspect of this thesis, this following chapter 
investigated the utility of PKM2 as a potentially useful biomarker in IBD.  
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Abstract 
 In inflammatory bowel disease (IBD) endoscopy remains the gold standard to diagnose 
and evaluate disease activity. The available biomarkers or their combinations cannot adequately 
predict IBD disease risk, diagnosis, progression or relapse, and response to therapy. A need 
continues for identification of more predictive serum biomarkers. Pyruvate kinase M2 (PKM2) is 
suggested to be a significant mediator of the inflammatory process. To evaluate a role for PKM2 
as a potential biomarker in IBD we assessed serum samples from newly diagnosed IBD patients 
for PKM2 levels. We measured serum PKM2 by ELISA and correlated levels with several disease 
activity scoring systems, IBD disease type, and intestinal microbiota in newly diagnosed IBD 
patients. Furthermore, we tested the genetic expression of PKM2 after exposure of a in vitro  
intestinal  cell lines to lipopolysaccharide (LPS) in the absence and presence of novel anti-
inflammatory molecules of flaxseed currently under investigation in our laboratory. When 
compared against standard healthy controls, serum PKM2 levels were 6-fold higher in IBD 
patients, with no sensitivity to disease phenotype (Crohn`s Disease or Ulcerative Colitis) or 
localization of inflammation, and had less interindividual variability than established IBD 
biomarkers. We also observed a positive correlation (r = 0.6121) between serum PKM2 and 
Bacteroidetes fecal levels in Crohn`s disease (CD), in addition to a negative (r = -0.6128) 
correlation between serum PKM2 and Actinobacteria fecal levels. Furthermore, LPS (500 ng/mL) 
significantly upregulated PKM2 expression in vitro, which was significantly suppressed by the 
flaxseed bioactive, Linoorbitide-A (LOB-A), at 200 nM. In conclusion, our data suggests PKM2 
as a putative biomarker for IBD and the dysbiosis of microflora in IBD. Furthermore, we continue 
to develop a body of evidence for the potential utility of flaxseed bioactives in IBD. 
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4.1 Introduction 
IBD presents in two different distinct pathologies, Ulcerative Colitis (UC) and Crohn`s 
Disease (CD)137. IBD is a very important chronic inflammatory disease with a significant burden 
on the health care system and the quality of life for those who suffer from it186, 295. Currently, 
several biomarkers and their combinations are considered to aid diagnosis of IBD including C-
reactive protein (CRP), erythrocyte sedimentation rate (ESR), fecal lactoferrin, fecal calprotectin 
and calgranulin C188. In addition, biomarkers to distinguish between IBD phenotypes have been 
utilized in clinical practice to help assess the severity of disease including anti-Saccharomyces 
cerevisiae antibody, anti-glycoprotein-2, anti-granulocyte macrophage colony-stimulating factor, 
anti-neutrophil cytoplasmic antibody, anti-mannobioside carbohydrate IgG antibody, and anti-
CBir1189. However, these biomarkers lack sufficient sensitivity and specificity190-192 193, 194 and 
endoscopy remains the gold standard to diagnose and to stage disease severity in IBD patients189, 
195. The identification of alternative less invasive biological markers to adequately predict IBD 
disease risk, diagnosis, progression or relapse, and response to therapy remains an urgent need in 
the field of gastroenterology. 
A recent abstract published by Marin et al. identified a significant correlation between 
PKM2 levels and active UC296. Furthermore, PKM2 is gaining attention as a mediator of the 
inflammatory process by acting as a bridge between energy metabolism and inflammatory cellular 
processes297. Elevated PKM2 has been associated with patients diagnosed with lung cancer, renal 
cancer, ovarian cancer, and melanoma298-301. Pyruvate kinase (PK) regulates the final step of 
glycolysis by catalyzing the transfer of a phosphate group from phosphoenolpyruvate (PEP) to 
ADP to produce ATP and pyruvate302. PK is involved in the Warburg effect in cancer cells, and 
its activity is a determinant of cell proliferation through the shunting of metabolites into the pentose 
phosphate pathway to support nucleotide biosynthesis required by a rapidly dividing cell, whether 
it is cancerous or epithelial 303-305. On the cellular level, the exact role of PKM2 in the inflammatory 
process is not known, but proteomic profiling of neutrophilic granules showed high abundance of 
PKM2 as an evidence for critical role in immune cell recruitment306. In the intestinal epithelium, 
PKM2 upregulation is believed to impart a favourable effect by repressing apoptosis305. In 
addition, the high turnover of intestinal epithelial cells is considered a shared characteristic with 
cancerous cells. 
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This study aimed to confirm an association with serum PKM2 levels and patients newly 
diagnosed with IBD and whether it may differentiate between CD and UC. Moreover, this study 
assessed whether PKM2 elevation is observed in an in vitro model of intestinal inflammatory 
stimulation and whether novel bioactives from flaxseed may ameliorate elevations in this enzyme. 
4.2 Materials and methods 
4.2.1 IBD patient recruitment and assessment  
Newly diagnosed (within the past 12 months) IBD patients as determined by the treating 
physician at the Royal University Hospital and Saskatoon area were considered eligible subjects. 
Individuals ages 18 and older with a diagnosis of IBD based on Lennard-Jones et al. criteria307, 
and able to provide a written informed consent participated in the study. The study was conducted 
between November 2012 to July 2014307. Several disease activity scoring modules were utilized, 
including; Crohn`s Disease Activity Index (CDAI), IBDQ, Mayo in UC, and Harvey scoring for 
CD308-310. Exclusion criteria included patients with end-stage kidney disease, cardiovascular 
disease, infectious disease or hepatic disorders or who are pregnant. This study was approved by 
the University of Saskatchewan’s Biomedical Research Ethics Board (Bio-REB) (Bio# 09-26).  
At baseline and follow-up visits (3-6 months) over the two-year period, endoscopy, disease 
activity scores, fecal collection and blood work were performed for each participant in the trial. 
Fecal samples were aliquoted (50 gm) and frozen immediately and sent out for microbiota analysis 
by Contango Strategies Limited (Sasktoon, SK). 
Fecal calprotectin was measured using a Quantum Blue® FC High Range Rapid Test using 
a company recommended reader (AlPCO, Salem, NH, USA). For this purpose, 30 mg of fecal 
sample was added to a base cap and subsequently fitted for extraction. Then, 4 mL of extraction 
buffer (provided with the kit) was added and the mixture was vortex-mixed for one minute. A 
sixteen times dilution (with chase buffer) was performed and only 80 µL was used in the reader. 
Fecal lactoferrin was determined using IBD-SCAN® (TechLab, Blacksburg, VA, USA). A 450 
mg fecal sample was transferred to an Eppendorf tube and diluted at 1:100 to 1:10,000. Samples 
and controls were plated on a 96-well plate provided with the kit and read at 450 and 620 nm 
excitation and emission, respectively, using a Biotek Synergy HT microplate reader (Fisher 
Scientific, Canada). 
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4.2.2 PKM2 Enzyme Linked-Immunosorbent Assay (ELISA) in human IBD patients 
Serum from thirty-three newly diagnosed IBD participants was collected and used to 
quantify their PKM2 content. In a 96-well plate, 100 μL of sample was diluted with 100 μL 
Dulbecco's phosphate-buffered saline (DPBS) buffer, then 100 μL was added to each well and the 
measurement was carried according to the manufacturer’s protocol (Elabscience Ltd., Bethesda, 
MD). These samples were compared against standard control serum purchased from Biocell 
Laboratories (Rancho Dominguez, CA, USA). In addition, PKM2 correlation analysis (see 
statistical methods for details) was conducted against disease localization, disease activity score, 
fecal microbiome content and other standard IBD biomarkers (fecal calprotectin and fecal 
lactoferrin). 
4.2.3 Cell culture 
 The colon adenocarcinoma epithelial cell line (Caco-2-BB2) and the mouse macrophage 
(RAW 264.7) cell line were acquired from American Type Culture Collection (ATCC) (Manassas, 
VA, USA) and maintained in DMEM-High Glucose media supplemented with 10% bovine serum 
albumin and 1% penicillin/streptomycin (10,000 U, 10 mg/mL) from Sigma-Aldrich (St. Louis, 
MA, USA). Initially, cells were passaged twice after removal from liquid nitrogen, media changed 
every two days, and cells in Corning™ T-75 flasks (Pittsburgh, PA, USA) were passaged at 70-
80% confluency using 0.25% Trypsin-EDTA (Sigma-Aldrich, St. Louis, MA, USA). Cells were 
maintained at 37°C and 5% CO2 all the time. For co-culture studies, a combination of both Caco-
2 and RAW 267.7 cell lines were added in a ratio of 100:1 to 6-well plates Corning™ Costar 
(Pittsburgh, PA, USA). Cell cultures were used at passage numbers 13-20 for RAW 264.7 and 52-
60 for Caco-2 for all experiments. 
4.2.4 Optimisation of PKM2 regulation in Caco-2 and verification of inflammation 
reduction with LOB-A 
After optimization, we used Caco-2 cells in DMEM-High Glucose supplemented media 
plated on 6-well plates at a seeding density of 1×105 cells per well. Cells were allowed to grow for 
a minimum of three days to achieve high confluency levels (~80%). At the time of inflammation 
induction, supplemented media was removed and substituted with serum free media with varying 
concentrations of lipopolysaccharide (LPS) from Escherichia coli 0111:B4 or TNF-α (Sigma-
Aldrich, St. Louis, MO, USA) or both for either 24 or 48 hours. After induction of inflammation, 
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total RNA was extracted from cells by using Trizol and Qiagen RNeasy mini kit (Toronto, ON, 
Canada) following the manufacturer protocols. Total RNA was then reverse transcribed by Life 
5X All-in-one RT Mastermix (Applied Biological Materials) to cDNA, and then gene expression 
quantified using Power Sybr® Green PCR Mastermix (Burlington, ON, Canada). The quantitative 
polymerase chain reaction was carried out on an Applied Biosystems® 7300 system (Foster City, 
CA, USA) with denaturation at 95ºC for 3 minutes, and after denaturation, 40 cycles of annealing 
at 95ºC and extension at 60ºC for 15 seconds and 30 seconds each, with a final dissociation curve 
per manufacturer setting. Primer sequences for target genes were: 5`-
GCTGACTCCTGCATAGGTTATC-3` (forward) and 5`-GCGAATGCCTCAGAGTAGAAA-
3`(reverse) for PKM2, 5`-    CAAGAGCACAAGAGGAAGAGAG-3` (forward) and 5`-CTACAT 
GGCAACTGTGAGGAG-3` (reverse) for GAPDH, which served as a housekeeping gene to 
normalize Ct values. The Delta-Delta threshold cycle (ΔΔCT) method was utilized to determine 
fold change in mRNA expression levels. 
Similar to the experimental design used for RNA expression, we quantified PKM2 protein 
expression after prolonged (48 hours) and high LPS activation (500 ng/mL). Cells were collected 
from 6-well plates using Trypsin-EDTA 0.25% then were centrifuged at 1000 g for 5 minutes and 
the pellet was reconstituted with one mL of DPBS. Subsequently, cells were frozen and thawed 
three times and homogenized with a microtube homogenizer for one minute on ice. The 
homogenate was centrifuged again at 1000 g for 20 minutes, and 100 μL of clear supernatant was 
added to the assay for assessment of PKM2 expression per manufacturer protocol (Elabscience 
Ltd., Bethesda, MD). 
4.2.5 Statistical Analysis 
Data are presented as mean ± SD unless otherwise mentioned. Effects of treatments relative 
to control were evaluated by using one-way ANOVA followed by Dunnett’s post-hoc test. 
Differences were considered significant at p-value < 0.05. All data analyses were performed by 
using GraphPad Prism 5 software (San Diego, CA, USA). Correlation analysis was also performed 
with GraphPad Prism 5 using two tailed correlations with linear regression of 95% confidence 
intervals and an assumption of data being sampled from a Gaussian population.  
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4.3 Results 
4.3.1 Serum PKM2 levels are elevated in newly diagnosed IBD patients 
Serum samples from 33 IBD patients were quantified for PKM2 concentrations using 
ELISA and compared with serum from four standard controls. Mean serum PKM2 levels were 
approximately six times higher than control serum (Figure 4.1). Serum PKM2 was compared 
against well-established IBD biomarkers, fecal calprotectin and fecal lactoferrin, from the same 
patients and demonstrated less variability of quantiles (Figure 4.2). When participants were 
stratified according to IBD diagnosis (location of inflammatory lesions by endoscopic evaluation), 
levels of PKM2 were not statistically significant with endoscopic results (data not shown). 
Similarly, there was a significant increase in serum PKM2 in both UC and CD patients compared 
to control, with no difference between UC and CD (Figure 4.3). To determine whether PKM2 
serum levels related to disease activity scores, we conducted a correlation analysis of PKM2 
concentrations with different disease activity score categories. Figure 4.4 indicated no significant 
correlation between serum PKM2 and disease activity indices. 
Among several types of intestinal microflora analyzed (Actinobacteri, Bacteroidetes, 
Cyanobacteria, Firmicutes, Fusobacteria, Proteobacteria, TM7, Tenericutes and 
Verrucomicrobia) for the 33 IBD patients only two types of bacteria showed significant correlation 
with PKM2 serum concentration. Both Bacteroidetes and Actinobacteria were significantly 
correlated to PKM2 concentrations in patients with CD, where increased PKM2 corresponded to 
an increase in Bacteroidetes (r = 0.6121) and reduction in Actinobacteria (r = -0.6126) (Figure 
4.5). 
4.3.2 PKM2 regulation is dependent on inflammation duration and cell line  
Initially two different types of culture systems were tested, a mono-culture of Caco-2 and 
a co-culture of Caco-2 and RAW 264.7. The two systems were treated with different 
concentrations of inflammatory inducers, TNF-α or LPS or their combination. At 24 hours, only 
LPS at the high concentration (500 ng/mL) in the Caco-2 system increased the expression of PKM2 
(data not shown). Increased incubation to 48 hours enhanced confluency in plates and resulted in 
a significant increase (~38%) of PKM2 expression. 
To confirm the involvement of PKM2 in the inflammatory response, we evaluated its levels 
in the absence and presence of a novel anti-inflammatory molecule of flaxseed currently under 
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investigation, Linoorbitide-A (LOB-A). At 200 nM, LOB-A in the presence of LPS reduced 
mRNA levels of PKM2 by 41% compared to LPS alone (Figure 4.7-A). Consistent with genetic 
expression data, ELISA quantification was performed and showed that PKM2 levels decreased 
from 1.5 ng/mL in the presence of LPS alone to 1 ng/mL after LOB-A treatment (Figure 4.7-B). 
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Figure 4.1 Mean ± SD serum PKM2 concentration in standard control (n=4) (from Biocell 
Laboratories) and newly diagnosed inflammatory bowel disease (IBD) patients (n=33) (Crohn’s 
Disease, n=21 and Ulcerative Colitis, n=12). Concentrations were measured using a PKM2 
ELISA kit. **p-value of two tailed t-test < 0.01. 
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Figure 4.2 Boxplots with inter-quartile ranges comparing serum PKM2, fecal lactoferrin (FL) 
and fecal calprotectin (FC)were measured as biomarkers for IBD in 33 patients with newly 
diagnosed inflammatory bowel disease (IBD). n.s No significant difference in the interquartile 
ranges.  
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Figure 4.3 Serum PKM2 concentrations (ng/mL) in newly diagnosed patients with Crohn`s 
Disease (CD) (n =21) and Ulcerative Colitis (UC) (n= 12) (as determined by endoscopic 
evaluation) in comparison to control (n = 4) serum. Serum PKM2 was measured by a PKM2 
ELISA kit. n.s No significant difference. **p-value of two tailed t-test < 0.01. 
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Figure 4.4 PKM2 serum concentrations (ng/mL) in correlation to disease activity scores in 
inflammatory bowel disease (IBD). Panel A represents IBD questionnaire (IBDQ) in Crohn`s 
disease patients. Panel B represents IBD questionnaire in Ulcerative Colitis patients. Panel C 
represents the dedicated Crohn`s disease activity index (CDAI) scoring system. Panel D 
represents the specialized Ulcerative Colitis Mayo scoring system. Panel E represents the Harvey 
B. scoring system. Data analysis used a two-tailed correlation with linear regression of 95% 
confidence intervals. The correlation was not significant at p<0.05. 
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Figure 4.5 Correlation of PKM2 serum concentration (pg/mL) to normal flora (percentage of 
total bacterial content) in CD. Two tailed correlation was performed with linear regression of 
95% confidence intervals. Correlations between serum PKM2 and Bacteroidetes and 
Actinobacteria were significant with a p-value <0.05.  
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Figure 4.6 Relative PKM2 mRNA expression in of Caco-2 to housekeeping gene GAPDH. Total 
RNA was collected after 48 hours of incubation with different inflammatory inducers (LPS 100 
ng/mL, LPS 500 ng/mL, TNF-α 100 ng/mL, TNF-α 200 ng/mL and (TNF-α + LPS 100 ng/mL)) 
and reverse transcribed to cDNA and amplified using qPCR. Data are presented as means ± 
S.D, n=3, * p-value < 0.05.  
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Figure 4.7 A- PKM2 genetic regulation upon exposure to LPS (500 ng/mL) for 48 hours. 
Expression of PKM2 mRNA relative to GAPDH mRNA in the presence of 500 ng/mL LPS. Data 
are presented as means ± S.D, n=3; one way ANOVA was performed and data were compared 
to LPS alone, * p-value < 0.05. B- ELISA-PKM2 concentration. Data are presented as means ± 
S.D, n=3, one way ANOVA was performed and data was compared to LPS alone, * p-value < 
0.05,** p- value < 0.01 and ,*** p- value < 0.001. 
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4.4 Discussion 
IBD is a chronic recurrent inflammation of the gastrointestinal tract of multifactorial 
origin137. Due to the high cost of treatment, morbidity, and high relapse rates104, 137, 168, 186, 311, in-
depth studies to discover biomarkers that can be used to assess disease progression and treatment 
effectiveness is a necessity. PKM2 is emerging as a hub between cellular energy consumption 
pathways and inflammatory processes297, 304. Therefore, an assessment of changes in PKM2 
expression in IBD and with/without treatment will facilitate its utilization as a biomarker for 
disease, disease progression, and response to treatment. In this study, we assessed the use of PKM2 
as a biomarker for IBD in vivo and in vitro. In addition, we assessed if treatment could alter this 
expression, and for a proof-of-principle for that concept we used LOB-A, which was shown to 
modulate inflammatory responses in our previous studies favorably. Through a combination of in 
vivo serum PKM2 protein expression analysis in newly diagnosed IBD patients and in vitro 
evaluation of PKM2, we identified that PKM2 could potentially serve as a biomarker in IBD. 
Lastly, PKM2 was predictive of dysbiotic gut microbiome in CD. 
Our findings in newly diagnosed IBD patients showed that serum PKM2 was elevated in 
comparison to serum from healthy adults, but serum PKM2 levels could not differentiate between 
CD and UC. This observation is consistent with several reports where elevated faecal PKM2 
helped differentiate between IBS and IBD, but not the sub-classification of IBD312. This could be 
due to the generalized involvement of PKM2 in inflammation and reduction of apoptosis with 
upregulation of this enzyme305, which is a common feature of both UC and CD. Serum PKM2 was 
not significantly correlated with disease activity scores in CD and UC. This relationship was not 
significant, perhaps in part due to the small sample size, or the inherent variability in these disease 
activity scores. 
In newly diagnosed IBD patients the elevated serum PKM2 showed limited interindividual 
variation, in contrast to the current biomarkers of IBD, FC and FL, which exhibited relatively large 
variability among this patient sample. This finding may be compared with Joshi et al who reported 
no changes in fecal PKM2 levels in three different age groups of healthy volunteers, while fecal 
samples of lactoferrin and calprotectin varied significantly across the age groups313. This low 
variability in serum PKM2 among IBD patients warrants further evaluation into its possible 
inclusion into the panel of biomarkers for IBD as it may improve accuracy and sensitivity of IBD 
diagnosis, disease progression, and or response to treatment314-316. The current biomarkers of IBD, 
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FC and FL, become elevated with activation and recruitment of macrophages, dendritic cells, and 
other immune cells in attempts to resolve inflammatory status317. However, both FC and FL are 
nonspecific as these molecules perform multifunctional roles associated with the inflammatory 
state and are observed in other chronic inflammatory conditions11, 318, 195, 319. Their lack of 
specificity and significant variation limits their effectiveness and, hence, the current biomarker 
panels fail to correlate strongly to endoscopy, “the gold standard” for IBD diagnosis316. The 
expansion of biomarker panels to capture multiple biological pathways can fortify the use of 
inflammatory biomarkers for disease diagnosis. Elevation of serum PKM2 captures a different 
aspect of the inflammatory process, where its increased expression in IBD may be the result of a 
sudden shift to increased metabolic rate and oxidative stress, which requires more efficient cellular 
ATP generation with reduced oxidative phosphorylation297, 320. Hence, PKM2 with its different 
functional role in inflammation, might add to the current biomarkers and collectively these 
biomarkers may improve accuracy of IBD diagnosis and disease progression.  
Prior to its further evaluation as a putative biomarker in IBD and possible inclusion into a 
panel of biomarkers, measurement of serum PKM2 must address an important limitation of the 
current study. The use of a commercially available ELISA kit to estimate serum PKM2 
concentration offered a convenient means to preliminarily investigate PKM2 in IBD patients. 
However, the available kit cannot differentiate between the different forms of PKM2, dimeric and 
tetrameric PKM2321, 322. These forms have different levels of endogenous activity, where the 
tetrameric form imparts the highest metabolic activity302. Therefore, advancing PKM2 utilization 
as a biomarker requires further analytical techniques and differentiation between isoforms to 
understand its role in IBD disease progression. Another important limitation is PKM2’s critical 
role in glucose metabolism and inflammation and its abundance in several tissues including brain, 
muscles, small intestine, pancreas and astrocytes323, 324. This variable abundance in tissues with 
high glucose consumption asserts the need to select the sampling source for the use as an IBD 
biomarker. The collection of samples from both feces and blood circulation may better represent 
PKM2 arising from the IBD pathology, namely the intestinal epithelium that is shed in feces and 
the concomitant immune system activation presented both locally at the intestine and systemically. 
Lastly, statistical power analysis for recruitment of newly diagnosed IBD patients was performed, 
however, recruitment issues and patients’ population in the city of Saskatoon limited the number 
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of participants involved. This potentially results in an underpowered study, where increasing study 
participants is necessary to increase the reliability of study power design. 
Interestingly, in the patient subsample there was a positive correlation between serum 
PKM2 concentration and intestinal Bacteroidetes. The role of microbiota in IBD has been widely 
studied and correlated to its severity, prognosis and localisation325-327. Dysbiosis in IBD favors an 
8-fold increase in the mucosal associated bacteria (aerobic and anaerobic) in patients with IBD in 
comparison to asymptomatic patients170. In CD, the gastrointestinal tract is leaky and potential 
penetration of microbiota to the systemic circulation is possible328. Appearance of Bacteroidetes 
in the systemic circulation could increase extraintestinal inflammatory symptoms, which could 
cause an indirect increase of serum PKM2. Further investigation that is focused on the CD 
population might reveal more details about PKM2 and its correlation to microbiota. 
 In conclusion, newly diagnosed IBD patients have elevated serum PKM2 levels, although 
PKM2 measured by ELISA cannot differentiate between the IBD phenotypes or disease 
localization. Its potential use as a biomarker, however, warrants further investigation as PKM2’s 
involvement in inflammation and cellular energy homeostasis and its small interindividual 
variability suggests its robustness as a biological indicator of IBD pathology regardless of age or 
IBD phenotype. Therefore, PKM2 might be a beneficial player in a panel of biomarkers that can 
be used to fortify the selectivity and sensitivity of the currently available biomarkers of IBD.  
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Enterolactone-glucuronide upregulates INSIG-1 to modulate cholesterol metabolism in 
Caco-2 cells 
 
Ahmed A. Almousa1, Alister Muir2, Ed S. Krol1, Jane Alcorn1* 
 
Transitioning rationale: 
  The previous chapters focused on the assessment of the local anti-inflammatory and 
antioxidative effects of LOBs and ENL effects on the intestinal epithelium and ability to maintain 
epithelial barrier integrity in two different in vitro models for application in IBD. The intestinal 
epithelium also plays an important role in cholesterol homeostasis. Despite positive correlations, 
reports on flaxseed effects on cholesterol modulation lack identification of mechanisms involved. 
One possible mechanism is modulation of cholesterol absorption at the intestine to explain the 
hypocholesterolemic effects associated with flaxseed consumption. Hence, a continuation to the 
main objective of this thesis then, this manuscript explored how flaxseed lignans might impart 
their hypocholesterolemic response at the level of the intestinal epithelium.   
 
 
 
Contribution statement: 
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Abstract 
Modulation of cholesterol metabolism is considered an integral part of risk factor reduction 
in cardiovascular disease. The increased tendency of using natural products in conjunction with 
prescribed medication heightens the importance of research and clinical trials in this area. Changes 
in cholesterol metabolism have been attributed to intake of lignans from several plant origins. 
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Evidence suggests that the lignan enterolactone (ENL), improves lipid profiles in 
hypercholesterolemic patients. However, the nature of this modulation is yet to be discovered. This 
study investigated the effect of ENL and its conjugated form ENL-Glucuronide (ENL-Gluc) on 
cholesterol metabolism. We measured the effect of both ENL and ENL-Gluc on cholesterol uptake 
in the Caco-2 intestinal cell line, in the presence of a cholesterol trapping molecule U-18666A. In 
addition, we screened for ENL and ENL-Gluc induced gene expression patterns. Results showed 
that treatment with ENL and ENL-Gluc reduced cholesterol uptake by 2.94 and 1.99-fold at 20 
µM, respectively, in comparison to vehicle control of 1% DMSO. Furthermore, only ENL-Gluc. 
significantly upregulated Insulin Induced Gene-1 (INSIG-1) by 3.8-fold when compared to 
untreated control at p-value < 0.01. Western blot analysis confirmed gene expression results. These 
changes were also confirmed phenotypically by increased retention of fluorescing cholesterol 
(NBD-Cholesterol) in the endoplasmic reticulum as a function of increased INSIG-1 expression. 
In conclusion, glucuronide conjugation of ENL alters its pharmacological effect in regards to 
cholesterol metabolism, through increased expression of INSIG-1. Further investigation is 
necessary in more metabolically active cell lines including hepatocytes, and in assessment of 
downstream pathways of cholesterol synthesis.  
 
 
 
 
 
 
 
5.1 Introduction 
Hypercholesterolemia is a known risk factor for coronary heart disease. In high income 
countries, hypercholesterolemia reaches incidence levels of up to 50% of the population329. 
Statistics from the United States also show that less than half of individuals with high LDL-
cholesterol (LDL-C) do not receive cholesterol lowering treatments330. For individuals who do not 
take hypocholesterolemic medications or fail to meet their target levels, increasing interest is 
turning towards natural products for the management of cardiovascular disease risk factors. 
Among those natural products with evidence of cholesterol reducing effects are the lignans, a 
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group of phenolic bioactives found in several plants like sesame, flax, oats, and nuts331, 332. The 
safe and effective use of lignans in the reduction of risk factors such as hypercholesterolemia, 
though, warrants a rigorous understanding of their mechanisms of action.  
Lignans are a group of phenylpropanoid dimers, where the phenylpropane units are linked 
by a central carbon -C8- of their propyl side chains333. The consumption of foods rich in lignan 
components is generally linked to reduced circulating blood cholesterol, an attribute confirmed by 
administration of lignan-enriched products or purified lignans2, 11, 12, 82, 334, 335. The ability of lignans 
to reduce circulating cholesterol may involve several molecular factors like upregulation of PPAR-
ɣ and LXR-α 336, key transcriptional regulators of fatty acid homeostasis, or upregulation of 
cholesterol efflux transporters ABCA1 and ABCG1, as noted with the lignans, arctigenin and 
sesamin337, 338. However, the exact mechanism through which lignans mediate reductions in 
circulating cholesterol remains largely unknown. 
With oral consumption, lignans undergo further metabolism to the mammalian lignans, 
enterodiol and enterolactone (ENL), by the colonic microbiota256, 339. Generally, the 
epidemiological literature attributes the health benefits of lignans to ENL44, 71, 230, 235, 340. 
Interestingly, the mammalian lignans are susceptible to extensive enterohepatic recirculation. Both 
intestinal and liver cells actively metabolize the mammalian lignans to glucuronide or sulfate 
metabolites during their absorption process219. Hepatic biliary excretion of glucuronide or sulfate 
conjugates of the mammalian lignans results in the presentation of the conjugated moieties to the 
gastrointestinal tract mucosa. Gastrointestinal luminal beta-glucuronidases and sulfatases can act 
to release the conjugated molecule to restore the mammalian lignan, which then can subsequently 
undergo a repeated cycle of enterohepatic circulation. The extensive conjugative metabolism of 
the mammalian lignans and the enterohepatic recirculation process results in the prolonged and 
repetitive exposure of the gastrointestinal tract mucosa and liver to the conjugated metabolites of 
the mammalian lignans. Although an understanding of the pharmacology of the mammalian 
lignans has received attention, almost no study has evaluated their conjugated metabolites.  
The objective of this study was to investigate a potential mechanism through which the 
mammalian lignan, ENL, and its glucuronidated metabolite, ENL-glucuronide (ENL-Gluc), might 
mediate the cholesterol reduction effects noted with lignan consumption. Although in vitro 
assessment of cholesterol metabolism is a challenging process, the amphipathic steroid U-18666A 
(Upjohn Co.) has become a highly versatile chemical tool to understand cholesterol uptake and 
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intracellular trafficking341, 342. We used U-18666A to evaluate the potential cellular and molecular 
responses upon exposure of the intestinal cell line, Caco-2, to ENL-Gluc and ENL with an aim to 
identify which lignan form exerts pharmacological activity and whether the active form modulates 
cholesterol uptake or intracellular trafficking. We demonstrate that the glucuronidated metabolite 
of ENL modulates cholesterol trafficking. This finding has substantive ramifications as very few 
glucuronide conjugates of drugs or natural products are known to exhibit pharmacological activity; 
glucuronidation generally is considered as a metabolic inactivation pathway. Yet, with oral 
consumption the conjugated metabolites of the mammalian lignans are the predominant circulating 
forms. Our results provide intriguing support for ENL-Gluc as the principal form mediating the 
hypocholesterolemic effects associated with lignan consumption.  
5.2 Materials and methods 
5.2.1 Chemicals and Reagents 
Cholesterol Uptake Cell-Based Assay Kit was purchased from Cayman Chemical (Ann 
Arbor, MI, USA). Ezetimibe-D-glucuronide (Ez-Gluc) and insulin induced gene-1 (INSIG-1) 
antibody (sc-390504) were purchased from Santa-Cruz Biotechnology (Dallas, TX, USA). Lamin 
B1 antibody (66095-1) was purchased from Proteintech Group (Rosemont, IL, USA), and served 
as a housekeeping protein. ER-ID® Red assay kit was purchased from Enzo Life Sciences 
(Framingdale, NY, USA). Enterolactone (ENL), fetal bovine serum (FBS), 0.025% trypsin–
EDTA, bovine serum albumin (BSA) and TWEEN-20 were purchased from Sigma-Aldrich (Saint 
Louis, MO, USA). Glucuronated ENL was synthesized in our according to a previously reported 
protocol232, 343. Colorectal adenocarcinoma-C2BBe1 (Caco-2-BBe) and dimethylsulfoxide 
(DMSO) was acquired from American Type Culture Collection (ATCC) (Manassas, VA, USA). 
Fab2-Goat anti-mouse IgG (H+L) secondary antibody-HRP conjugate (A24512), Dulbecco’s 
Modified Eagle medium (DMEM)-high glucose and penicillin-streptomycin (10,000 U/mL) were 
purchased from Thermo-Scientific (Waltham, MA, USA). T-75 flasks were from Corning™ 
(Pittsburgh, PA, USA). For microscopic imaging, a ZOE fluorescence microscope was used (Bio-
rad, Hercules, CA, USA). 
5.2.2 Cell culture 
The Caco-2 cell line was cultured in DMEM-High glucose (0.3 g/L glutamine and sodium 
pyruvate) supplemented with 10% (FBS), 1% penicillin/streptomycin, and maintained at 37°C 
97 
 
with 5% CO2 in a humidified atmosphere. Initially, cells were passaged twice after removal from 
liquid nitrogen, medium was changed every two days, and cells in T-75 flasks were passaged at 
70-80% confluency using 0.25% trypsin-EDTA. All experiments were carried out at passage 
number 52-65. 
5.2.3 Cholesterol uptake experiment  
Caco-2 cells were seeded onto 96-well plates at a density of 10,000 cells/well in regular 
supplemented DMEM-high glucose media (10 % FBS and 1% streptomycin and penicillin), and 
left to attach overnight (200 µL). After attachment, medium was removed and new medium (180 
µL) supplemented with 1% streptomycin and penicillin but no FBS was added in combination with 
the cholesterol uptake kit fluorescing compounds, NBD-cholesterol (20 µg/mL) and U18666A 
(1:1000 dilution) per kit manufacturer recommendation. Simultaneously, 20 µL of ENL and ENL-
Gluc (2 and 20 µM) were added to the wells, and 20 µM EZ-Gluc was used as a control for 
cholesterol uptake inhibition and 1% DMSO as a negative control. All chemicals were dissolved 
in 100% DMSO and diluted to 1% DMSO upon treatment. All experiments were done in triplicate 
on 3 different occasions and no wells contained more than 1% DMSO. After 24 hours of co-
treatment (lignans + NBD-cholesterol + U18666A), plates were centrifuged at 400 × g at room 
temperature for five minutes. The medium was aspirated and 100 µL of wash buffer provided with 
cholesterol uptake assay was added to each well. Fluorescence was measured using a Biotek 
Synergy HT microplate reader (Fisher Scientific, Canada) at excitation and emission wavelengths 
of 485 nm and 535 nm, respectively. On a different occasion, a similar procedure was performed 
but cells were imaged using a ZOE fluorescence microscope (Hercules, CA, USA). Concentrations 
used in this experiment were determined from EC50 values for Ez-Gluc, ENL, and ENL-Gluc 
reported in the literature68,350. 
5.2.4 Cholesterol and Endoplasmic reticulum co-localization 
ER-ID® Red assay kit was used to demonstrate potential localisation of cholesterol upon the 
co-administration of ENL-Gluc and U-18666A in the endoplasmic reticulum (ER). Using the same 
cell culture conditions and protocol as above, at the end of the exposure period an ER dye and 
Hoechst nuclear stains were added and incubated per manufacturer recommendations, washed with 
the cholesterol assay buffer, and visualized under the ZOE fluorescence microscope. 
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5.2.5 Extraction of total RNA and quantitative RT-PCR 
Caco-2 cells were treated with ENL or ENL-Gluc for 24 hours without the use U-18666A to 
eliminate its potential effect on cellular processes. Total RNA was extracted from cells cultured 
on 6-well plates using Trizol and Qiagen RNeasy mini kit (Toronto, ON, Canada) by following 
the manufacturer protocols. Total RNA was then reverse transcribed by abm® 5X All-In-One RT 
MasterMix to cDNA (abm, Richmond, BC, Canada), and then gene expression was quantified 
using Power Sybr® Green PCR mastermix (Burlington, ON, Canada). The polymerase chain 
reaction was carried out using a one-step method, where initial incubation with reverse 
transcriptase took place at 42ºC for 30 minutes, followed by denaturation at 95ºC for 3 minutes, 
and after denaturation 40 cycles of annealing and extension performed for 15 seconds and 30 
seconds each, with a final dissociation curve per manufacturer setting. This measurement was 
performed using an Applied Biosystems® 7300 system (Foster City, CA, USA). Primer sequences 
were designed using Integrated DNA Technologies Primer-Quest tool 
(https://www.idtdna.com/Primerquest/Home/Index) (Table 5.1). The ΔΔCT method was used to 
determine the fold change in genetic expression using GAPDH as a housekeeping gene. 
 
Table 5.1. Forward and reverse primer sequences for select genes involved in cholesterol 
transport and metabolism. Primers were designed using Primer-Quest tool on the IDT website.  
Gene 
Symbol* 
Forward primer Reverse primer 
INSIG-1 CTTGACTTTAGCAGCCCTATCT CGTGATCAGCGTAGCTAGAAA 
SREBP-1 CACTGAGGCAAAGCTGAATAAAT TAGGTTCTCCTGCTTGAGTTTC 
NPC1 CTAAACTTCTCCCAGCCTCTTC GGATCACATTCACAGCCATCTA 
LXR CGATCGAGGTGATGCTTCTG GGCAAAGTCTTCCCGGTTAT 
CYP7A CGGACAGCTAAGGAGGATTTC GTCAAAGGGTCTGGGTAGATTT 
NPC1L1 AGCACCTTGGTCATGGATTAG TGGCAGCAACAGCCTTAATA 
CETP CTTCAACACCAACCAGGAAATC CAGGAGATCTTGGGCATCTT 
ABCA1 CCTGTCATCTACTGGCTCTCTA CAGATTGGTGGAGGACACATAG 
GAPDH CAAGAGCACAAGAGGAAGAGAG CTACATGGCAACTGTGAGGAG 
*INSIG-1: Insulin induced gene-1, SREBP-1: Sterol receptor element binding protein-1, NPC1: 
Niemann-Pick Disease, Type C1, LXR: Liver X Receptor, CYP7A: cholesterol 7-alpha-
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hydroxylase, NPC1L1: Niemann-Pick C1-Like 1, CETP: Cholesterylester transfer protein, 
ABCA1: ATP-binding cassette A1 and GAPDH: Glyceraldehyde 3-phosphate dehydrogenase. 
 
5.2.6 Western blots of INSIG-1 
Caco-2 cells were seeded in T-25 flasks at 1x106 cells/mL density, and left to attach for 24 
hours. Treatment with various concentrations of ENL-Gluc (2 and 20 µM) and 1% DMSO vehicle 
control was carried out for another 24 hours. Cells were lysed for protein extraction using the 
radioimmunoprecipitation assay buffer (RIPA) from Millipore (Billerica, MA, USA) in ice-cold 
conditions, where linearity of protein concentrations was verified. Protein concentrations were 
determined using Pierce™ BCA Protein Assay Kit (Rockford, IL, USA). Subsequently, 20 μg of 
total protein were transferred for gel electrophoresis using 10 % Mini-Protean Gel (Bio-Rad 
Technologies) at 120 volts for 15 minutes then 70 volts for 60 minutes. Transfer took place on a 
nitrocellulose membrane at 300 mA for 2 hours. Membrane blocking was carried out using 5% 
BSA in PBS for one hour. All primary antibodies (INSIG-1 and Lamin-B) (1:1000) were incubated 
overnight at 4°C in PBST and then incubated with the secondary antibody (1:3000) for 2 hours at 
room temperature. The blots were developed using enhanced chemiluminescence detection system 
(Novex® ECL) from Life Technologies (Burlington, ON, Canada). Images were taken using the 
AlphaImager™, and analyzed using AlphaView software through the band analysis module (San 
Jose, CA, USA). INSIG-1 protein band intensity was normalized to its corresponding 
housekeeping protein Lamin B intensity. 
5.2.7 Statistical Analysis 
All data were reported as means ± standard deviation (SD). Effects of treatments relative to 
controls were evaluated by using one-way ANOVA followed by Dunnett’s post-hoc test. 
Differences were considered significant at p-value < 0.05. All data analyses were performed using 
GraphPad Prism 5 software (San Diego, CA, USA). 
5.3 Results 
5.3.1 Simultaneous incubation with U-18666A to study the ENL and ENL-Gluc effects on 
cholesterol metabolism 
To understand the potential differential effect of ENL and ENL-Gluc on cholesterol metabolism 
simultaneously by trapping cholesterol, our initial experiments showed that when using U-18666A 
alone as a positive control for cholesterol uptake no significant difference was observed with the 
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corresponding NBD-cholesterol (negative control) wells in the Caco-2 cell line (data not shown). 
Therefore, the experimental design was adjusted where U-18666A was co-incubated with ENL 
and ENL-Gluc in order to study their effect on cholesterol localization and the potential 
mechanism for modulation of cholesterol homeostasis. Ezetimibe-glucuronide, used as a positive 
control, verified the plausibility of this experimental design as its co-incubation with U-18666A 
resulted in a significant reduction (56%) in fluorescence associated with tagged cholesterol (NBD). 
Unconjugated ENL reduced NBD-cholesterol fluorescence by 39.9% and 65.9% at 2 and 20 µM 
ENL, respectively (Figure 5.1). Similarly, ENL-Gluc showed reduction in NBD-cholesterol 
fluorescence when compared to control by 58.9% and 49.7% for 2 and 20 µM, respectively. 
When visualized by fluorescence microscopy, both ENL and ENL-Gluc at 20 µM showed 
reduction in NBD-cholesterol fluorescence, but more reduction was observed in the unconjugated 
form as seem in Figure 5.2. Interestingly, ENL-Gluc showed clusters of concentrated NBD-
cholesterol, which were not observed in ENL and Ez-Gluc and the distribution of NBD-
Cholesterol was considerably different from ENL and Ez-Gluc.  
5.3.2 Effect of ENL and ENL-Gluc on INSIG-1 and SREBP expression. 
To test for the potential mechanism involved in ENL and ENL-Gluc regulation of cholesterol 
trafficking, we assessed the genetic expression of a number of proteins important in cholesterol 
homeostasis namely INSIG-1, SREBP-1, NPC1, LXR, CYP7A, NPC1L1, CETP and ABCA1. 
Among the genes tested, only INSIG-1 and SREBP-1 showed significant differences in mRNA 
levels with exposure to ENL and ENL-Gluc. In particular, ENL-Gluc upregulated INSIG-1 by 1.9 
and 3.8-fold at 2 and 20 µM, respectively (Figure 5.3A). ENL increased INSIG-1 expression 
(insignificantly) by 1.4 and 2.06 fold at 2 and 20 µM, respectively for the same duration of 
incubation (Figure 5.3C). Additionally, SREBP-1 was significantly downregulated by ENL-Gluc 
(0.45 fold of the control), while ENL did not influence the regulation of SREBP (Figure 5.3B and 
D). Western blot analysis further confirmed upregulation of INSIG-1 at the protein level in Caco-
2 cells exposed to ENL-Gluc (1.4-fold at 2 µM (insignificant) and 1.8-fold at 20 µM ENL-Gluc) 
(Figure 5.4). 
5.3.3 NBD-Cholesterol retention in the endoplasmic reticulum 
 To visually localize and understand the distribution of NBD-Cholesterol, we tagged the 
endoplasmic reticulum (ER) with a specific dye (ER-ID®) to verify the co-localization with 
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cholesterol upon administration of ENL-Gluc at 2 and 20 µM. As can be seen in Figure 5.5, 
increased accumulation of NBD-cholesterol was observed with increased concentrations of ENL-
Gluc.  
C
o
n
tr
o
l
2
0
 
M
 E
Z
-G
lu
c
2
 
M
 E
N
L
2
0
 
M
 E
N
L
2
 
M
 E
N
L
-G
lu
c
2
0
 
M
 E
N
L
-G
lu
c
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
*
*
* *
* * * *
F
lu
o
r
e
s
c
e
n
c
e
, 
A
U
 
Figure 5.1 NBD-Cholesterol fluorescence in Caco-2 cell line after 24 hours of treatments with 
enterolactone (ENL) and enterolactone glucuronide (ENL-Gluc) and U18666A (cholesterol 
trapping molecule). Control represents NBD-cholesterol and U18666A alone. Positive control 
was achieved by using 20 µM EZ-Gluc (cholesterol absorption inhibitor) with NBD-cholesterol 
and U18666A. Fluorescence was measured using a Biotek Synergy HT microplate reader. Data 
are presented as means ± S.D, n=3, * p-value < 0.01, ** p- value < 0.001.
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Figure 5.2 Images of NBD-Cholesterol fluorescence in Caco-2 cells after 24 hours of treatments with enterolactone (ENL) and 
enterolactone glucuronide (ENL-Gluc) and U18666A (cholesterol trapping molecule). Control represents NBD-cholesterol and 
U18666A alone; Negative control was U18666A; Positive control was achieved by using 20 µM EZ-Gluc (cholesterol absorption 
inhibitor) with NBD-cholesterol and U18666A. Images were taken using a ZOE fluorescence microscope.  
Control (NBD-Cholesterol + 
U18666A)  
Negative control (U18666A 
only) 
 
Positive control (Ezetimibe-
Gluc. + U18666A)  
20 μM ENL-Gluc. + NBD-
Cholesterol+ U18666A 
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1
0
2
 
103 
 
 
Figure 5.3 Mean mRNA expression ± S.D of INSIG-1 and SREBP-1 in Caco-2 cell line after 
treatment with 2 and 20 µM enterolactone (ENL) and enterolactone glucuronide (ENL-Gluc) 
without U18666A. Controls were treated with 1% DMSO. A- INSIG-1 expression after 24 hours 
ENL-Gluc treatment. B- SREBP-1 expression after 24 hours ENL-Gluc treatment. C- INSIG-1 
expression after 24 hours ENL treatment and D- SREBP-1 expression after 24 hours ENL 
treatment. Data are presented as means ± S.D, n=3, * p-value < 0.05, ** p- value < 0.01. 
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Figure 5.4 Protein expression of INSIG-1 in Caco-2 cell line after 24 hours treatment with 1% 
DMSO (control), 2 and 20 µM ENL-Gluc. Lamin B served as a housekeeping protein and was 
used to normalize band intensity at each corresponding band. Images were taken using the 
AlphaImager™, and analyzed using AlphaView software through the band analysis module 
(San Jose, CA, USA). Data were presented as means ± S.D, ** p- value < 0.01.
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Figure 5.5 Distribution of NBD-cholesterol within the endoplasmic reticulum with different ENL-Gluc concentrations. Caco-2 cells 
were treated with 1% DMSO, 2 and 20 µM ENL-Gluc for 24 hours simultaneously with U18666A and NBD-Cholesterol. Staining 
used ER-ID® for ER, Hoescht for nuclear stain, and NBD tagged cholesterol. Images were taken using a ZOE fluorescence 
microscope at 10X magnification.
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5.4 Discussion 
An understanding of the pharmacological mechanism of action of natural products is 
becoming increasingly important for evidence based decision making on their utility in clinical 
practice. Such understanding will help to identify the nature of usage, whether it is 
chemopreventive or therapeutic, and identify potential interactions or potentiation of effects with 
currently approved therapeutics. Unlike regular therapeutics, natural products are often mixtures 
of several components with significant differences in their chemistry and biological activities, 
suggesting the importance of studying individual components of a natural product. The 
mammalian lignan, ENL, arises from a number of different precursor plant lignans, and has been 
associated with improved cholesterol levels, reduced tumor growth, improved glycemic control, 
and amelioration of inflammation3-5, 8, 9, 70, 75, 344. The mechanism through which ENL improves 
cholesterol levels in interventional studies, remains unclear.  
Cholesterol in the intestine is supplied from three sources; diet, circulating bile and 
intestinal epithelium sloughing. Cholesterol from these sources is taken up by intestinal cells and 
is either effluxed again (ABCG5/8) to the lumen or sequestered in the form of chylomicrons to be 
transferred to the basolateral side of the polarized intestinal epithelium345. Cholesterol molecules 
are absorbed passively through the formation of micellar structure. More recently, an apical protein 
receptor, the NPC1L1 was identified to facilitate cholesterol absorption. Inhibition of NPC1L1 is 
attributed to be Ezetimibe’s mechanism of action to lower total cholesterol levels in the blood. 
Studies also suggest that NPC1L1 is the rate limiting step for cholesterol uptake. Other scavenger 
receptors might be involved in cholesterol uptake including scavenger receptor type B (SR-BI), 
but these are thought not to be as critical as NPC1L1346.  
In this work we investigated the effect of the mammalian lignan, ENL, and its glucuronic 
acid conjugated form, ENL-Gluc, on cholesterol metabolism in the intestinal cell in an effort to 
understand the underlying mechanism of action. Similar to ezetimibe that requires glucuronidation 
to inhibit NPC1L1, we speculated that ENL would require a similar mechanism. 
We used the combination of the Caco-2 intestinal epithelium cell line with the cholesterol 
trafficking inhibition molecule, U18666A, and fluorescing NBD-cholesterol to assess cholesterol 
uptake and metabolism. This is an increasingly used in vitro system for assessment of the effect of 
new chemical entities on cholesterol homeostasis347. In the hepatocyte, studies show the ability of 
phytoestrogens, such as genistein and daidzein,  to favourably modulate cholesterol homeostasis 
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through mechanisms involving inhibition of cholesterol synthesis, inhibition of esterification and 
reduced expression of LDL-receptors348. As well, ENL is reported to upregulate the LDL receptor 
in hepatocytes349 suggesting this as a potential mechanism for reduced cholesterol levels. 
However, our understanding that ENL undergoes extensive phase II metabolism (particularly 
glucuronidation) and enterohepatic recirculation is suggestive of ENL and ENL-Gluc presence at 
the intestinal mucosal layer.  
Both ENL and ENL-Gluc caused reductions in the amount of fluorescing cholesterol within 
the intestinal cell similar to the FDA approved cholesterol absorption inhibitor prodrug, ezetimibe. 
In our experiments, we used a system that enhances cholesterol accumulation (U18666A) within 
the cell (only if it gets absorbed) and simultaneously added ENL or ENL-Gluc. This system 
allowed differentiation between cholesterol absorption inhibitors like Ez-Gluc, as seen in Figure 
5.2 where NBD-cholesterol is almost absent intracellularly, and cholesterol metabolism 
modulators, which allows the uptake of cholesterol to the cell, but imparts their effect through 
altered cholesterol trafficking. This system showed that ENL and ENL-Gluc both reduced the 
concentrations of NBD-cholesterol as seen in Figures 5.1 and 5.2. But we observed different 
intracellular accumulations in the case of ENL-Gluc, where cholesterol was retained in the ER and 
its trafficking was altered. Upon further investigation, we found that ENL-Gluc significantly 
upregulated INSIG-1. Although it was not significant, ENL gave a trend toward upregulation of 
INSIG-1, an observation that could be explained by the initiation of glucuronidation of ENL in the 
Caco-2 cell line. Previously, our laboratory demonstrated the ability of Caco-2 cells to mediate the 
rapid metabolism of ENL to glucuronic acid conjugates with complete metabolism within 24 hours 
of incubation221. Conventionally, glucuronidation is a drug deactivation pathway, but in some 
instances, it results in the activation of parent drugs like ezetimibe or production of an active 
metabolite in the case of morphine350, 351. Similarly, ENL glucuronidation seems to be involved in 
the activation of ENL and its potential role in cholesterol homeostasis. Typically, glucuronidation 
takes place intracellularly, mainly within the endoplasmic reticulum membrane352, and it either 
interacts with the target receptor or is effluxed to exert its effect through a signaling pathway that 
is currently unknown. 
INSIG-1 upregulation has a role in inhibition of lipogenesis in adipocytes and reduction in 
risk of coronary heart disease353-355. Under cholesterol rich conditions, INISIG-1 acts as an anchor 
protein to trap sterol regulatory element-binding proteins and its cleavage-activating protein 
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(SREBP-SCAP) in the endoplasmic reticulum and prevent their dissociation356, 357. Thus, SREBP 
cannot translocate to the Golgi for proteolytic activation and further to the nucleus to activate 
cholesterol synthesis and fatty acid synthesis358. The observed SREBP-1 downregulation is 
correlated with a possible reduction in cholesterol synthesis as well as potential treatment for fatty 
liver disease359. In addition, INSIG-1 upregulation considerably increases the sensitivity of cells 
to sterol-mediated feedback inhibition of cholesterol synthesis360, suggesting fortified activity at 
increased levels of cellular cholesterol. This is consistent with clinical reports that showed a 
beneficial effect in hypercholesterolaemic patients11, 82 but not in the healthy population98. In 
addition to trapping SCAP complex in the ER and preventing further cholesterol synthesis, INSIG-
1 upregulation accelerates the degradation of HMG-CoA reductase conferring an effect similar to 
statins361. These combined effects of INSIG-1 make this gene a plausible target for cholesterol 
metabolism as a hub in cellular metabolism358. Reports on cholesterol modulation by the lignan, 
sesamin, is restricted to downregulation of SREBP-1, or upregulation of the cholesterol efflux 
transporters (ABCA1 and ABCG1)338, 362. However, involvement of the INSIG-1 pathway was not 
explored to explain the cholesterol modulating effects of sesamin. Upregulation of INSIG-1 
represents a novel finding for lignan modulation of cholesterol homeostasis. 
In conclusion, we are the first to report the possible hypocholesterolemic mechanism of 
action for the mammalian lignan, ENL, which involves upregulation of INSIG-1 with concomitant 
alteration in intracellular cholesterol trafficking. Furthermore, it appears that the glucuronide 
metabolite is the active form that mediates this effect. Further investigations are necessary to 
understand the fate of enhanced cholesterol trafficking to the ER and to confirm this potential 
mechanism of action in appropriate in vivo models of hypercholesterolemia. 
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CHAPTER 6 
GENERAL DISCUSSION 
6.1  Discussion 
Translational health research that connects clinical practice to benchtop sciences shall not be 
exclusive to conventional therapeutics, rather it should be extended to natural health products and 
alternative medicine. Unlike conventional therapeutics a plethora of natural products are available 
in the market without significant correlation to health benefits and lack of support to claims 
typically coming from allopathic health care providers, the internet, and by word of mouth363. 
Reportedly, this is a natural human inclination toward products obtained from mother nature and 
perceived as a safe and sometimes effective alternative to conventional medicine364. This public 
behavior leaves the health care professional and translational health researcher with significant 
responsibility to enhance scientific evidence available for clinical utilization of natural products365. 
Therefore, in depth safety and pharmacological behavior evaluations are becoming a necessity to 
aid clinical recommendations by physicians, pharmacists and other health care professionals. 
Flaxseed bioactives are among those natural products that require translational verification of 
specific pharmacological activities. 
My laboratory has been focused on flaxseed natural product safety, tolerability, metabolism, 
and mechanism of action12, 22, 51, 206, 217, 221, 232. Current knowledge of flaxseed extracts reveals a 
strong association in several chronic diseases like cancer, diabetes, high blood pressure and 
inflammatory disorders2-7. This association can be attributed to significant anti-inflammatory 
activity, immunosuppressant potential, antioxidant activity and sex hormone modulating effects9, 
44, 47, 366. However, the current understanding of distinct flaxseed lignan pharmacokinetic properties 
shows reduced oral bioavailability and susceptibility to enterohepatic circulation257. In addition, 
flaxseed cyclic peptides (LOBs) have high molecular weights that theoretically preclude their 
ability to permeate through the intestinal epithelium upon oral intake244. Based on these 
pharmacokinetic observations and reported pharmacological activity, we proposed the potential 
utilization of flaxseed bioactives (lignans represented by ENL and LOBs) to impart local effects 
on the intestinal epithelium. Specifically, our interest focused on inflammatory bowel disease 
(IBD) and hypercholesterolemia, where intestinal epithelium is crucially involved in their 
pathogenesis and progression116, 168, 367, 368. Among the flaxseed bioactives we focused on ENL, 
LOB-A, LOB-J and LOB-ACEJ, as limitation in resources (time, money, workforce and purified 
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individual components in the case of LOBs) precluded the assessment of other bioactives. In 
addition, we focused on these LOBs due to the distinct cytotoxicity profile differences between 
LOB-A and LOB-J, where LOB-A is significantly more toxic at lower concentrations (5 µM when 
compared to LOB-J). Indeed, observation of positive findings with the examined compounds will 
warrant further evaluation of other lignans and LOBs. We performed several in vitro experiments 
including effects on barrier integrity, potential immune regulators, oxidative stress, biomarker 
verification and cholesterol metabolism to verify the proposed benefits in IBD and 
hypercholesterolemia.  
The intestine plays a critical role in cholesterol metabolism. On its apical side (intestinal 
lumen), cholesterol molecules are absorbed either passively through the formation of micellar 
structure or through Niemann-Pick C1-Like 1 (NPC1L1) receptor which was identified to facilitate 
cholesterol absorption369. Intracellularly, cholesterol in the intestine is supplied from three sources; 
diet, circulating bile and intestinal epithelial cell sloughing. Cholesterol from these sources is taken 
up by intestinal cells and is either effluxed to the lumen or sequestered in the form of chylomicrons 
to be transferred to the basolateral side of the polarized intestinal epithelium and then to systemic 
circulation345. These functions render the evaluations of ENL and LOB effects on cholesterol 
metabolism and absorption important to explain the hypocholesterolemic effect noted with the use 
of BeneFlax® (a flax lignan enriched complex) in a randomized clinical trial of 
hypercholesterolemic Chinese participants11. These studies warranted the need for investigations 
into how the lignans caused the hypocholesterolemic effects. The use of Caco-2 is an appropriate 
system to evaluate this as evidenced from studies that use this system in the literature370. In addition 
to its role in cholesterol metabolism and trafficking, the intestine plays a major role in IBD through 
several immune functions. These functions are presented through the maintained barrier integrity, 
modulation of oxidative stress and inflammation137. Therefore, an in vitro system that is simple 
yet capable of removing confounding effects is critical to begin understanding how ENL and LOBs 
may favorably modulate these key functions.  
In our pursuit to verify the effect of flaxseed bioactives on IBD, we initially assessed their 
effect (LOBs and ENL) on intestinal barrier maintenance. Significant barrier loss and leakage was 
observed in subjects with active disease, rendering its maintenance a prime goal for the 
development of treatments and preventive measures. Hence, we used an in vitro system of HCT-8 
(Chapter 2) cell line that mimics the intestinal epithelium and left it to polarize for eight days to 
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create distinct apical and basal membranes on a transwell system. This approach simulates 
intestinal lumen on the apical side and lamina propria on its basal side (where immune cells are 
typically concentrated). Other in vitro or ex vivo systems available include Ussing chambers, which 
mounts a graft of intestinal epithelium on a dynamic electrolyte flow device allowing enhanced 
representation of transporters and other cellular components when compared to an immortalized 
cell line (HCT-8)371. Another potential cell line that can be used is Caco-2, which requires longer 
incubation to achieve proposed polarization (14-21 days)277, 372. With the goal of conducting an 
initial screen, we used the HCT-8 cell line for rapid polarization patterns and proof of concept.  
With the HCT-8 cell line we observed different behaviors for different bioactives at different 
incubation periods and concentrations. Among the bioactives tested, LOB-A showed a reverse 
concentration-response with extended incubation periods of 48 hours and reduced protection of 
the epithelial barrier for the highest concentration at 24 hours (200 nM). Prior to these experiments 
we evaluated the cytotoxicity of all bioactives to define our working concentrations, and LOB-A 
showed potent cytotoxicity at lower concentrations when compared to ENL and other LOBs. 
Nonetheless, we used this to aid treatment concentrations, but higher concentrations of LOB-A 
might have induced apoptosis with enhanced loss of barrier integrity in the in vitro system. This 
can be explained by increased stress on cells in transwells, and the use of Hanks Balanced Saline 
Solution (HBSS) for an extended duration making cells more fragile and susceptible to cytotoxicity 
at lower concentrations of LOB-A. Unlike LOB-A, ENL showed a mild protection at 24 hours and 
a more consistent concentration-response effect at 48 hours. This observation could potentially be 
attributed to what we observed with enhanced effects after conjugation with glucuronide  (Chapter 
5), where forty eight hours duration is sufficient for intestinal epithelial cell lines to introduce a 
glucuronide moiety to ENL219,221. Typically, glucuronidation is considered a detoxification 
pathway resulting in pharmacologically inert metabolites. In some instances, this metabolic 
pathway results in an active metabolite and in some cases a very potent drug (e.g. morphine-6-
glucuronide, morphine-3-glucuronide, ezetimibe-glucuronide)352. Similarly, we speculate that 
ENL has to undergo glucuronic acid conjugation to provide anti-inflammatory and cholesterol 
reduction effects. 
To further evaluate the anti-inflammatory effect, we assessed ENL and LOBs effects on the 
genetic expression of several cytokines, chemokines and inflammatory mediators. Interestingly, 
ENL and LOB-A caused upregulation of PPAR-γ. This transcription factor is involved in several 
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critical metabolic and immune functions and contributes to important side effects in the human 
body373. In IBD, PPAR-γ downregulation is associated with IBD in murine models and UC in 
humans265, 266. In addition, the PPAR-γ agonist, rosiglitazone269, 374, is clinically proven to 
effectively treat mild to moderate UC in humans270, suggesting its critical role in IBD. In a related 
fashion, our data suggests that the increased expression of PPAR-γ associated with ENL and LOB-
A will positively reduce inflammation in IBD in general and with higher odds of benefits in UC 
patients.  
Oxidative stress is a hallmark of IBD pathogenesis, where increased reactive oxygen species 
are reported to alter barrier integrity and exacerbate immune reactions146, 151. In addition to 
assessments of barrier integrity, we used a co-culture system that closely simulated the intestinal 
epithelium environment that is also capable of producing significant amounts of reactive oxygen 
species. In this system, the Caco-2 cell line was plated on the apical side of the transwell and RAW 
264.7 macrophage cell line was introduced to the basal compartment276. Due to abundant 
expression of Toll-Like receptors in RAW 264.7, inflammatory induction was carried out with 
LPS rather than with TNF-α and INF-γ375.  In assessing intracellular oxidation experiments using 
the fluorogenic DCFH-DA oxidation marker, ENL and LOBs reduced fluorescence (as an 
indicator of oxidative stress) with the exception of LOB-J. When evaluating secondary oxidative 
stress protection through enzymatic modulation, ENL was superior and consistent relative to the 
LOBs. Most importantly, when we assessed the effect on ROS-damaged lipids through an MDA 
index of lipid peroxidation we found that ENL and LOBs provided a protective effect. Therefore, 
we hypothesize that ENL consistency and superiority in ROS suppression could be attributed to 
its capacity to act as both a ROS scavenging agent by the virtue of its phenolic structure, and 
through transcriptional and enzymatic modulation due to its small size (298.3 g/mol) and capacity 
to permeate through the cell membrane. This role can also be supported by evidence of PPAR-γ 
upregulation (Chapter 2), which is also suggested to be involved in cellular protection against 
oxidative stress336, 376, confirming involvement of intracellular transcriptional modulation. But it 
is unlikely that LOBs are involved in transcriptional and intracellular processes, due to their high 
molecular weights and unlikely ability to permeate the cell membrane thereby mostly acting 
through neutralization of free radicals by activity at the extracellular cell membrane surface or by 
other cell surface mechanisms377, 378.  
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Barrier integrity in the co-culture model of the Caco-2 intestinal cell line and RAW265.7 
macrophage cell line confirmed previous results observed in the HCT-8 intestinal cell monoculture 
system. Enterolactone showed a concentration-response effect that was maintained for up to 48 
hours, which relates again to the possible role of the glucuronidated metabolite rather than 
unconjugated ENL. Unlike ENL, the concentration-response behavior of LOBs was lost in some 
instances, which could indicate a lack of stability for those molecules in an in vitro system. LOB-
A and LOB-J are stable and are not subject to chemical oxidation. For LOB-A at high 
concentration (2 µM) the cellular stress caused by the combination of LPS and incubation in HBSS 
media might result in increased sensitivity of the cells to this LOB resulting in toxicity and cell 
death of RAW 265.7, which is the source of inflammation. For LOB-J, the lowest concentration 
(20 nM) employed was most effective, but this protection was lost with higher (high nM and µM) 
concentrations after eight hours. This possibly suggests a clear immunosuppressive behavior. 
Interestingly, when combined together LOB-ACEJ was most effective at the mid- concentration 
(200 nM) possibly supporting the notion that higher concentrations of LOB-J counteract the 
benefits of high LOB-A concentrations. Despite the inconsistent behavior of LOBs, both ENL and 
LOBs impart a significant barrier protection on Caco-2 polarized epithelium in a co-culture 
system.  
 In addition to barrier integrity and previous experimentation on genetic expression changes in 
the HCT-8 cell line, we opted to investigate the effect of ENL and LOBs on innate and adaptive 
immune response through a dedicated microarray. For this purpose, we used the RAW 264.7 cell 
line and pooled concentrations of ENL and LOBs. The selection of the RAW 264.7 cell line 
(macrophages) was made because of their role in both acute and chronic inflammatory response 
reported in IBD pathogenesis. In addition, the RAW 264.7 cell line is susceptible to LPS 
sensitization as an alternative to microorganism infection. Furthermore, RAW 264.7 and Caco-2 
utilized the same growth media with plausible growth conditions that renders in vitro simulation 
reasonably performable. Results from the microarray experiment identified Interleukin-5 (IL-5) as 
a major player involved in the immune response induced by pooled ENL and LOBs. The major 
role of IL-5 is reported to be in eosinophilic activation, and controversy exists regarding its 
beneficial/harmful role in IBD. Eosinophil recruitment is involved in clearing parasitic, viral and 
bacterial infection289-291, making it possible to help clear infections before exacerbation of 
intestinal inflammation288. Recently, a shift in paradigm has been suggested by studies showing 
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that worm infections (that activate IL-5) are associated with selective microbiotal colonization that 
favours protection of barrier integrity379. Interestingly, in the DSS colitis murine model, activation 
of the eosinophilic pathway was associated with attenuation of gastrointestinal inflammation292.  
 To further understand the role of ENL and LOBs in immunological processes, we utilized 
microarray data obtained from pooled ENL and LOBs treatment in RAW 264.7 cells in gene set 
enrichment analysis (GSEA). We further used a set of 20 genes (top 20 down-regulated genes) and 
used gene set enrichment for those genes in a human metabolome database utilizing 
Expression2Kinases software380. This method provides information on how a list of genes correlate 
to a set of terms in a specific database, and further ranks these correlations by their significance. 
In our case, the top 20 downregulated genes that were generated from microarray data analysis 
were applied into Expression2Kinases software. This evaluation resulted in a significant 
enrichment of terms in table 6.1, including phenylalanine, atorvastatin, formaldehyde, hydrogen 
peroxide, heme and iron. Both, L-phenylalanine and atorvastatin are of critical interest to our 
hypothesis. The latter (atorvastatin) is a blockbuster agent used to treat variants of 
hypercholesterolemia, and L-phenylalanine is a potent inhibitor of pyruvate kinase M2 (PKM2)381, 
382. These two terms suggest the involvement of ENL and LOBs in both pharmacological functions 
our hypotheses are trying to test. The relationship to our hypotheses comes as atorvastatin is 
directly involved in cholesterol metabolism and modulation, and PKM2 acts as a key bridge 
between cellular energy consumption and inflammation320. Therefore, we decided to further 
investigate the utility of PKM2 as a potential biomarker in IBD. Our study involved extracting 
information from a previous newly diagnosed IBD patient dataset on IBD patient diagnosis, fecal 
IBD biomarker values, and microbiota content and correlating these to serum PKM2 
concentrations utilizing ELISA for quantification. Our assessment of serum PKM2 suitability as a 
possible biomarker shows that it is correlated with IBD in general but cannot differentiate between 
CD and UC. The use of serum PKM2 may explain the inability to differentiate the IBD patient 
data set and we surmise that fecal PKM2 may have more relevance, due to our understanding of 
PKM2 being an abundant protein in epithelial tissues and other highly proliferative cell types such 
as neoplastic cells304, 305. In addition, the difference between CD and UC is also correlated to the 
length of damage in the intestinal epithelium structure, where UC is extended over the length of 
the colon and CD tends to be patchier and localized. Therefore, we predict that PKM2 fecal levels 
might show superior correspondence to UC than CD, if assessed.  
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Table 6.1. Gene set enrichment analysis (GSEA) of top 20 down-regulated genes in respect to 
human metabolome database. GSEA was performed using freely available software 
(Expression2Kinases). 
Term Molecule 
HMDB00159 L-Phenylalanine 
HMDB05006 Atorvastatin 
HMDB01426 Formaldehyde 
HMDB03125 Hydrogen peroxide 
HMDB03178 Heme 
HMDB00692 Iron 
HMDB00547 Magnesium 
 
 Concurrent experimentation for the discovery of a biomarker in IBD by Marc Morris 
facilitated these experiments through microbiota, serum and other biomarkers quantification383. 
Marc reports that the inclusion of several biomarkers in scoring models will improve the 
predictability of disease relapse and response to therapy clinically when compared to patient 
reported outcomes.  In concordance with this we see that our experiments together might further 
the development of a panel of biomarkers that will fortify the selectivity, specificity and utility of 
serum and fecal biomarkers in the clinical setting.  
 In addition to our GSEA that listed atorvastatin as a significantly enriched term in the 
downregulated gene set, the literature reports lignan involvement in cholesterol modulation and 
metabolism. In our studies, we developed a novel method for assessing the effect of ENL and 
LOBs on cholesterol absorption. Our initial assumption that lignans (ENL) inhibit cholesterol 
absorption was due to lack of evidence supporting an effect on cholesterol metabolic enzymes and 
potential similarity to sesamin lignan335. This investigation was challenging due to the lack of in 
vitro methods that differentiate between a cholesterol absorption inhibitor and cholesterol 
metabolism modulator. The use of U18666A, a cholesterol trafficking molecule that traps absorbed 
cholesterol intracellularly, helped eliminate the possibility of lignan effect on cholesterol uptake, 
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due to the persistent appearance of fluorescing cholesterol (NBD-cholesterol) after co-treatment 
with ENL and ENL-Gluc. The absence of NBD-cholesterol upon use of the approved cholesterol 
absorption inhibitor Ezetimibe-Gluc supported the idea that the lignans fail to influence cholesterol 
uptake. 
Clinically, a hypocholesterolemic effect is observed with oral supplementation with 
lignans from flaxseed and other sources82, 84, 384. The mechanism through which lignans modulate 
cholesterol is still unknown. Our results showed that ENL-Gluc upregulated INSIG-1 expression. 
To elaborate more on INSIG-1 functions, under cholesterol rich conditions, INISIG-1 acts as an 
anchor protein to trap sterol regulatory element-binding proteins and its cleavage-activating 
protein (SREBP-SCAP) in the endoplasmic reticulum and prevent their dissociation and activation 
of cholesterol synthesis356, 357. In addition, INSIG-1 upregulation increases the sensitivity of cells 
to sterol-mediated feedback inhibition of cholesterol synthesis360, suggesting fortified activity at 
increased levels of cellular cholesterol. This is consistent with clinical reports that showed a 
potential beneficial effect in hypercholesterolemic patients11, 82, but not in the healthy population 
98.  
In alignment with INSIG-1 upregulation, the observed upregulation of PPAR-γ that we 
have seen as an anti-inflammatory indicator is intertwined with cholesterol metabolism. König et 
al.384 provided evidence on how fibrate- and thiazolidinedione-mediated upregulation of PPAR-γ 
will upregulate INSIG-1, -2 and downregulate SREBP-1, and eventually reduce de novo synthesis 
of cholesterol. Therefore, the dual activity of upregulating PPAR-γ which will result in increased 
barrier integrity and anti-inflammatory status, in addition to upregulation of INSIG-1 that will 
reduce cholesterol synthesis, supports our hypothesis of flaxseed involvement in IBD and 
hypercholesterolemia. Furthermore, this adds more reliability of utilizing PKM2 as a biomarker 
for IBD as both energy generation and immune response is becoming more interconnected. 
 This research provides important information about how different bioactives from flaxseed 
might trigger different anti-inflammatory mechanisms. In addition, this work identifies the 
potential need for ENL glucuronide conjugation to observe the beneficial hypocholesterolemic 
effect of flaxseed lignan consumption, which provides important information to translate this 
research into animal models. Therefore, these studies were premised on evaluating key active 
components of flaxseed to ultimately provide more robust in vitro (and subsequently animal 
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model) evidence for their ability to ameliorate inflammation and modulate cholesterol metabolism, 
to utilize in pathologies like IBD and hypercholesterolemia.    
6.2 Challenges and limitations 
This research faced several challenges. At the beginning of the project the main challenge was 
the induction of inflammation and disruption of barrier integrity in a transwell system that is 
composed of polarized intestinal epithelium cells. Upon induction with either TNF-α or LPS, 
reduction in TEER was not observed. This was due to lack of complete protocols for in vitro 
inflammatory induction guidelines, where small details impart a significant difference. For 
example, excess glutamate in media has a significant protective effect on barrier integrity. In 
addition, significant inter-lab variation existed with respect to the concentration of the 
inflammatory stimulus used. Therefore, several optimization studies had to be performed. 
Similarly, the duration of incubation in the transwell system to ensure a polarized epithelium with 
high integrity varies among labs, and in house optimization was a necessity. This in vitro design 
has its limitations as utilization of Caco-2 and HCT-8 cell lines will simulate and correspond to 
different specific areas of the gastrointestinal system. Given our understanding of the 
gastrointestinal system where different regions impart different physiological functions, one cell 
line system will not duly simulate the whole organ. Further, the co-culture system where we used 
RAW 264.7 cell (mouse macrophages) is limited by the potential cross-species immunogenic 
reaction. Later, when we started assessing LOBs effects, the erratic behavior and lack of 
concentration-response relationships in some experiments caused some concern on the stability of 
these compounds in vitro. Our experiments were limited by the number of bioactives we tested 
and the need to select a limited number, which excludes valuable information concerning the 
potential of other bioactives in favourably modulating cholesterol homeostasis and the hallmarks 
of IBD pathogenesis. Another limitation is that the LOB combinations (e.g. LOB-ACEJ) we used 
to understand their pharmacological activity cannot fully represent the actual ingestion of a 
standardized natural product. This is due to the lack of understanding of ratios of each individual 
component and how accurate is its representation in a standardized natural product.  
In the evaluation of PKM2 levels in newly diagnosed IBD patients, the main challenge was 
the need for greater patient recruitment to increase the sample size to enhance the robustness of 
PKM2 utility as a biomarker. Another challenge that will remain is to develop a protein 
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quantitation method that encompasses all the forms of PKM2 (dimeric, tetrameric and 
monomeric). These forms have different levels of endogenous activity, where the tetrameric form 
has the highest metabolic activity and dimeric form has the least302. Therefore, a simple straight 
forward method to selectively analyze all these at once may enhance clinical utility and allow 
stronger correlations.  
6.3  Future work 
 This current research is helpful to establish several other future work under the umbrella of 
translational health research for natural products. Due to the variable techniques and pathologies 
examined in this research, different directions in my future work will take place. 
 In regards to the lack of the concentration-response relationship for LOBs in some instances, 
stability studies for those LOBs is a necessity. Despite the availability of industrial scale stability, 
we propose that a systematic analysis of stability in a drug discovery unit is critical for proceeding 
with using LOBs as potential anti-inflammatory mediators. This can be done through the 
development of an analytical method and accurate quantitation by LC-MS/MS. In addition, to 
confirm that LOBs will lack permeation through the intestinal epithelium and exert a local effect, 
we suggest extensive permeability studies be performed to further justify the utilization as a local 
anti-inflammatory in the intestine. 
 After confirmation of stability in different in vitro medias, pharmacological activity should be 
translated to appropriate animal models that are consistent with results in this dissertation research, 
specifically in regards to INSIG-1 upregulation. This model should utilize animals that are already 
hypercholesterolemic which are suitable for the pathways in which INSIG-1 is involved, this could 
include diet-induced hypercholesterolemia due to what has been observed in human populations. 
Subsequently, after induction of hypercholesterolemia, administration of a standardized lignan 
enriched flaxseed product for a period of time would be followed by blood collection to assess 
lipid profile (e.g. total cholesterol, triglycerides, LDL-cholesterol and HDL-cholesterol), in 
addition to physical measures (e.g. central obesity), histopathological assessment of lipid tissues 
and blood vessels, and molecular and biochemical evaluations to confirm INSIG-1 pathway 
involvement in vivo.   
 Finally, the identification of PKM2 as a biomarker in IBD needs to be expanded to include 
more patients to improve the robustness of PKM2 as a biomarker. Furthermore, elevated PKM2 
should be verified with samples obtained from participants’ feces, where fecal samples might 
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improve the differentiation between CD and UC due to differences in the intestinal surface 
involved in inflammation between the two pathologies. This comes in the alignment of PKM2`s 
extended involvement in epithelial cells. Furthermore, assessment of all isoforms of PKM2 must 
be carried out for possible identification of more selective testing kits. These results, in addition to 
what have been reported by our colleagues about the usage of the composite scoring systems, 
might incite the development of a biomarkers panel that encompasses PKM2 to help diagnose and 
stratify the nature of disease activity.  
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